Abstract:
The present invention relates to triazine derivatives as cell adhesion inhibitors. The compounds of this invention can be useful inter alia, for inhibition and prevention of cell adhesion and cell adhesion-mediated pathologies, including inflammatory and autoimmune diseases such as bronchial asthma, rheumatoid arthritis, type I diabetes, multiple sclerosis, allograft rejection, psoriasis. The compounds can be used to formulate pharmacological compositions, and the methods of treating bronchial asthma, rheumatoid arthritis, multiple sclerosis, type I diabetes, psoriasis, allograft rejection, and other inflammatory and/or autoimmune disorders, using the compounds are also provided herein.

Description:
FIELD OF THE INVENTION  
       [0001]     The present invention relates to triazine derivatives as cell adhesion inhibitors. The compounds of this invention can be useful inter alia, for inhibition and prevention of cell adhesion and cell adhesion-mediated pathologies, including inflammatory and autoimmune diseases such as bronchial asthma, rheumatoid arthritis, type I diabetes, multiple sclerosis, allograft rejection, psoriasis. The compounds can be used to formulate pharmaceutical compositions, and the methods of treating bronchial asthma, rheumatoid arthritis, multiple sclerosis, type I diabetes, psoriasis, allograft rejection, and other inflammatory and/or autoimmune disorders, using the compounds are also provided herein.  
       BACKGROUND OF THE INVENTION  
       [0002]     Cell adhesion is a process by which cells associate with each other, migrate towards a specific target or localize within the extra-cellular matrix. These interactions are mediated by specialized molecules called cell adhesion molecules (CAM). CAMs have been demonstrated to participate in various cell-cell, cell-extracellular matrix, and platelet interactions. They influence the adhesion of leukocytes to the vascular endothelium, their transendothelial migration, retention at extravascular sites and activation of T cells and eosinophils. These processes are central to the pathogenesis of inflammatory and autoimmune diseases. Therefore, adhesion molecules are considered as potential targets to treat such disorders.  
         [0003]     CAMs can be classified into three groups—integrins, selectins and the immunoglobulin superfamily. Out of these, integrins are key mediators in the adhesive interactions between hemopoietic cells and their microenvironment. They include alpha-beta heterodimers and integrate signals from outside of the cells to inside and vice versa. Integrins can be classified on the basis of the alpha and beta subunits they contain. For example, the beta-1 subfamily contains beta-1 subunit non-covalently linked to one of the 10 different alpha subunits.  
         [0004]     The alpha-4 beta-1 integrin, also known as VLA 4  (very late activation antigen 4), is a member of beta 1 integrin family and consists of alpha-4 and beta-1 subunits. VLA 4  interacts with two specific ligands—the vascular cell adhesion molecule (VCAM-1) and the the CS1 region of fibronectin. Adhesion mediated by VLA 4  is central to the process of transendothelial migration of leukocytes. Ligation of VLA 4  is followed by gross rearrangement of the cytoskeleton leading to flattening of cells along the blood vessel wall followed by expression of specific molecules which digest the endothelial cell wall and diapedesis. Once in the extraluminal region, the interactions of VLA 4  with extracellular fibronectin play a crucial role in migration to the site of inflammation, T cell proliferation, expression of cytokines and inflammatory mediators. In addition, VLA 4  ligation provides costimulatory signal to the leukocytes resulting in enhanced immunoreactivity. Therefore, it is expected that VLA 4  antagonists would ameliorate the immune response through twofold actions—inhibition of T cell recruitment at the site of inflammation and inhibition of costimulatory activation of immune cells.  
         [0005]     In this respect, inhibitors of VLA 4  interactions have demonstrated beneficial therapeutic effects in several animal models of inflammatory, and allergic diseases including sheep allergic asthma, experimental allergic encephomyelitis, contact hypersensitivity and inflammatory bowel.  
         [0006]     Region of CS1 moiety of fibronectin involved in the interaction with VLA 4  was identified as the tripeptide Leu-Asp-Val. also known as LDV. Taking a lead from this, several peptides containing the LDV sequence were synthesised which have shown to inhibit the in vivo interaction of VLA 4  to its ligands.  
         [0007]     Despite these advances, there remains a need for small and specific inhibitors of VLA 4  dependent cell adhesion molecules. Ideally such inhibitors should be water soluble with oral efficacy. Such compounds would provide useful agents for treatment, prevention or suppression of various inflammatory pathologies mediated by VLA 4  binding.  
         [0008]     In support of this concept, inhibitors of VLA-4 interactions have demonstrated beneficial therapeutic effects in several animal models of inflammatory, and allergic diseases including sheep allergic asthma (Abraham et al,  J. Clin. Invest.,  93, 776 (1994)), arthritis (Wahl et al,  J. Clin. Invest.  94, 655 (1994)); experimental allergic encephomyelitis (Yednock et al,  Nature  ( Lond ), 356, 63 (1992) and Baron et al,  J. Exp. Med.,  177, 57 (1993)); contact hypersensitivity (Chisolm et al,  Eur J. Immunol.,  23, 682 (1993)); type I diabetes (Yang et al,  Proc. Natl. Acad. Sci . (USA), 90, 10494 (1993)) and inflammatory bowel disease (Podolsky et al,  J. Clin. Invest.,  92, 372 (1993)).  
         [0009]     U.S. Pat. No. 6,329,344 B1 discloses monosaccharide derivatives as cell adhesion inhibitors. It generally relates to a group of substituted pentose and hexose monosaccharide derivatives, which exhibit potent anti-cell adhesion and anti-inflammatory activities. PCT application WO 00/42054 discloses several monosaccharide derivatives as cell adhesion inhibitors.  
         [0010]     U.S. patent application 2002/0055509 A1 discloses a series of phenylalanine derivatives which are potent and selective inhibitors of α 4  integrins. They employ various heterocycles as derivatives, including substituted diazines, pyrrolyls, furyls, triazolyls, triazinyls, imidyls and other heterocyclic groups.  
         [0011]     Patent application WO 00/43369 provides compounds which bind to VLA-4, and also relates to triazine derivatives which inhibit leukocyte adhesion mediated by VLA-4.  
         [0012]      Bioorganic and Medicinal Chemistry Letters  12 (2002) 1591-1594 relates to discovery and evaluation of N-(triazin-1,3,5-yl) phenylalanine derivatives as VLA-4 integrin antagonists in which SAR studies aimed at improving the rate of clearance of a series of VLA-4 integrin antagonists by the introduction of a 1,3,5-triazine as an amide isostere are described.  
         [0013]      Bioorganic and Medicinal Chemistry Letters  12 (2002) 1595-1598 relates to N-(pyrimidin-4-yl) and N-(pyridin-2-yl) phenylalanine derivatives as VLA-4 integrin antagonists in which SAR studies to optimize both potency and rate of clearance in the rat for a series of pyrimidine and pyridine based VLA-4 integrin antagonists are described.  
         [0014]     This patent application discloses compounds containing triazine moiety coupled with urea or its bioisosteric analogues which may be used as therapy for the inhibition, prevention and suppression of VLA-4 mediated cell adhesion and the treatment of pathologies associated with that adhesion.  
         [0015]     The compounds of the present invention may be screened for inhibitory activity in VLA-4 mediated cell adhesion assay and the classical murine hypersensitivity assay in mice. These compounds could be used in treatment of chronic, cell adhesion mediated, allergic, autoimmune and inflammatory disorders, such as bronchial asthma and rheumatoid arthritis. Some of the prior art describes development of peptide derivatives as cell adhesion antagonists for treatment of these diseases. However, because treatment of chronic diseases requires prolonged (mid term to long term) administration of drugs, development of small molecule, specific, orally available inhibitors of cell adhesion would be very beneficial.  
         [0016]     There is no disclosure in the prior art wherein the compounds described herein, containing a triazine nucleus coupled with a urea or its bioisosteric analogues, are used as therapy for inhibition, prevention, and suppression of VLA 4 -mediated cell adhesion and the treatment of pathologies associated with that adhesion.  
       SUMMARY OF THE INVENTION  
       [0017]     Herein is provided a new class of compounds that exhibit significant activity as VLA-4 antagonist, and these triazine-based molecules exhibit potential anti-inflammatory activity.  
         [0018]     The introduction of a urea moiety, or bioisosteric analogues at various positions of the triazine nucleus introduces VLA-4 antagonism activity.  
         [0019]     In one particular aspect there is provided a compound having the structure of Formula I:  
                         
 
 its pharmaceutically acceptable salts, pharmaceutically acceptable solvates, esters, enantiomers, diastereomers, polymorphs, N-oxides or metabolites 
 
 wherein 
 
         [0020]     In Formula I,  
         [0021]     R 1  can represent, hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aralkyl, heteroaryl, heterocyclyl, heteroarylalkyl, or heterocyclylalkyl.  
         [0022]     R 2  can represent, alkyl, cycloalkyl, aryl, aralkyl, heteroaryl, heterocyclyl, heteroarylalkyl, heterocyclylalkyl, or —NR 5 R 6  (wherein R 5  and R 6  are independently selected from hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, aralkyl, or SO 2 R 12  [wherein R 12  is selected from the group alkyl, aryl, or heteroaryl], C(═O)R z  [wherein R z  is selected from the group alkyl, aralkyl, heteroarylalkyl, aryl, heteroaryl, or heterocyclyl], or C(═O)OR z  wherein R z  is the same as defined above, heterocyclyl, heteroaryl, heteroarylalkyl, heterocyclylalkyl).  
         [0023]     X can represent oxygen atom, -sulphur atom, N(CN), N(NO 2 ) or CH(NO 2 ), provided that X is N(CN), N(NO 2 ) or CH(NO 2 ) when R 2  is NR 5 R 6 .  
         [0024]     R 3  can represent halogen (F, Cl, Br and I), alkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, alkoxy, aryl, aralkyl, aryloxy, heterocyclyl, heteroaryl, heteroarylalkyl, heterocyclylalkyl, or NR 7 R 8  (wherein R 7  and R 8  are independently selected from hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, aralkyl, biaryl, SO 2 R 12  [wherein R 12  is selected from the group alkyl, aryl or heteroaryl], C(═O)R z  [wherein R z  is selected from the group alkyl, aralkyl, heteroarylalkyl, aryl, heteroaryl, or terocyclyl], C(═O)OR z  wherein R z  is the same as defined above, heteroaryl, heterocyclyl, heteroarylalkyl, or heterocyclylalkyl).  
         [0025]     R 4  can represent hydrogen, alkyl, alkenyl, alkynyl, aryl, aralkyl, halogen (F, Cl, Br and I), alkoxy, CH(CO 2 R) 2  (wherein R represents hydrogen, alkyl, or aralkyl), heteroaryl, heterocyclyl, heteroarylalkyl, heterocyclylalkyl, NR 9 R 10  (wherein R 9  and R 10  are independently selected from the group hydrogen, lower (C 1 -C 6 )alkyl, [further 1-2 hydrogens in the lower alkyl(C 1 -C 6 ) may be substituted with (CH 2 ) t CO 2 R 11  {wherein t is an integer in the range of 0-6 and R 11  is selected from hydrogen, alkyl, alkenyl, alkynyl, aralkyl, metal ions (Na + , K + , Ca 2+  or Mg 2+ ), ammonia, alkylated ammonia derivatives such as tris hydroxymethylaminomethyl}, aryl, aralkyl, heterocyclyl, heteroaryl, heteroarylalkyl, or heterocyclylalkyl], SO 2 R 12  [wherein R 12  is selected from the group alkyl, aryl or heteroaryl], C(═O)R z  [wherein R z  is selected from the group alkyl, aralkyl, heteroarylalkyl, aryl, heteroaryl, or heterocyclyl], C(═O)OR z  wherein R z  is the same as defined above —(CH 2 )mCO2R11 [wherein m is an integer in the range varying from 1 to 6, R 11  is the same as defined earlier and further one hydrogen of CH 2  of —(CH 2 ) m CO 2 R 11  may be substituted with heteroaryl or heterocyclyl], aryl, aralkyl, heteroaryl, heterocyclyl, heteroarylalkyl, or heterocyclylalkyl).  
         [0026]     The following definitions apply to terms as used herein.  
         [0027]     The term “alkyl” unless and otherwise specified refers to a monoradical branched or unbranched saturated hydrocarbon chain having from 1 to 20 carbon atoms. It may further be substituted with one or more substituents selected from alkenyl, alkynyl, alkoxy, cycloalkyl, cycloalkenyl, acyl, acylamino, acyloxy, amino, aminocarbonyl, alkoxycarbonylamino, azido, cyano, halogen, hydroxy, keto, thiocarbonyl, carboxy, carboxyalkyl, arylthio, thiol, alkylthio, aryloxy, aminosulfonyl, aminocarbonylamino, hydroxyamino, alkoxyamino, nitro, —SO-alkyl, —SO-aryl, —SO-heteroaryl, —SO 2 -alkyl, SO 2 -aryl and —SO 2 -heteroaryl. Unless otherwise constrained by the definition, all 1-3 substituents chosen from alkyl, carboxy, carboxy-alkyl, aminocarbonyl, hydroxy, alkoxy, halogen, CF 3 , amino, substituted amino, cyano, and —S(O) n R 12 , where R 12  is alkyl, aryl, or heteroaryl and n is 0, 1 or 2; or an alkyl group as defined above that is interrupted by 1-5 atoms of groups independently chosen from oxygen, sulfur and —NR a —, where R a  is chosen from hydrogen, alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, aryl. Unless otherwise constrained by the definition, all substituents may optionally be further substituted by 1-3 substituents chosen from alkyl, carboxy, carboxyalkyl, aminocarbonyl, hydroxy, alkoxy, halogen, CF 3 , amino, substituted amino, cyano, and —S(O) n R 12 , where n and R 12  are the same as defined earlier; or an alkyl group as defined above that has both substituents as defined above and is also interrupted by 1-5 atoms or groups as defined above.  
         [0028]     The term “alkenyl” refers to a monoradical of a branched or unbranched unsaturated hydrocarbon group preferably having from 2 to 20 carbon atoms with cis or trans geometry either in a acyclic or cyclic ring system wherein the cyclic may include mono- or multicyclic ring forms. In the event that alkenyl is attached to the heteroatom, the double bond cannot be alpha to the heteroatom. It may further be substituted with one or more substituents selected from alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, cycloalkenyl, acyl, acylamino, acyloxy, amino, aminocarbonyl, alkoxycarbonylamino, azido, cyano, halogen, hydroxy, keto, thiocarbonyl, carboxy, carboxyalkyl, arylthio, thiol, alkylthio, ary, aryloxy, aminosulfonyl, aminocarbonylamino, hydroxyamino, alkoxyamino, nitro, —SO-alkyl, —SO-aryl, —SO-heteroaryl, —SO 2 -alkyl, SO 2 -aryl and —SO 2 -heteroaryl. Unless otherwise constrained by the definition, all substituents may optionally be further substituted by 1-3 substituents chosen from alkyl, carboxy, carboxyalkyl, aminocarbonyl, hydroxy, alkoxy, halogen, CF 3 , amino, substituted amino, cyano, and —S(O) n R 12 , where R 12  is alkyl, aryl, or heteroaryl and n is 0, 1 or 2.  
         [0029]     The term “alkynyl” refers to a monoradical of an unsaturated hydrocarbon, preferably having from 2 to 20 carbon atoms. In the event that alkynyl is attached to the heteroatom, the triple bond cannot be alpha to the heteroatom. It may further be substituted with one or more substituents selected from alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, cycloalkenyl, acl, acylamino, acyloxy, amino, aminocarbonyl, alkoxycarbonylamino, azido, cyano, halogen, hydroxy, keto, thiocarbonyl, carboxy, carboxyalkyl, arylthio, thiol, alkylthio, aryl, aryloxy, aminosulfonyl, aminocarbonylamino, hydroxyamino, alkoxyamino, nitro, —SO-alkyl, —SO-aryl, —SO-heteroaryl, —SO 2 -alkyl, SO 2 -aryl and —SO 2 -heteroaryl. Unless otherwise constrained by the definition, all substituents may optionally be further substituted by 1-3 substituents chosen from alkyl, carboxy, carboxyalkyl, aminocarbonyl, hydroxy, alkoxy, halogen, CF 3 , amino, substituted amino, cyano, and —S(O) n R 12 , where R 12  is alkyl, aryl, or heteroaryl and n is 0, 1 or 2.  
         [0030]     The term “cycloalkyl” refers to cyclic alkyl groups of from 3 to 20 carbon atoms having a single cyclic ring or multiple condensed rings. It may further be substituted with one or more substituents selected from alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, cycloalkenyl, acyl, acylamino, acyloxy, amino, aminocarbonyl, alkoxycarbonylamino, azido, cyano, halogen, hydroxy, keto, thiocarbonyl, carboxy, carboxyalkyl, arylthio, thiol, alkylthio, aryl, aryloxy, aminosulfonyl, aminocarbonylamino, hydroxyamino, alkoxyamino, nitro, —SO-alkyl, —SO-aryl, —SO-heteroaryl, —SO 2 -alkyl, —SO 2 -aryl and —SO 2 -heteroaryl. Unless otherwise constrained by the definition, all substituents may optionally be further substituted by 1-3 substituents chosen from alkyl, carboxy, carboxyalkyl, aminocarbonyl, hydroxy, alkoxy, halogen, CF 3 , amino, substituted amino, cyano, and —S(O) n R 12 , where R 12  is alkyl, aryl or heteroaryl and n is 0, 1 or 2.  
         [0031]     “Alkoxy” denotes the group O-alkyl wherein alkyl is the same as defined above.  
         [0032]     “Aralkyl” refers to (CH 2 ) p  aryl, wherein p is an integer in the range of 1-6 and aryl is as defined below.  
         [0033]     “Aryl” refers to an optionally substituted phenyl or naphthyl ring wherein the substituents may be selected from alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, halogen (F, Cl, Br and I), hydroxyl, alkoxy, aryl, nitro, amino or substituted amino, aminothiocarbonyl, alkoxycarbonyl, cyano, azido, oxo, thiocarbonyl, thiol, SO n R 12  (wherein n is an integer in the range of 0-2 and R 12  is selected from the group alkyl, aryl, or heteroaryl), aminosulfonyl, aminocarbonylamino, or C(═O)R x  wherein R x  is selected from the group of hydrogen, alkyl, aryl, aralkyl, hydroxyl, alkoxy, amino or substituted amino)  
         [0034]     “Aryloxy” denotes the group O-Aryl wherein aryl is the same as defined above.  
         [0035]     “Substituted amino” refers to a group —N(R r ) 2  wherein each R r  can be independently selected from Hydrogen, provided that both Rr groups are not hydrogen (defined as “amino”) alkyl, alkenyl, alkynyl, aralkyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, heterocyclylalkyl, heteroarylalkyl, SO 2 R 12  wherein R 12  is selected from the group alkyl, aryl or heteroaryl), C(═O)R z  (wherein R z  is selected from the group alkyl, aralkyl, heteroarylalkyl, aryl, heteroaryl, or heterocyclyl), C(═O)OR z  wherein R z  is the same as defined above, or —(CH 2 ) m CO 2 R 11 , wherein m is an integer in the range varying from 1 to 6 and R 11  is the same as defined earlier). Unless otherwise constrained by the definition, all substituents may optionally be further substituted by 1-3 substituents chosen from alkyl, carboxy, carboxyalkyl, aminocarbonyl, hydroxy, alkoxy, halogen, CF 3 , amino, substituted amino, cyano, and —S(O) n R 12 , where R 12  is alkyl, aryl or heteroaryl and n is 0, 1 or 2.  
         [0036]     “Heteroaryl” refers to a monocyclic or bicyclic aromatic ring structure containing one to four heteroatom(s) selected from N, O and S, it may optionally be substituted with one or more of substituents selected from alkyl, alkenyl, alkynyl, halogen (F, Cl, Br and I), hydroxyl, alkoxy, nitro, amino or substituted amino, cyano, oxo, C(═O)R x  wherein R x  is the same as defined earlier, SO n R 12  wherein n and R 12  are the same as defined earlier, or further it may optionally be fused to an aryl ring wherein aryl is the same as defined earlier.  
         [0037]     “Heterocyclyl” refers to a saturated or unsaturated carbocyclic group having a single ring or multiple condensed rings which may be bridged or unbridged having at least one heteroatom selected from N, O and S within the ring, it may optionally be substituted with one or more of substituents selected from alkyl, alkenyl, alkynyl, halogen (F, Cl, Br and I), hydroxyl, alkoxy, aryl, aralkyl, nitro, amino or substituted amino, cyano, oxo, C(═O)R x  wherein R x  is the same as defined earlier, SO n R 12  wherein n and R 12  are the same as defined earlier, or further it may optionally be fused to an aryl ring wherein aryl is the same as defined earlier. When the heteroatom is nitrogen, the nitrogen may be suitably substituted with hydrogen, alkyl, aryl, aralkyl, heteroaryl, SO 2 R 12  wherein R 12  is the same as defined earlier, C(═O)OR y  (wherein R y  is selected from the group of, alkyl, alkenyl or aralkyl), and further the heterocyclyl ring may also be optionally fused to an aryl ring wherein aryl is the same as defined earlier.  
         [0038]     “Heteroarylalkyl” refers to alkyl-heteroaryl group wherein the alkyl and heteroaryl are the same as defined earlier.  
         [0039]     “Heterocyclylalkyl” refers to alkyl-heterocyclyl group wherein the alkyl and heterocyclyl are the same as defined earlier.  
         [0040]     In accordance with a second aspect of the present invention, there is provided a list of compounds as shown below.  
                                             Com-           pound       No.   Chemical Name                                1.   1-[4-Chloro-6-(napthalen-2-yloxy)-[1,3,5]triazin-2-yl]-3-(2-           methoxyphenyl)urea       2.   1-[4-Chloro-6-(napthalen-2-yloxy)-[1,3,5]triazin-2-yl]-3-(2-           chlorophenyl)urea       3.   1-[4-Chloro-6-(napthalen-2-yloxy-[1,3,5]triazin-2-yl]-3-[4-           chlorophenyl)urea       4.   1-[4-Choro-6-(napthalen-2-yloxy)-[1,3,5]triazin-2-yl]-3-[4-           methoxyphenyl)urea       5.   2-[4-[3-(2-Methoxyphenyl)ureido]-6-(napthalen-2-yloxy)-           [1,3,5]triazin-2-yl]malonic acid-di-tert-butyl ester       6.   1-[4-Methoxy-6-(naphthalen-2-yloxy]-[1,3,5]triazin-2-yl]-3-(2-           methoxyphenyl)urea       7.   4-[3-(2-Methoxyphenyl)ureido]-6-naphthalen-2-yloxy)-           [1,3,5]triazin-2-yl]aminoacetic acid       8.   4-[3-(2-Chlorophenyl)ureido]-6(naphthalen-2-yloxy)-           [1,3,5]triazin-2-yl]aminoacetic acid       9.   4-[3-(2-Methylphenyl)ureido]-6-(naphthalen-2-yloxy)-           [1,3,5]triazin-2-yl]aminoacetic acid       10.   4-[3-(4-Methoxyphenyl)ureido]-6-(naphthalen-2-yloxy)-           [1,3,5]triazin-2-yl]aminoacetic acid       11.   4-[3-(4-Chlorophenyl)ureido]-6-(naphthalen-2-yloxy]-           [1,3,5]triazin-2-yl]aminoacetic acid       12.   4-[3-(4-Methylphenyl)ureido]-6-(naphthalen-2-yloxy]-           [1,3,5]triazin-2-yl]aminoacetic acid       13.   2S-[4-[3-(2-Methoxyphenyl)-ureido]-6-(naphthalen-2-yloxy)-           [1,3,5]triazin-2-ylamino}-3-phenylpropionic acid       14.   3-{4-[3-(2-Methoxyphenyl)ureido]-6-(napthalen-2-yloxy)-           [1,3,5]triazin-2-ylamino}3-phenylpropoionic acid       15.   3-{Benzo[1,3]dioxo-5-yl-[4-[3-(2-methoxyphenyl) ureido]-6-           napthalen-2-yloxy)-[1,3,5]triazin-2-ylamino) propionic acid           ethyl ester       16.   3-(Benzo[1,3]dioxo-5-yl-([4-[3-(2-methoxyphenyl)-ureido]-6-           napthalen-2-yloxy)-[1,3,5]triazin-2-ylamino} propionic acid       17.   1-[4-(Biphenyl-2-ylamino)-[1,3,5]triazin-2-yl-3-(2-           methoxyphenyl)urea       18.   1-[4-(Biphenyl-2-ylamino)-[1,3,5]triazin-2-yl}-3-(2-           methoxyphenyl)urea       19.   1-[4-(Biphenyl-2-ylamino)-6-methoxy-[1,3,5]triazin-2-yl}-3-(2-           methoxyphenyl)urea       20.   {4-Biphenyl-2-ylamino)-6-[3-(2-methoxyphenyl)ureido]-           [1.3.5]triazin-2-ylamino]acetic acid       21.   2S-{4-(Biphenyl-2-ylamino)-6-[3-(2-methoxyphenyl) ureido]-           [1,3,5]triazin-2-ylamino}-3-phenylpropionic acid       22.   3-{4-Biphenyl-2-ylamino)-6-[3-(2-methoxyphenyl) ureido]-           [1,3,5]triazin-2-ylamino}-3-phenylpropionic acid       23.   3-{3-Benzo[1,3]dioxo-5-yl-{4-(biphenyl-2-ylamino)-6-[3-(2-           methoxyphenyl)ureido]-[1,3,5]triazin-2-ylamino} propionic           acid       24.   2S-[4-(Biphenyl-2-ylamino)-6-[3-(2-methoxyphenyl) ureido]-           [1,3,5]triazin-2-ylamino]-4-methylpentanoic acid       25.   2-{4-(Biphenyl-2-ylamino)-6-[3-(2-methoxyphenyl) ureido]-           [1,3,5]triazin-2-ylamino}benzoic acid       26.   3-[{(Benzo[1,3]dioxo-5-ylmethyl-{4-(biphenyl-2-yl amino)-6-           [3-(2-methoxyphenyl)ureido]-[1,3,5]triazin-2-           yl}amino]propanoic acid       27.   3-[{4-(Biphenyl-2-ylamino)-6-[3-(2-methoxyphenyl) ureido]-           [1,3,5]triazin-2-yl}-(3,4-dimethoxybenzyl) amino]-propionic           acid       28.   3-[{4-(Biphenyl-2-ylamino)-6-[3-(2-methoxyphenyl) ureido]-           [1,3,5]triazin-2-yl}-(4-methoxybenzyl)amino]-propionic acid       29.   3-[{4-(Biphenyl-2-ylamino)-6-[3-(2-methoxyphenyl) ureido]-           [1,3,5]triazin-2-yl}-(3-methoxybenzyl)-amino] propionic acid       30.   3-[{4-(Biphenyl-2-ylamino)-6-[3-(2-methoxyphenyl)-ureido]-           [1,3,5]triazin-2-yl}-(2-methoxybenzyl)amino] propionic acid       31.   3-[{4-(Biphenyl-2-ylamino]-6-[3-(2-methoxyphenyl) ureido]-           [1,3,5]triazin-2-yl}-(3-methylbenzyl)amino] propionic acid       32.   3-[{4-(Biphenyl-2-ylamino)-6-[3-(2-methoxyphenyl) ureido]-           [1,3,5]triazin-2-yl}-(4-methylbenzyl)amino] propionic acid       33.   3-[{4-(Biphenyl-2-ylamino)-6-[3-(2-methoxyphenyl) ureido-           [1,3,5]triazin-2-yl}-(2-fluorobenzyl)amino] propionic acid       34.   3-[{4-(Biphenyl-2-ylamino]-6-[3-(2-methoxyphenyl) ureido]-           [1,3,5]triazin-2-yl}-(4-fluorobenzyl)amino] propionic acid       35.   3-[{4-(Biphenyl-2-ylamino]-6-[3-(2-methoxyphenyl) ureido]-           [1,3,5]triazin-2-yl}-(2-chlorophenyl)amino] propionic acid       36.   3-[{4-(Biphenyl-2-ylamino)-6-[3-(2-methoxyphenyl) ureido]-           [1,3,5]triazin-2-yl}-(3,4-dichlorobenzyl)amino] propionic acid       37.   3-[{4-(Biphenyl-2-ylamino)-6-[3-(2-methoxyphenyl) ureido]-           [1,3,5]triazin-2-yl}-(2,4-dichlorobenzyl)amino] propionic acid       38.   3-{4-(Biphenyl-2-ylamino]-6-[3-(2-methoxyphenyl) ureido]-           [1,3,5]triazin-2-yl}amino}propionic acid       39.   [{4-(Biphenyl-2-ylamino)-6-[3-(2-methoxyphenyl) ureido-           [1,3,5]triazin-2-yl}-(4-methylbenzyl)amino] acetic acid       40.   3-[{4-(Biphenyl-2-ylamino]-6-[3-(2-methoxyphenyl)-ureido-           [1,3,5]triazin-2-yl}-(4-methoxybenzyl)amino] acetic acid       41.   [{4-(Biphenyl-2-ylamino)-6-[3-(2-methoxyphenyl) ureido]-           [1,3,5]triazin-2-yl}-(3,4-dimethoxybenzyl) amino] acetic acid       42.   [{4-(Benzyl-2-ylamino)-6-[3-(2-methoxyphenyl)ureido]-           [1,3,5]triazin-2-yl}-[4-fluorobenzyl]amino]acetic acid       43.   3-{4-[3-(2-Methoxyphenyl)ureido]-6-(naphthalen-2-yloxy)-           [1,3,5,]triazin-2-ylamino}propionic acid       44.   3-{(3-Methoxybenzyl)-[4-[3-(2-methoxyphenyl)ureido]-6-           (naphthalen-2-yloxy)-[1,3,5]triazin-2-yl]amino} propionic acid       45.   3-{(4-Methoxybenzyl)-[4-[3-(2-methoxyphenyl)ureido]-6-           [naphthalen-2-yloxy)-[1,3,5]triazin-2-yl]amino} propionic acid       46.   3-{(4-Fluorobenzyl)-[4-[3-(2-methoxyphenyl)-ureido]-6-           [naphthalen-2-yloxy)-[1,3,5]triazin-2-yl]amino} propionic acid       47.   3-{(4-Methylbenzyl)-[4-[3-(2-methoxyphenyl)ureido]-6-           [naphthalen-2-yloxy)-[1,3,5]triazin-yl]amino}propionic acid       48.   Tris salt of 3-[{4-(Biphenyl-2-ylamino)-6-[3-(2-           methoxyphenyl) ureido]-[1,3,5]triazin-2-yl}-(3-           methylbenzyl)amino] propionic acid       49.   Na salt of 3-[{4-(Biphenyl-2-ylamino)-6-[3-(2-methoxyphenyl)-           ureido]-[1,3,5]triazin-2-yl}-(3-methylbenzyl)amino] propionic           acid       50.   3-{Benzo[1,3]dioxo-5-ylmethyl-[4-[3-(2-methoxyphenyl)-           ureido]-6-(napthanalene-2-yloxy)-[1,3,5]triazin-2-           yl]amino}propionic acid       51.   3-{2-Methoxybenzyl)-[4-[3-(2-methoxyphenyl)ureido]-6-           (naphthalen-2-yloxy)-[1,3,5]triazin-2-yl]amino} propionic acid       52.   3-{(3,4-Dimethoxybenzyl)-[4-[3-(2-methoxyphenyl) ureido-6-           (naphthalen-2-yloxy)-[1,3,5]triazin-2-yl] amino}propionic acid       53.   3-{(3-Methylbenzyl)-[4-[3-2-(methoxyphenyl)ureido-6-           (naphthalen-2-yloxy)-[1,3,5]triazin-2-yl]amino} propionic acid       54.   3-{(2-Fluorobenzyl)-[4-[3-2-(methoxyphenyl)ureido-6-           (naphthalen-2-yloxy)-[1,3,5]triazin-2-yl]amino} propionic acid       55.   3-{(2-Chlorobenzyl)-[4-[3-2-methoxyphenyl)ureido-6-           (naphthelen-2-yloxy)-[1,3,5]triazin-2-yl]amino] propionic acid       56.   3-{(2,4-Dichlorobenzyl)-[4-[3-2-methoxyphenyl)ureido-6-           (naphthalen-2-yloxy)-[1,3,5]triazin-2-yl]amino} propionic acid       57.   3-{3,4-Dichlorobenzyl)-[4-[3-2-methoxyphenyl)ureido-6-           (naphthalen-2-yloxy)-[1,3,5,]triazin-2-yl]amino} propionic acid       58.   3-[(4-[3-(2-Methoxyphenyl)ureido]-6-chloro-[1,3,5] triazin-2-           yl)(3-methyl-benzyl)amino]propionic acid       59.   3-[{4-(2-methoxyphenyl)ureido)-6-chloro-[1,3,5]triazin-2-yl}-           (3,4-dichlorobenzyl)amino]propionic acid       60.   3-{(1H-Indol-3-yl)-2S([4-(2-methoxypheyl)ureido]-6-           (naphthalen-2-yloxy-[1,3,5]triazin-2-yl)amino]propionic acid       61.   2-{4-[3-(2-Methoxyphenyl)ureido]-6-(naphthalen-2-yloxy)-           [1,3,5]triazin-2-yl}1,2,3,4-tetrahydro-isoquinoldine-3-           carboxylic acid       62.   2-{(4-Fluorobenzyl)-[4-[3-(2-methoxyphenyl)ureido-6-           (naphthalen-2-yloxy)-[1,3,5]triazin-2-yl]amino}-acetic acid       63.   2-{(4-Methoxybenzyl)-[4-[3-(2-methoxyphenyl)ureido-6-           (naphthalen-2-yloxy)-[1,3,5]triazin-2-yl]amino}acetic acid       64.   2-{(4-Methylbenzyl)-[4-[3-(2-methoxyphenyl)ureido-6-           (naphthalen-2-yloxy)-[1,3,5]triazin-2-yl]amino}acetic acid       65.   3-{3,4-Difluorobenzyl)-[4-(3-(2-methoxyphenyl)ureido-6-           naphthalen-2-yloxy)-[1,3,5]triazin-2-yl]amino} propanoic acid       66.   3-{[4-[3-(2-Methoxyphenyl)ureido]-6-(naphthalen-2-yloxy)-           [1,3,5]triazin-2-yl]-thiophen-2-yl-methylamino} propionic acid       67.   3-{(4-Trifluoromethylbenzyl)-[4-[3-(2-methoxyphenyl) ureido-           6-(naphthalen-2-yloxy)-[1,3,5]triazin-2-yl] amino}propanoic           acid       68.   3-{[2-(1H-Indol-3-yl)ethyl]-[4-[3-(2-methoxyphenyl) ureido]-6-           (naphthalen-2-yloxy)-[1,3,5]triozin-2-yl] amino]propionic acid       69.   1-[4-[2-(4-Hydroxyphenyl)ethylamino]-6-(naphthalen-2-yloxy)-           [1,3,5]triazin-2-yl]-3-(2-methoxyphenyl)urea       70.   1-[4-2-(1H-Indol-3-yl)ethylamino]-6-(naphthalen-2-yloxy)-           [1,3,5]triazin-2-yl]-3-(2-methoxyphenyl)urea       71.   1-(2-Methoxyphenyl)-3-[(4-(3-methylbenzyl)amino)-6-           (naphthalen-2-yloxy)-[1,3,5]triazin-2-yl]urea       72.   1-[(4-(3,4-Dichlorobenzyl)amino)-6-(naphthalen-2-yloxy)-           [1,3,5]triazin-2-yl]-3-(2-methoxyphenyl)urea       73.   3-{4-(Biphenyl-2-ylamino)-6-[3-(2-methoxyphenyl) ureido]-           [1,3,5]triazin-2-yl}-(4-trifluoromethyl benzyl) amino]propionic           acid       74.   3-[{4-(Biphenyl-2-ylamino)-6-[3-(2-methoxyphenyl) ureido]-           [1,3,5]triazine-2-yl}-(thiophen-2-ylmethyl) amino]propionic           acid       75.   3-[{4-(Biphenyl-2-ylamino)-6-[3-(2-methoxyphenyl) ureido]-           [1,3,5]triazin-2-yl}-(3,4-diflourobenzyl)amino] propionic acid       76.   3-[{4-(Biphenyl-2-ylamino)-6-[3-(2-methoxyphenyl) ureido]-           [1,3,5]trazin-2-yl}-(2-((4-hydroxyphenyl)ethyl)           amino]propionic acid       77.   3-[{4-(Biphenyl-2-ylamino)-6-[3-(2-methoxyphenyl) ureido)-           [1,3,5]triazin-2-yl}-[2-(1H-indol-3-yl)ethyl] amino]propionic           acid       78.   4-[{4-(Biphenyl-2-ylamino)-6-[-(2-methoxyphenyl) ureido]-           [1,3,5]triazin-2-yl]amino}phenylacetic acid       79.   4-[{4-{3-(2-Methoxyphenyl)ureido}-6-(naphthalen-2-yloxy)-           [1,3,5]triazin-2-yl}amino]phenylacetic acid       80.   3-{(3,4-Dichlorobenzyl)-{4-isopropylamine-6-[3-(2-           methoxyphenyl)ureido}[1,3,5]triazin-2-yl}amino] propionic           acid       81.   3-((3,4-Dichlorobenzyl)-{4-(3-(2-methoxyphenyl) ureido)-6-           (morpholin-4-yl)[1,3,5]triazin-2-yl}amino} propionic acid       82.   3-[{4-(Biphenyl-4-ylamino)-6-[3-(2-methoxyphenyl) ureido]-           [1,3,5]triazin-2-yl}-(3-methylbenzyl)amino] propionic acid       83.   3-[{6-[3-(2-Methoxyphenyl)ureido]-4-oxo-4,5-dihydro-           [1,3,5]triazin-2-yl}-(3-methylbenzyl)amino]propionic acid       84.   3-[{4-[(Benzo[1,3]dioxo-5-ylmethyl)amino]-6-[3-(2-           methoxyphenyl)ureido]-[1,3,5]triazin-2-yl}-(3-           methylbenzyl)amino]-propionic acid       85.   3-[{4-[3-(2-Methoxyphenyl)ureido]-6-[(thiophen-2-yl-           methyl)amino]-[1,3,5]triazin-2-yl}-(3-methylbenzyl)           amino]propionic acid       86.   3-[{4-(2,3-Dihydro-indol-1-yl)-6-[3-(2-methoxyphenl)-ureido]-           [1,3,5]triazin-2-yl}-(3-methylbenzyl)amino] propionic acid       87.   3-[(4-[3-(2-Methoxyphenyl)ureido]-6-piperidin-1-yl-           [1,3,5]triazin-2-yl}-(3-methyl-benzyl)amino]propionic acid       88.   3-[{4-[3-(2-Methoxyphenyl)ureido]-6-pyrrolidin-1-yl-           [1,3,5]triazin-2-yl}-(3-methylbenzyl)amino]propionic acid       89.   3-[{4-[3-(2-Methoxyphenyl)ureido]-6-morpholin-4-yl-           [1,3,5]triazin-2-yl}-(3-methylbenzyl)amino]propionic acid       90.   3-[{4-Allylamino-6-[3-(2-methoxyphenyl)ureido]-[1,3,5]           triazin-2-yl}-(3-methylbenzyl)amino]propionic acid       91.   3-[{4-Methoxy-6-[3-(2-methoxyphenyl)ureido]-[1,3,5] triazin-           2-yl}-(3-methylbenzyl)amino]propionic acid       92.   3-[(3,4-Dichlorobenzyl)-{6-[3-(2-methoxyphenyl) ureido]-4-           oxo-4,5-dihydro-[1,3,5]triazin-2-yl}amino) propionic acid       93.   3-[{4-(Biphenyl-4-ylamino)-6-[3-(2-methoxyphenyl) ureido]-           [1,3,5]triazin-2-yl}-(3,4-dichlorobenzyl)amino] propionic acid       94.   3-{(3,4-Dichlorobenzyl)-[4-(3-[2-methoxyphenyl) ureido]-6-           (naphthalen-2-ylamino)-[1,3,5]triazin-2-yl}amino]-propionic           acid       95.   3-((3,4-Dichlorobenzyl)-{4-[4-(2-isopropoxyphenyl)-piperazin-           1-yl]-6-[3-(2-methoxyphenyl)ureido]-[1,3,5] triazin-2-           yl}amino)-propionic acid       96.   3-((3,4-Dichlorobenzyl)-{4-[4-(2-methoxyphenyl) piperazin-1-           yl]-6-[3-(2-methoxyphenyl)ureido]-[1,3,5] triazin-2-yl}amino]           propionic acid       97.   3-[{4-[{benzo[1,3]dioxo-5-ylmethyl)amino]-6-[3-(2-           methoxyphenyl)ureido]-[1,3,5]triazin-2-yl}-(3,4-dichloro-           benzyl)amino]propionic acid       98.   3-((3,4-Dichlorobenzyl)-{4-[4-[3-(2-methoxyphenyl) ureido]-6-           [(thiophen-2-ylmethyl)amino]-[1,3,5]triazin-2-           yl}amino]propionic acid       99.   3-[(3,4-Dichlorobenzyl)-{4-(2,3-dihydro-indol-1-yl)-6-[3-(2-           methoxyphenyl)ureido]-[1,3,5]triazin-2-yl}amino] propionic           acid       100.   3-((3,4-Dichlorobenzyl)-{4-[3-(2-methoxyphenyl) ureido]-6-           piperidin-1-yl-[1,3,5]triazin-2-yl}amino) propionic acid       101.   3-[(3,4-Dichlorobenzyl)-{4-[3-(2-methoxyphenyl) ureido]-6-           pyrrolidin-1-yl-[1,3,5]triazin-2-yl}amino) propionic acid       102.   3-{[{4-Allylamino-6-[3-(2-methoxyphenyl)ureido]-           [1,3,5]triazin-2-yl}-(3,4-dichlorobenzyl)-amino] propionic acid       103.   3-((3,4-Dichlorobenzyl)-{4-methoxy-6-[3-(2-methoxy phenyl)-           ureido]-[1,3,5]triazin-2-yl}amino]propionic acid       104.   3-{[4-[3-(2-Methoxyphenyl)ureido]-6-(naphthalen-2-yloxy)-           [1,3,5]triazin-2-yl]-methylamino}-propionic acid       105.   3-{(3-Fluorobenzyl)-[4-[3-(2-methoxyphenyl)ureido]-6-           (naphthalen-2-yloxy)-[1,3,5]triazin-2-yl]amino} propionic acid       106.   3-{(3-Chlorobenzyl)-[4-[3-(2-methoxyphenyl)ureido]-6-           (napthalen-2-yloxy)-[1,3,5]triazin-2-yl]amino}propionic acid       107.   3-{[4-[3-(2-Methoxyphenyl)ureido]-6-(napthalen-2-yloxy]-           [1,3,5]triazin-2-yl]-(2-trifluoromethylbenzyl) amino}propionic           acid       108.   3-{[4-[3-(2-Methoxyphenyl)ureido]-6-(naphthalen-2-yloxy)-           [1,3,5]triazin-2-yl]-(3-trifluoromethylbenzyl) aminopropionic           acid       109.   3-{(2,4-Bis-trifluoromethylbenzyl}-[4-[3-(2-methoxy           phenyl)ureido]-6-(naphthalen-2-yloxy)-[1,3,5] triazin-2-           yl]amino}propionic acid       110.   3-{(Biphenyl-4-ylmethyl)-[4-[3-(2-methoxyphenyl) ureido]-6-           (naphthalen-2-yloxy)-[1,3,5]triazin-2-yl] amino}propionic acid       111.   3-{[4-[3-(2-Methoxyphenyl)ureido]-6-(naphthalen-2-yloxy)-           [1,3,5]triazin-2-yl]-(naphthalen-1-ylmethyl) amino}-propionic           acid       112.   3-[{4-(Biphenyl-2-ylamino)-6-[3-(2-hydroxyphenyl) ureido]-           [1,3,5]triazin-2-yl}-(3-methylbenzyl)amino] propionic acid       113.   1-{4-[(2-Carboxyethyl)-(3,4-dichlorobenzyl)amino]-6-[3-(2-           methoxyphenyl)ureido]-[1,3,5]triazin-2-yl}-pyrrolidine-2S-           carboxylic acid       114.   3-[{4-(Biphenyl-2-ylamino)-6-[3-(2-methoxyphenyl) ureido]-           [1,3,5]triazin-2-yl}-(3-fluorobenzyl)amino] propionic acid       115.   3-[{4-(Biphenyl-2-ylamino)-6-[3-(2-methoxyphenyl) ureido]-           [1,3,5]triazin-2-yl}-(3-chlorobenzyl)amino] propionic acid       116.   3-[{4-(Biphenyl-2-ylamino)-6-[3-(2-methoxyphenyl)           ureido][1,3,5]triazin-2-yl]-(2-trifluoromethylbenzyl)           amino]propionic acid       117.   3-[{4-(Biphenyl-2-ylamino)-6-[3-(2-methoxyphenyl) ureido]-           [1,3,5]triazin-2-yl}-(3-trifluoromethylbenzyl) amino]propionic           acid       118.   3-[{4-(Biphenyl-2-ylamino)-6-[3-(2-methoxyphenyl) ureido]-           [1,3,5]triazin-2-yl}-(3,5-bis-trifluoromethyl           benzyl)amino]propionic acid       119.   3-({4-(Biphenyl-2-ylamino)-6-[3-(2-methoxyphenyl) ureido]-           [1,3,5]triazin-2-yl}-(biphenyl-4-ylmethyl) amino]propionic acid       120.   3-({4-(Biphenyl-2-ylamino)-6-[3-(2-methoxyphenyl) ureido]-           [1,3,5]triazine-2-yl}-(naphthalen-1-ylmethyl) amino]propionic           acid       121.   3-[{4-(Biphenyl-2-ylamino)-6-[3-(2-methoxyphenyl) ureido]-           [1,3,5]triazin-2-yl}-(2-pyridin-2-ylethyl)amino] propionic acid       122.   1-{4-(Biphenyl-2-ylamino}-6-[2-cyanoethyl)-(3-methylbenzyl)-           amino]-[1,3,5]triazin-2-yl}-3-(2-methoxyphenyl)urea       123.   3-((3,4-Dichlorobenzyl)-{4-(4-hydroxypiperidinyl)-6-[3-(2-           methoxyphenyl)ureido]-[1,3,5]triazin-2-yl}amino] propionic           acid       124.   3-[{4-(4-Hydroxypiperidinyl-1-yl)-6-[3-(2-methoxy           phenyl)ureido]-[1,3,5]triazin-2-yl}-(3-methylbenzyl)-           amino]propionic acid       125.   1-{4-(Biphenyl-2-ylamino)-6-[3-(2-methoxyphenyl) ureido-           [1,3,5]triazin-2-yl}-pyrrolidine-2S-carboxylic acid       126.   1-{4-(Biphenyl-2-ylamino)-6-[3-(2-methoxyphenyl) ureido]-           [1,3,5]triazin-2-yl}-thiazolidine-4-carboxylic acid       127.   1-{4-(Biphenyl-2-yl-amino)-6-[3-(2-methoxyphenyl) ureido]-           [1,3,5]triazin-2-yl}-piperidine-3-carboxylic acid       128.   1-{4-(Biphenyl-2-yl-amino)-6-[3-(2-methoxyphenyl) ureido]-           [1,3,5]triazin-2-yl}-piperidine-4-carboxylic acid       129.   2-{4-(Biphenyl-2-yl-amino)-6-[3-(2-methoxyphenyl) ureido]-           [1,3,5]triazin-2-yl}-1,2,3,4-tetrahydro-isoquinoline-3-           carboxylic acid       130.   1-{4-(Biphenyl-2-ylamino)-6-[3-(2-methoxyphenyl) ureido]-           [1,3,5]triazin-2-yl}piperidine-2-carboxylic acid.                  
 
         [0041]     In accordance with a further aspect, there are provided methods of preventing, inhibiting or suppressing cell adhesion in an animal, the term “animal” as defined herein includes human or mammal, comprising administering to said animal compounds as described above.  
         [0042]     In accordance with a still further aspect, there are provided methods for treating animals suffering from bronchial asthma, rheumatoid arthritis, multiple sclerosis, type 1 diabetes, psoriasis, allograft rejection and other inflammatory and/or autoimmune disorders, comprising administering to said animal compounds as described above.  
         [0043]     In accordance with still further aspect, there is provided a method for preventing, inhibiting or suppressing cell adhesion—associated inflammation, immune or autoimmune response in an animal by administering compounds as described above.  
         [0044]     In accordance with yet further aspect, there is provided a method for treating or preventing a disease selected from asthma, arthritis, psoriasis, transplantation rejection, multiple sclerosis, diabetes and inflammatory bowel disease in an animal, by administering compounds as described above.  
         [0045]     In accordance with a further aspect, there are provided processes for preparing the above compounds.  
         [0046]     In accordance with a still further aspect, there are provided pharmaceutical compositions for the above methods, comprising compounds as described above, and a pharmaceutically acceptable carrier.  
         [0047]     Salts of the above compounds can be obtained by the addition of various bases, including TRIS [tris(hydroxymethylaminomethane)] or alkaline hydroxides, carbonates or bicarbonates, etc, and are also included in the invention.  
         [0048]     The compounds of the present invention exhibit significant potency in terms of their activity, which was determined by in vitro VLA 4  mediated cell adhesion assay. 
     
    
     DETAILED DESCRIPTION OF THE INVENTION  
       [0049]     The compounds of the present invention may be readily prepared by methods familiar to a person of ordinary skill in the art. In addition, the compounds of the present invention may be prepared by following illustrative reaction sequences as depicted below:  
                         
                         
 
         [0050]     In Scheme I, 2-amino-4,6-dichloro-13,5-triazine of Formula II (prepared following the procedure described in  J. Chem. Soc.,  1960, 4525), was reacted with biphenylamine in a suitable solvent and in presence of a suitable base to give the compound of Formula IV which on reaction with the isocyanate of Formula V gave the compound of Formula VI (Formula I, when  
                         
 
 where 
        Y=Y 1  is hydrogen, alkyl, alkoxy, or halogen,  
                         
 
 which on reaction with substituted amino alkyl carboxylic acid in a suitable solvent gave the compound of Formula X (Formula I, when  
                         
 
 where Y=Y 1 =hydrogen alkyl, alkoxy, halogen,  
                         
 
 where X 1 =X 2 =are the same as defined above, X═O) Further dehydrogenation of Formula VI gave the compound of Formula VII while the compound of Formula VI (Formula I, when R 1 =H, R 4 =H) on reaction with sodium methoxide gave the compound of Formula VIII (Formula I, when  
                         
 
 where Y=Y 1 =hydrogen, alkyl, alkoxy, halogen,  
                         
       
 
         [0052]     The reaction of compound of Formula II with the compound of Formula III is generally carried out in an organic solvent for example, acetone, chloroform, dichloromethane, tetrahydrofuran or dioxane.  
         [0053]     The reaction of compound of Formula II with the compound of Formula III can be carried out in the presence of a base, for example potassium carbonate, sodium carbonate, triethylamine, diisopropylamine, pyridine or lutidine.  
         [0054]     The reaction of compound of Formula IV with the isocyanate of Formula V is generally carried out in a solvent, for example tetrahydrofuran or dioxane. The reaction can be carried out in presence of a base, for example sodium hydride.  
         [0055]     The reaction of compound of Formula VI with the acid compound of Formula IX is generally carried out in a solvent, for example tetrahydrofuran or dioxane to give the compound of Formula X.  
         [0056]     The hydrogenation of compound of Formula VI to give the compound of Formula VII is generally carried out in a solvent, for example tetrahydrofuran. The reaction compound of Formula VI with sodium methoxide to give the compound of Formula VIII is generally carried out in a solvent, for example tetrahydrofuran, methanol or ethanol.  
                         
                         
 
         [0057]     Particular compounds described herein may also be prepared by following the illustrative reaction sequence as depicted in Scheme II, where the 2-amino-4,6-dichloro-1,3,5-triazine of Formula II is reacted with β-naphthol of Formula XI in a suitable solvent and in presence of a suitable base to give the compound of Formula XII which on reaction with isocyanate of Formula V in a suitable solvent and in presence of a suitable base gave the compound of formula XIII (Formula I,  
                         
 
 where Y, Y 1  are the same as defined earlier,  
                         
 
 which on reaction with compound of Formula IX (where X 1 , X 2 =hydrogen, substd. Alkyl, substd. Aryl etc.) gave the compound of Formula XVII (Formula I, when  
                         
 
 where Y, Y 1 , X are the same as defined earlier, X═O). Further, the reaction of compound of Formula XIII with an alkali metal alkoxide such as sodium methoxide in presence of a base in a suitable solvent gave the compound of Formula XIV, while compound of Formula XIII on reaction with a dialkyl malonate such as dibutyl malonate gave the compound of Formula XV. 
 
         [0058]     The reaction of compound of Formula II with the compound of Formula XI is generally carried out in a solvent, for example acetone, chloroform, dichloromethane, tetrahydrofuran and dioxane. The reaction can be carried out in presence of a base, such as potassium carbonate, sodium carbonate, cesium carbonate, triethylamine, lutidine or pyridine.  
         [0059]     The reaction of compound of Formula XII with the isocyanate of Formula V is generally carried out in a solvent, for example tetrahydrofuran or dioxane, and in presence of a base, such as sodium hydride.  
         [0060]     The reaction of compound of Formula XIII with the compound of Formula IX is generally carried out in a solvent, for example tetrahydrofuran, dioxane, water or acetone.  
         [0061]     The reaction of compound of Formula XIII with alkoxide to give the compound of Formula XIV is generally carried out in a solvent, such as tetrahydrofuran, methanol, ethanol or butanol.  
         [0062]     The reaction of compound of Formula XIII with malonate is generally carried out in a solvent, for example tetrahydrofuran or dioxane. The reaction can be carried out in presence of a base, such as sodium hydride, sodium methoxide or tert-butoxide.  
                         
                         
 
         [0063]     In Scheme III, the amine of Formula II is reacted with a compound of Formula IX in a suitable solvent and in presence of a suitable base to give the compound of Formula XVII which on reaction with the isocyanate of Formula V gives the compound of Formula XVIII (Formula I when  
                         
 
 where Y, Y 1 , X 1  &amp; X 2  are the same as defined earlier, x=o) which on reaction with the compound of Formula XXI in a suitable solvent gives the compound of Formula XXII (Formula I, when  
                         
 
 where Y, Y 1 , Z, Z 1 , X 1  &amp; X 2  are the same as defined earlier, x=o). Further the compound of Formula XVIII on hydrolysis gives the compound of Formula XIX (Formula I, when  
                         
 
 where Y, Y 1 , X 1  &amp; X 2  are the same as defined earlier, x=o) which on reaction with an alkali metal alkoxide such as sodium methoxide gives the compound of Formula XX (Formula I, when  
                         
 
 wherein Y, Y 1 , X 1  and X 2  are the same as defined earlier, x=o). 
 
         [0064]     The reaction of compound of Formula II with the compound of Formula IX is generally carried out in a solvent, such as acetone, chloroform, dichloromethane, tetrahydrofuran or dioxane.  
         [0065]     The reaction of compound of Formula XVII with the isocyanate of Formula V can be carried out in presence of a base, for example sodium hydride.  
         [0066]     The reaction of compound of Formula XVIII with compound of Formula XXI can be carried out in presence of a base, for example triethylamine, potassium carbonate, sodium hydroxide or lutidine.  
         [0067]     The hydrolysis of compound of Formula XVIII to give the compound of Formula XIX is generally carried out in a solvent mixture, such as, for example tetrahydrofuran and t-butanol. The reaction can be carried out in presence of a strong base, for example, potassium t-butoxide.  
         [0068]     To give the compound of Formula XX the reaction of compound of Formula XVIII with alkoxide is generally carried out in a solvent, such as tetrahydrofuran, methanol or ethanol.  
         [0069]     The compound of general Formula I (X═S) can readily be prepared by following the illustrative procedures of any one of the above Schemes I-III by using corresponding isothiocyanate instead of isocyanates to yield the corresponding thioureas.  
         [0070]     The compound of general Formula I (X═N(CN)) can readily be prepared by following the illustrative procedures of any one of the above Schemes I-III by treating 1 eq. of an amine/aniline with diphenyl cyanocaboimidate, followed by the addition of second amine to yield the corresponding N-cyanoguanidine derivatives.  
         [0071]     The compound of general Formula I (X═CNO 2 ) can readily be prepared by following the illustrative procedures of any one of the above Schemes I-III by reacting 1 eq. of an amine/aniline with 1,1-bis(methylthio)-2-nitroethylene, further the monomethylthio derivative can be reacted with a second amine to obtain the nitroethylene derivative.  
         [0072]     The compound of the general Formula I (R 2 =lower alkyl(C 1 -C 6 ), cycloalkyl(C 3 -C 7 ), aryl) can readily be prepared by following the illustrative procedures of any one of the above Schemes I-III by reacting the compound of Formula II with acid chloride or coupling with an acid via methods well known in the prior art.  
         [0073]     Particular compounds capable of being produced, for example, by Schemes 1-3 are listed below in Table 1:  
                                             TABLE 1                               Formula I                                                      S. No.   R 1     X   R 2     R 3     R 4                                              1.   H   O                                                               Cl                2.   H   O                                                               Cl                3.   H   O                                                               Cl                4.   H   O                                                               Cl                5.   H   O                                                                                                          6.   H   O                                                               OMe                7.   H   O                                                               —NHCH 2 COOH                8.   H   O                                                               —NHCH 2 COOH                9.   H   O                                                               —NHCH 2 COOH                10.   H   O                                                               —NHCH 2 COOH                11.   H   O                                                               —NHCH 2 COOH                12.   H   O                                                               —NHCH 2 COOH                13.   H   O                                                                                                          14.   H   O                                                                                                          15.   H   O                                                                                                          16.   H   O                                                                                                          17.   H   O                                                               Cl                18.   H   O                                                               H                19.   H   O                                                               OMe                20.   H   O                                                               —NHCH 2 COOH                21.   H   O                                                                                                          22.   H   O                                                                                                          23.   H   O                                                                                                          24.   H   O                                                                                                          25.   H   O                                                                                                          26.   H   O                                                                                                          27.   H   O                                                                                                          28.   H   O                                                                                                          29.   H   O                                                                                                          30.   H   O                                                                                                          31.   H   O                                                                                                          32.   H   O                                                                                                          33.   H   O                                                                                                          34.   H   O                                                                                                          35.   H   O                                                                                                          36.   H   O                                                                                                          37.   H   O                                                                                                          38.   H   O                                                                                                          39.   H   O                                                                                                          40.   H   O                                                                                                          41.   H   O                                                                                                          42.   H   O                                                                                                          43.   H   O                                                                                                          44.   H   O                                                                                                          45.   H   O                                                                                                          46.   H   O                                                                                                          47.   H   O                                                                                                          48.   H   O                                                                                                          49.   H   O                                                                                                          50.   H   O                                                                                                          51.   H   O                                                                                                          52.   H   O                                                                                                          53.   H   O                                                                                                          54.   H   O                                                                                                          55.   H   O                                                                                                          56.   H   O                                                                                                          57.   H   O                                                                                                          58.   H   O                                 Cl                                              59.   H   O                                 Cl                                              60.   H   O                                                                                                          61.   H   O                                                                                                          62.   H   O                                                                                                          63.   H   O                                                                                                          64.   H   O                                                                                                          65.   H   O                                                                                                          66.   H   O                                                                                                          67.   H   O                                                                                                          68.   H   O                                                                                                          69.   H   O                                                                                                          70.   H   O                                                                                                          71.   H   O                                                                                                          72.   H   O                                                                                                          73.   H   O                                                                                                          74.   H   O                                                                                                          75.   H   O                                                                                                          76.   H   O                                                                                                          77.   H   O                                                                                                          78.   H   O                                                                                                          79.   H   O                                                                                                          80.   H   O                                                                                                          81.   H   O                                                                                                          82.   H   O                                                                                                          83.   H   O                                 OH                                              84.   H   O                                                                                                          85.   H   O                                                                                                          86.   H   O                                                                                                          87.   H   O                                                                                                          88.   H   O                                                                                                          89.   H   O                                                                                                          90.   H   O                                                                                                          91.   H   O                                 OMe                                              92.   H   O                                 OH                                              93.   H   O                                                                                                          94.   H   O                                                                                                          95.   H   O                                                                                                          96.   H   O                                                                                                          97.   H   O                                                                                                          98.   H   O                                                                                                          99.   H   O                                                                                                         100.   H   O                                                                                                         101.   H   O                                                                                                         102.   H   O                                                                                                         103.   H   O                                 OMe                                             104.   H   O                                                                                                         105.   H   O                                                                                                         106.   H   O                                                                                                         107.   H   O                                                                                                         108.   H   O                                                                                                         109.   H   O                                                                                                         110.   H   O                                                                                                         111.   H   O                                                                                                         112.   H   O                                                                                                         113.   H   O                                                                                                         114.   H   O                                                                                                         115   H   O                                                                                                         116   H   O                                                                                                         117   H   O                                                                                                         118   H   O                                                                                                         119.   H   O                                                                                                         120.   H   O                                                                                                         121.   H   O                                                                                                         122.   H   O                                                                                                         123.   H   O                                                                                                         124.   H   O                                                                                                         125.   H   O                                                                                                         126.   H   O                                                                                                         127.   H   O                                                                                                         128.   H   O                                                                                                         129.   H   O                                                                                                         130.   H   O                                                                                                         131.*                                 S                                                                                                         132.*   H   N(CN)                                                                                                         133.*   H   N(CN)                                                                                                         134.*   H   CH(NO 2 )                                                                                                         135.*   CH 3     O                                                                                                           *represents hypothetical examples             
 
         [0074]     The present invention also includes within its scope the enantiomers, diastereomers, N-oxides and pharmaceutically acceptable salts of these compound as well as metabolites having the same type of activity.  
         [0075]     In the above syntheses, where specific acids, bases, solvents, catalysts, oxidizing agents, reducing agents etc. are mentioned, at is to be understood that the other acids, bases, solvents, catalysts, oxidizing agents, reducing agents etc. may be used. Similarly, the reaction temperature and duration of the reaction may be adjusted as desired.  
       EXPERIMENTAL DETAILS  
       [0076]     Various solvents, such as acetone, methanol, ether, tetrahydrofuran, hexanes, and dichloromethane, were dried using various drying reagents according to procedures described in the literature. IR spectra were recorded as Nujol mulls or a thin neat film on a Perkin Elmer Paragon instrument. Nuclear Magnetic Resonance (NMR) data (H, C) were recorded on a Varian XL-300 MHz instrument using tetramethylsilane as an internal standard. Chemical Ionization Mass Spectra (CIMS) were obtained using a Finnigan MAT-4510 mass spectrometer equipped with an INCOS data system. Generally, a direct exposure probe and methane as the reagent gas (0.33 mm Hg, 120° C. source temperature) were used.  
       Example 1  
     Synthesis of 3-[{4-(Biphenyl-4-ylamino)-6-[3-(2-methoxyphenyl)ureido]-[1,3,5]triazin-2-yl}-(4-methylbenzyl)amino]propionic acid (Compound No. 32)  
     Step 1: Synthesis of N-Biphenyl-2-yl-6-chloro-[1,3,5]triazine-2,4-diamine  
       [0077]     To 2-amino-4,6-dichloro-[1,3,5]triazine (prepared as described in  J. Chem. Soc.,  1960, 4525) (5 g, 30 mmol) and potassium carbonate (4.2 g, 30 mmol) in acetone (50 ml) at 0° C. were added dropwise to a solution of 2-aminobiphenyl (5.15 g, 30 mmol) in acetone (50 ml). The reaction mixture was then stirred at room temperature for 2 hour and at 40-50° C. for 8 hour. The reaction mixture was poured over ice-water and extracted with ethyl acetate (2×200 ml). The combined organic extracts were washed with brine and dried over anhydrous Na 2 SO 4 . Evaporation of the solvent followed by purification of the residue over a silica gel column using 30% EtOAc-hexane as eluent furnished the title compound (2.6 g, 29%) as a white solid.  
         [0078]      1 HNMR (300 MHz, CDCl 3 ): δ 8.09 (1H, d, J=8.1 Hz) and 7.1-7.40 (8H, m), [aromatic], 6.98 (1H, bs, NH) and 5.37 (2H, bs, NH 2 ).  
         [0079]     LCMS (m/z): 298.0 (M+1, 55%).  
       Step 2: Synthesis of 1-[4-(Biphenyl-2-ylamino)-[1,3,5]triazin-2-yl-3-(2-methoxyphenyl)urea (Compound No. 17)  
       [0080]     To the compound obtained from Step 1 above (1 g, 3.3 mmol) in tetrahydrofuran at 0° C. was added sodium hydride (NaH) (158 mg, 50% dispersion in oil, 3.3 mmol) immediately followed by 2-methoxyphenyl isocyanate (0.5 g, 3.3 mmol), The reaction mixture was stirred at 0° C. for 30 min and at room temperature for 12 h. The reaction mixture was then poured into cold water (100 ml) and extracted with ethyl acetate (3×50 ml). The combined organic extracts were washed with water and brine and dried over anhydrous Na 2 SO 4 . The solvent was then evaporated to obtain a sticky mass that was treated with hexane (100 ml) and dichloromethane (10 ml). The precipitated white solid was filtered and dried under vacuum to obtain the title compound (1.4 g, 95%).  
         [0081]     m.p.: 239° C.  
         [0082]      1 HNMR (DMSO-d 6 , 300 MHz): δ 11.15 (bs), 10.81 (bs) 10.26 (bs) and 10.12 (bs) [NH×3] 6.80-8.20 [13H, m, aromatic] and 3.70 (3H, bs, OCH 3 ).  
         [0083]     LCMS (m/z): 447.1 (M+1, 45%)  
       Step 3: Synthesis of 3-[{4-(Biphenyl-2-ylamino)-6-[3-(2-methoxyphenyl) ureido]-[1,3,5]triazin-2-yl}-(4-methylbenzyl)amino]propionic acid (Compound No. 32)  
       [0084]     To the lithium salt of the 3-aminopropionic acid derivative (obtained by the hydrolysis of ethyl 3-(4-methylbenzyl)amino propionate (198 mg, 0.89 mmol) with LiOH in H 2 O (38 mg, 0.89 mmol) in THF (10 ml)) was added the chlorotriazine (400 mg, 0.89 mmol) as obtained from Step 2. The reaction mixture was refluxed for 6 hours, cooled and poured over ice cold water. It was then extracted with ethyl acetate (2×50 ml) and the combined organic extracts here washed with water and brine and dried with anhydrous sodium sulfate. Evaporation of the solvent followed by purification of the residue over a silica gel column using 50% EtOAc-Hexane as eluent furnished the title compound (280 mg, 52%)  
         [0085]     m.p.: 102° C.  
         [0086]      1 HNMR (DMSO-d 6 , 300 MHz): δ10.91 (1H, s, NH), 9.50 (1H, s, NH), 8.28, (1H, bs, NH), 7.91 (1H, s), 7.57 (d, J=6 Hz) and 7.740 (d, J=6 Hz), [1H], 6.85-7.40 (15H, m) [aromatic], 4.85 (s) &amp; 4.66 (s), [2H, NCH 2 Ar], 3.71 (1H, m), 3.52 (s) &amp; 3.49 (s) [3H, OCH 3 ], 2.47 (m, CH 2 CO 2 H) and 2.27 (s) &amp; 2.25 (s) [3H, ArCH 3 ].  
         [0087]     LCMS (m/z): 604.2 (M+1, 100%).  
         [0088]     The following compounds were prepared similarly:  
       1-{4-(Biphenyl-2-ylamino}-6-[2-cyanoethyl)-(3-methylbenzyl)-amino]-[1,3,5] triazin-2-yl}-3-(2-methoxyphenyl)urea (Compound No. 122)  
       [0089]     1-{4-(Biphenyl-2-ylamino}-6-[2-cyanoethyl)-(3-methylbenzyl)-amino]-[1,3,5] triazin-2-yl}-3-(2-methoxyphenyl)urea was prepared following the procedure of Example 1, by using 3-(3-methylbenzyl)amino propiononitrile in place of 3-(4-methylbenzyl)amino propionic acid in Step 3 of Example 1.  
         [0090]     m.p.: 114-116° C.  
         [0091]      1 HNMR (DMSO-d 6 , 300 MHz): δ 10.86 (1H, bs, NH), 9.57 (1H, bs, NH) 8.45 (1H, bs, NH), 6.90-7.90 (17H, m, aromatic), 4.56 (s) &amp; 4.69 (s) [2H, NCH 2 Ar], 3.82 (2H, t, NCH 2 ), 3.54 (3H, s, OCH 3 ), 2.78 (t) &amp; 2.75 (t, J=9 Hz) [2H, CH 2 CN] and 2.25 (s) &amp; 2.19 (s) [3H, Ar CH 3 ].  
         [0092]     LCMS (m/z): 585.4 (M+1, 100%).  
       {4-Biphenyl-2-ylamino)-6-[3-(2-methoxyphenyl)ureido]-[1,3,5]triazin-2-yl amino]acetic acid (Compound No. 20)  
       [0093]     {4-Biphenyl-2-ylamino)-6-[3-(2-methoxyphenyl)ureido]-[1,3,5]triazin-2-yl amino]acetic acid was prepared as described in Example 1 by using glycine instead of 3-(4-methylbenzyl)aminopropionic acid in Step 3 of Example 1.  
         [0094]     m.p.: 210° C.  
         [0095]      1 HNMR (DMSO-d 6 , 300 MHz): δ 11.82 (s) &amp; 10.99 (s) [1H, NH], 9.45 (s) &amp; 9.43 (s) [1H, NH], 8.32 (1H, bs, NH), 8.15 (d, J=7.2 Hz) &amp; 7.94 (d, J=7.5 Hz), [1H], 7.74 (1H, d, J=7.5 Hz), 7.20-7.50 (9H, m), 7.00 (3H, bs) and 6.89 (bs) &amp; 6.47 (bs) [1H] 
         [0096]     [aromatic], 4.02 (3H, s, OCH 3 ) and 3.72 (s) &amp; 3.64 (s) [N CH 2 ].  
         [0097]     LCMS (m/z): 486.2 (M+1, 35%).  
       2S-{4-(Biphenyl-2-ylamino)-6-[3-(2-methoxyphenyl)ureido]-[1,3,5]triazin-2-yl amino}-3-phenylpropionic acid (Compound No. 21)  
       [0098]     2S-{4-(Biphenyl-2-ylamino)-6-[3-(2-methoxyphenyl)ureido]-[1,3,5]triazin-2-yl amino}-3-phenylpropionic acid was prepared as described in Example 1, by using 2-amino-3-phenylpropionic acid (2-phenylalanine) in Step 3, Example 1, instead of 3-(4-methylbenzyl)amino propionic acid.  
         [0099]     m.p.: 140° C.  
         [0100]      1 HNMR (CDCl 3 , 300 MHz): δ 11.84 (1H, bs, NH), 9.93 (1H, bs, NH), 8.75 (1H, bs NH), 8.19 (1H, bs), 7.89 (1H, bs) and 6.72-7.40 (16H, m) [aromatic], 4.80 (1H, bs NCH), and 3.07-3.27 (5H, m, OCH 3  and CH 2 Ar).  
         [0101]     IR (ν max , KBr): 1685.3, 1479.4, 1341.9, 816.8, 747.1 cm −1 .  
         [0102]     LCMS (M/Z): 576.1 (M+1, 85%).  
       3-{4-Biphenyl-2-ylamino)-6-[3-(2-methoxyphenyl)ureido]-[1,3,5]triazin-2-yl amino}-3-phenylpropionic acid (Compound No. 22)  
       [0103]     3-{4-Biphenyl-2-ylamino)-6-[3-(2-methoxyphenyl)ureido]-[1,3,5]triazin-2-yl amino}-3-phenylpropionic acid was prepared by using 3-amino-3-phenylpropionic acid in Step 3, Example 1, instead of 3-(4-methylbenzyl)aminopropionic acid.  
         [0104]     m.p.: 151° C.  
         [0105]      1 HNMR (DMSO-D 6 , 300 MHz): δ 11.33 (bs) &amp; 10.95 (bs) [1H, NH], 9.45 (bs) &amp; 9.41 (bs) [1H, NH], 8.06 (d, J=9.3 Hz), 7.88 (d) [2H, 1NH], 7.72 (d) &amp; 7.69 (d, J=8.4 Hz) [1H] and 6.90-7.35 (18H) [aromatic], 5.43 (1H, bs) &amp; 5.15 (1H, bs) [NCH], 3.64 (s) &amp; 3.59 (s) [3H, OCH 3 ] and 2.50-2.88 (2H, m, CH 2 CO).  
         [0106]     IR (ν max , KBr): 1692.1, 1600.6, 1271.0, 748.3 cm −1 .  
         [0107]     LCMS (m/z) 576.2 (M+1, 100%).  
       3-{3-Benzo[1,3]dioxo-5-yl-{4-(biphenyl-2-ylamino)-6-[3-(2-methoxyphenyl) ureido]-[1,3,5]triazin-2-ylamino}propionic acid (Compound No. 23)  
       [0108]     3-{3-Benzo[1,3]dioxo-5-yl-{4-(biphenyl-2-ylamino)-6-[3-(2-methoxyphenyl) ureido]-[1,3,5]triazin-2-ylamino}propionic acid was prepared by using 3-amino-3-benzo[1,3]dioxo-5-ylpropionic acid in place of 3-(4-methylbenzyl)aminopropionic acid in Step 3, of Example 1.  
         [0109]      1 HNMR (DMSO-d 6 , 300 MHz): δ 11.36 (bs) &amp; 10.97 (bs) [1H, NH], 9.49 (s) &amp; 9.40 (s) [1H, NH], 7.6-7.97 (4H, m), 7.25-7.60 (8H, m), and 6.68-7.0 (6H, m) [aromatic and 2 NH], 5.95 (s) &amp; 5.92 (s) [OCH 2 O], 5.35 (m) &amp; 5.17 (bs) [1H, NCH], 3.61 (s) &amp; 3.60 (s) [3H, OCH 3 ] and 2.50-2.86 (2H, m, CH 2 CO).  
         [0110]     LCMS (m/z): 600.0 (M+1, 100%).  
       3-{3-Benzo[1,3]dioxo-5-yl-{4-(biphenyl-2-ylamino)-6-[3-(2-methoxyphenyl) ureido]-[1,3,5]triazin-2-ylamino}propionic acid (Compound No. 24)  
       [0111]     3-{3-Benzo[1,3]dioxo-5-yl-{4-(biphenyl-2-ylamino)-6-[3-(2-methoxyphenyl) ureido]-[1,3,5]triazin-2-ylamino}propionic acid was synthesized by using 2S-amino-4-methylpentanoic acid (L-Leucine) instead of 3-(4-methylbenzyl)aminopropionic acid in Step 3, Example 1.  
         [0112]     m.p.: 123° C.  
         [0113]      1 HNMR (DMSO-d 6 , 300 MHz): δ 12.64 (1H, bs, CO 2 H), 11.39 (bs) &amp; 10.75 (bs) [1H, NH], 9.44 (1H, s, NH), 8.10 (1H, bs, NH), 6.87-8.06 (1H, m, aromatic), 4.52 (t) &amp; 4.39 (bs) [1H, NCHCO], 3.64 (s) &amp; 3.56 (s) [3H, OCH 3 ], 2.18 (t) &amp; 1.89 (m) [1H CH], 1.23-1.66 (2H, m, CH 2 ) and 0.88 (d, J=6 Hz), 0.84 (d, J=6 Hz) &amp; 0.82 (d, J=5.7 Hz) [6H, CH 3 ×2].  
         [0114]     IR (ν max , KBr): δ 1718.0, 1694.3, 1599.3, 747.3  
         [0115]     LCMS (m/z): 548.0 (M+1, 80%).  
       2-[4-(Biphenyl-2-ylamino)-6-[3-(2-methoxyphenyl)ureido]-[1,3,5]triazin-2-ylamino}benzoic acid (Compound No. 25)  
       [0116]     2-[4-(Biphenyl-2-ylamino)-6-[3-(2-methoxyphenyl)ureido]-[1,3,5]triazin-2-ylamino}benzoic acid was prepared by using 2-aminobenzoic acid in place of 3-(4-methyl benzyl)aminopropionic acid in Step 3, Example 1.  
         [0117]     m.p.: 228° C.  
         [0118]      1 HNMR (DMSO-d 6 , 300 MHz): δ 11.0 (2H, bs, NH and CO 2 H), 9.81 (1H, s, NH), 9.04 (1H, bs, NH), 8.63 (1H, bs, NH), 7.97 (2H, d, J=7.2 Hz), 7.55 (1H, d, J=7.05 Hz), 7.31 (9H, bs) and 6.87-7.06 (4H, m) [aromatic] and 3.61 (3H, s, OCH 3 ).  
         [0119]     IR (ν max , KBr): 1680.4, 1545.6, 1254.7, 746.6 cm −1 .  
         [0120]     LCMS (m/z): 548.2 (M+1, 20%).  
       3-[{(Benzo[1,3]dioxo-5-yl)methyl-{4-biphenyl-2-ylamino}-6-[3-(2-methoxy phenyl)ureido]-[1,3,5]triazin-2-yl]}amino]propanoic acid (Compound No 26)  
       [0121]     3-[{(Benzo[1,3]dioxo-5-yl)methyl-{4-biphenyl-2-ylamino}-6-[3-(2-methoxy phenyl)ureido]-[1,3,5]triazin-2-yl]}amino]propanoic acid was prepared by using 3-benzo[1,3]dioxo-5-yl)methylamino propanoic acid in place of 3-(4-methylbenzyl)aminopropanoic acid in Step 3, Example 1.  
         [0122]     m.p.: 97° C.  
         [0123]      1 HNMR (DMSO-d 6 , 300 MHz): δ 10.88 (1H, NH), 9.53 (s) &amp; 9.46 (s) [1H, NH], 7.90 (1H, bs), 7.41 (bs) &amp; 7.62 (bs) [1NH], 7.00-7.50 (9H, m), 6.6-7.00 (6H, m) [aromatic], 5.95 (s) &amp; 5.94 (s) [2H, OCH 2 O], 4.75 (s) &amp; 4.57 (s) [2H, NCH 2 Ar], 3.67 (1H, t, J=6 Hz), 3.51 (s) &amp; 3.46 (s) [3H, OCH 3 ] and 2.42 (2H, m, CH 2 CO 2 H).  
         [0124]     IR (ν max , KBr): 1709.1, 1533.8, 1036.8, 746.9 cm −1 .  
         [0125]     LCMS (m/z): 634.3 (M+1, 100%).  
       3-[{4-Biphenyl-2-yl-amino}-6-[3-(2-methoxyphenyl)ureido][1,3,5]triazin-2-yl}-(3,4-dimethoxybenzyl)amino]propionic acid (Compound No. 27)  
       [0126]     3-[{4-Biphenyl-2-yl-amino}-6-[3-(2-methoxyphenyl)ureido][1,3,5]triazin-2-yl}-(3,4-dimethoxybenzyl)amino]propionic acid was prepared by using 3-(3,4-dimethoxybenzyl)aminopropionic acid instead of 3-(4-ethylbenzyl)aminopropionic acid in Step 3, Example 1.  
         [0127]     m.p.: 97° C.  
         [0128]      1 HNMR (DMSO-d 6 , 300 MHz): δ 12.20 (1H, bs, CO 2 H), 10.94 (1H, bs, NH), 9.53 (s) &amp; 9.50 (s) [1H, NH], 8.22 (1H, bs, NH), 7.93 (1H, s), 7.42 (1H, d, J=9 Hz) &amp; 7.34 (1H, d, J=9 Hz) 7.20-7.45 (8H, m) &amp; 6.73-7.00 (6H, m) [aromatic], 4.80 (s) &amp; 4.64 (s) [2H, NCH 2 Ar], 3.72 (s), 3.70 (s), 3.62 (s) 3.57 (s), 3.51 (s) and 3.40 (s) [11H, OCH 3 ×3 and NCH 2 ] and 2.47 (2H, m, CH 2 CO 2 H).  
         [0129]     IR (ν max , KBr): 1706.1, 1606.3, 1258.8, 749.0 cm −1 .  
         [0130]     LCMS (m/z) 650.2 (M+1, 100%).  
       3-[{4-Biphenyl-2-ylamino)-6-[3-(2-methoxyphenyl)ureido]-[1,3,5]triazin-2-yl}-(4-methoxybenzyl)amino]propionic acid (Compound No. 28)  
       [0131]     3-[{4-Biphenyl-2-ylamino)-6-[3-(2-methoxyphenyl)ureido]-[1,3,5]triazin-2-yl}-(4-methoxybenzyl)amino]propionic acid was synthesized by using 3-(4-methoxybenzyl)amino propionic acid in place of 3-(4-methylbenzyl)aminopropionic acid in Step 3, Example 1.  
         [0132]     m.p.: 95° C.  
         [0133]      1 HNMR (DMSO-d 6 , 300 MHz): δ 10.92 (1H, bs, NH), 9.52 (s) &amp; 9.49 (s) [1H, NH], 8.2 (1H, bs, NH), 7.94 (1H, t, J=6 Hz), 6.84-7.6 (16H, m) [aromatic], 4.82 (s) &amp; 4.63 (s) [2H, NCH 2 Ar] 3.72 (s), 3.71 (s), 3.53 (s) &amp; 3.48 (s) [8H, OCH 3 ×2 and NCH 2 ] and 2.46 (2H, m, CH 2 CO 2 H).  
         [0134]     IR (ν max , KBr): 1708.3, 1609.9, 1509.0, 747.9 cm −1 .  
         [0135]     LCMS (m/z): 620.3 (M+1, 100%).  
         [0136]     LCMS (m/z): 634.3 (M+1, 100%).  
       3-[{4-Biphenyl-2-yl-amino}-6-[3-(2-methoxyphenyl)ureido][1,3,5]triazin-2-yl}-(3,4-dimethoxybenzyl)amino]propionic acid (Compound No. 27)  
       [0137]     3-[{4-Biphenyl-2-yl-amino}-6-[3-(2-methoxyphenyl)ureido][1,3,5]triazin-2-yl}-(3,4-dimethoxybenzyl)amino]propionic acid was prepared by using 3-(3,4-dimethoxybenzyl)aminopropionic acid instead of 3-(4-ethylbenzyl)aminopropionic acid in Step 3, Example 1.  
         [0138]     m.p.: 97° C.  
         [0139]      1 HNMR (DMSO-d 6 , 300 MHz): δ 12.20 (1H, bs, CO 2 H), 10.94 (1H, bs, NH), 9.53 (s) &amp; 9.50 (s) [1H, NH], 8.22 (1H, bs, NH), 7.93 (1H, s), 7.42 (1H, d, J=9 Hz) &amp; 7.34 (1H, d, J=9 Hz) 7.20-7.45 (8H, m) &amp; 6.73-7.00 (6H, m) [aromatic], 4.80 (s) &amp; 4.64 (s) [2H, NCH 2 Ar], 3.72 (s), 3.70 (s), 3.62 (s) 3.57 (s), 3.51 (s) and 3.40 (s) [11H, OCH 3 ×3 and NCH 2 ] and 2.47 (2H, m, CH 2 CO 2 H).  
         [0140]     IR (ν max , KBr): 1706.1, 1606.3, 1258.8, 749.0 cm −1 .  
         [0141]     LCMS (m/z) 650.2 (M+1, 100%).  
       3-[{4-Biphenyl-2-ylamino)-6-[3-(2-methoxyphenyl)ureido]-[1,3,5]triazin-2-yl}-(4-methoxybenzyl)amino]propionic acid (Compound No. 28)  
       [0142]     3-[{4-Biphenyl-2-ylamino)-6-[3-(2-methoxyphenyl)ureido]-[1,3,5]triazin-2-yl}-(4-methoxybenzyl)amino]propionic acid was synthesized by using 3-(4-methoxybenzyl)amino propionic acid in place of 3-(4-methylbenzyl)aminopropionic acid in Step 3, Example 1.  
         [0143]     m.p.: 95° C.  
         [0144]      1 HNMR (DMSO-d 6 , 300 MHz): δ 10.92 (1H, bs, NH), 9.52 (s) &amp; 9.49 (s) [1H, NH], 8.2 (1H, bs, NH), 7.94 (1H, t, J=6 Hz), 6.84-7.6 (16H, m) [aromatic], 4.82 (s) &amp; 4.63 (s) [2H, NCH 2 Ar] 3.72 (s), 3.71 (s), 3.53 (s) &amp; 3.48 (s) [8H, OCH 3 ×2 and NCH 2 ] and 2.46 (2H, m, CH 2 CO 2 H).  
         [0145]     IR (ν max , KBr): 1708.3, 1609.9, 1509.0, 747.9 cm −1 .  
         [0146]     LCMS (m/z): 620.3 (M+1, 100%).  
       3-[{4-Biphenyl-2-ylamino)-6-[3-(2-methoxyphenyl)ureido]-[1,3,5]triazin-2-yl}-(3-methoxybenzyl)-amino]propionic acid (Compound No. 29)  
       [0147]     3-[{4-Biphenyl-2-ylamino)-6-[3-(2-methoxyphenyl)ureido]-[1,3,5]triazin-2-yl}-(3-methoxybenzyl)-amino]propionic acid was synthesized by using 3-(3-methoxybenzyl)aminopropionic acid in place of 3-(4-ethylbenzyl)aminopropionic acid in Step 3, Example 1.  
         [0148]     m.p.: 93° C.  
         [0149]      1 HNMR (DMSO-d 6 , 300 MHz): δ 12.05 (1H, bs, CO 2 H), 10.91 (1H, s, NH), 9.52 (1H, s, NH), 8.25 (1H, bs, NH), 7.90 (1H, s), 7.20-7.75 (10H, m) &amp; 6.75-7.20 (6H, m) [aromatic], 4.86 (s) &amp; 4.70 (s) [NCH 2 Ar], 3.76 (s), 3.75 (s) &amp; 3.65 (s) [8H, OCH 3 ×2 and NCH 2 ] and 2.50  
         [0150]     (DMSO+2H of CH 2 CO 2 H).  
         [0151]     IR (ν max , KBr): 1709.2, 1535.2, 1254.6, 746.8 cm −1 .  
         [0152]     LCMS (m/z): 620.1 (M+1, 100%).  
       3-[{4-Biphenyl-2-ylamino)-6-[3-(2-methoxyphenyl)-ureido]-[1,3,5]triazin-2-yl]-(2-methoxybenzyl)amino]propionic acid (Compound No. 30)  
       [0153]     3-[{4-Biphenyl-2-ylamino)-6-[3-(2-methoxyphenyl)-ureido]-[1,3,5]triazin-2-yl]-(2-methoxybenzyl)amino]propionic acid was prepared by using 3-(2-methoxybenzyl)aminopropionic acid in place of 3-(4-ethylbenzyl)aminopropionic acid in Step 3, Example 1.  
         [0154]     m.p.: 125-132° C.  
         [0155]      1 HNMR (TFA-d, 300 MHz): δ 7.80-8.60 (18H, m, aromatic and 1 NH), 5.87 (s) &amp; 5.77 (s) [2H, NCH 2 Ar], 4.75-5.05 (2H, m, NCH 2 ), 4.83 (s), 4.81 (s) &amp; 4.79 (s) [6H, OCH 3 ×2] and 3.58 (bs) &amp; 3.03 (bs) [2H, CH 2 CO 2 H].  
         [0156]     IR (ν max , KBr): 1708.5, 1579.1, 1505.9, 742.3 cm −1 .  
         [0157]     LCMS (m/z): 620.3 (M+1, 100%).  
       3-[{4-Biphenyl-2-ylamino)-6-[3-(2-methoxyphenyl)ureido]-[1,3,5]triazin-2-yl}-(3-methylbenzyl)amino]propionic acid (Compound No. 31)  
       [0158]     3-[{4-Biphenyl-2-ylamino)-6-[3-(2-methoxyphenyl)ureido]-[1,3,5]triazin-2-yl}-(3-methylbenzyl)amino]propionic acid was prepared by using 3-(3-methylbenzyl)aminopropionic acid instead of 3-(4-methylbenzyl)aminopropionic acid in Step 3, Example 1.  
         [0159]     m.p.: 205-212° C.  
         [0160]      1 HNMR (TFA-d, 300 MHz) δ 7.80-8.40 (18H, m, aromatic &amp; 1 NH), 5.82 (s) &amp; 5.72 (s) [2H, NCH 2 Ar], 4.75-5.25 (2H, m, NCH 2 ], 4.85 (s) &amp; 4.83 (s) [3H, OCH 3 ], 3.74 (bs) &amp; 3.56 (bs) [2H, CH 2 CO 2 H] and 3.26 (s) &amp; 3.23 (s) [3H, ArCH 3 ].  
         [0161]     LCMS (m/z): 604.2 (M+1, 100%).  
       3-[{4-Biphenyl-2-ylamino)-6-[3-(2-methoxyphenyl)ureido]-[1,3,5]triazin-2-yl}-(2-fluorobenzyl)amino]propionic acid (Compound No. 33)  
       [0162]     3-[{4-Biphenyl-2-ylamino)-6-[3-(2-methoxyphenyl)ureido]-[1,3,5]triazin-2-yl}-(2-fluorobenzyl)amino]propionic acid was prepared by using 3-(2-fluorobenzyl)aminopropionic acid in place of 3-(4-methylbenzyl)aminopropionic acid in Step 3, Example 1.  
         [0163]     m.p.: 208-215° C.  
         [0164]      1 HNMR (TFA-d, 300 MHz): δ 7.83-8.45 (20H, m, aromatic and 3 NH), 5.94 (s) &amp; 5.79 (s) [2H, NCH 2 Ar], 5.02 (1H, bs) &amp; 4.87 (4H, bs) [NCH 2  and OCH 3 ], 3.79 (bs) &amp; 3.61 (bs) [2H, CH 2 CO 2 H].  
         [0165]     LCMS (M/Z): 608.2 (m+1, 50%).  
       3-[{4-(Biphenyl-2-ylamino)-6-[3-(2-methoxyphenyl)ureido]-[1,3,5]triazin-2-yl}-(4-fluorobenzyl)amino]propionic acid (Compound No. 34)  
       [0166]     3-[{4-(Biphenyl-2-ylamino)-6-[3-(2-methoxyphenyl)ureido]-[1,3,5]triazin-2-yl}-(4-fluorobenzyl)amino]propionic acid was prepared by using 3-(4-fluorobenzyl)aminopropionic acid instead of 3-(4-methylbenzyl)aminopropionic acid in Step 3, Example 1.  
         [0167]     m.p.: 108° C.  
         [0168]      1 HNMR (DMSO-d 6 , 300 MHz): δ 10.90 (1H, bs, NH), 9.53 (s) &amp; 9.51 (s) [1H, NH], 6.89-8.30 (19H, m, 17H aromatic and 2 NH), 4.86 (s) &amp; 4.67 (s) [2H, NCH 2 Ar], 3.83 (2H, m, NCH 2 ) and 3.54 (s) &amp; 3.49 (s) [3H, OCH 3 ].  
         [0169]     IR (ν max , KBr): 1710.0, 1608.1, 1537.7, 746.7 cm −1 . dichlorobenzyl)aminopropionic acid instead of 3-(4-methylbenzyl)aminopropionic acid in Step 3, Example 1.  
         [0170]     m.p.: 185-192° C.  
         [0171]      1 HNMR (TFA-d, 300 MHz): δ 7.75-8.40 (19H, m, 16H aromatic and 3 NH), 5.96 (s) &amp; 5.81 (s) [2H, NCH 2 Ar], 4.7-5.1 (2H, m, NCH 2 ), 4.86 (3H, bs, OCH 3 ) and 3.78 (bs) &amp; 3.61 (bs) [2H, CH 2 CO 2 H].  
         [0172]     IR (ν max , KBr): 1719.6, 1660.6, 1262.9, 1020.8, 744.6 cm −1 .  
         [0173]     LCMS (m/z): 658.2 (M+1, 100%).  
       3-[{4-(Biphenyl-2-ylamino]-6-[3-(2-methoxyphenyl)ureido]-[1,3,5]triazin-2-yl}amino]propionic acid (Compound No. 38)  
       [0174]     3-[{4-(Biphenyl-2-ylamino]-6-[3-(2-methoxyphenyl)ureido]-[1,3,5]triazin-2-yl}amino]propionic acid was prepared by using 3-aminopropionic acid (β-alanine) instead of 3-(4-methyl benzyl)aminopropionic acid in Step 3, Example 1.  
         [0175]     m.p.: 196-205° C.  
         [0176]      1 HNMR (TFA-d, 300 MHz): δ 8.10-8.85 (13H, m, aromatic), 5.01 (5H, bs, OCH 3  and NCH 2 ) and 3.91 (2H, bs, CH 2 CO 2 H).  
         [0177]     IR (ν max , KBr): 1690.1, 1600.8, 1549.5, 1251.8, 747.4 cm −1 .  
         [0178]     LCMS (m/z): 500.2 (M+1, 100%).  
       [{4-(Biphenyl-2-ylamino)-6-[3-(2-methoxyphenyl)ureido]-[1,3,5]triazin-2-yl}-(4-methylbenzyl)amino]acetic acid (Compound No. 39)  
       [0179]     [{4-(Biphenyl-2-ylamino)-6-[3-(2-methoxyphenyl)ureido]-[1,3,5]triazin-2-yl}-(4-methylbenzyl)amino]acetic acid was prepared by using 3-(4-methylbenzyl)amino acetic acid instead of 3-(4-methylbenzyl)amino propionic acid in Step 3, Example 1.  
         [0180]     m.p.: 132-145° C.  
         [0181]      1 HNMR (DMSO-d 6 , 300 MHz): δ 10.90 (s) &amp; 10.84 (s) [1H, NH], 9.58 (s) &amp; 9.49 (s) [1H, NH], 8.32 (1H, bs, NH), 7.90 (1H, t), 7.66 (d) &amp; 7.40 (d) [1H, J=3 Hz], 6.85-7.35 [15H, m] [aromatic], 4.83 (s), 4.62 (s), 4.27 (s) &amp; 4.01 (s) [4H, NCH 2 ×2], 3.59 (3H, s, OCH 3 ) and 2.26 (s) &amp; 2.25 (s) [3H, Ar CH 3 ].  
         [0182]     IR (ν max , KBr): 1696.0, 1598.7, 1507.1, 1246.3, 748.0 cm −1 .  
         [0183]     LCMS (m/z): 590.0 (M+1, 100%).  
       [{4-(Biphenyl-2-ylamino]-6-[3-(2-methoxyphenyl)ureido]-[1,3,5]triazin-2-yl}-(4-methoxybenzyl)amino]acetic acid (Compound No. 40)  
       [0184]     [{4-(Biphenyl-2-ylamino]-6-[3-(2-methoxyphenyl)ureido]-[1,3,5]triazin-2-yl}-(4-methoxybenzyl)amino]acetic acid was prepared by using 2-(4-methoxybenzyl)aminoacetic acid instead of 3-(4-methylbenzyl)aminopropionic acid in Step 3, Example 1.  
         [0185]     m.p.: 147-149° C.  
         [0186]      1 HNMR (DMSO-d 6 , 300 MHz): δ 12.5 (1H, bs, CO 2 H), 10.92 (s) &amp; 10.85 (s) [1H, NH], 9.61 (s) &amp; 9.50 (s) [1H, NH], 8.3 (1H, bs, NH), 7.92 (1H, t), 7.70 (d) &amp; 7.59 (d) [1H] and 6.80-7.50 (15H, m) [aromatic], 4.80 (s) &amp; 4.58 (s), 4.27 (s) &amp; 4.01 (s) [4H, NCH 2 ×2] and 3.74 (s), 3.71 (s), 3.59 (s) &amp; 3.49 (s) [6H, OCH 3 ×2].  
         [0187]     IR (ν max , KBr): 1692.9, 1597.6, 1508.6, 1246.6, 748.2 cm −1 .  
         [0188]     LCMS (m/z): 606.3 (M+1, 20%).  
       [{4-(Biphenyl-2-ylamino)-6-[3-(2-methoxyphenyl)ureido]-[1,3,5]triazin-2-yl}-(3,4-dimethoxybenzyl)amino]acetic acid (Compound No. 41)  
       [0189]     [{4-(Biphenyl-2-ylamino)-6-[3-(2-methoxyphenyl)ureido]-[1,3,5]triazin-2-yl}-(3,4-dimethoxybenzyl)amino]acetic acid was prepared by using 2-(3,4-dimethoxybenzyl)aminoacetic acid in place of 3-(4-methylbenzyl)aminopropionic acid in Step 3, Example 1.  
         [0190]     m.p.: 115-120° C.  
         [0191]      1 HNMR (DMSO-d 6 , 300 MHz): δ 12.5 (1H, bs, CO 2 H), 10.92 (s) &amp;10.85 (s) [1H, NH], 9.61 (s) &amp; 9.50 (s) [1H, NH], 8.3 (1H, bs, NH), 7.92 (1H, t), 7.70 (d), 7.59 (d) [1H] and 6.80-7.50 (15H, m) [aromatic], 4.80 (s), 4.58 (s), 4.27 (s) &amp; 4.01 (s) [4H, NCH 2 ×2] and 3.74 (s), 3.71 (s), 3.59 (s) &amp; 3.49 (s) [6H, OCH 3 ×2].  
         [0192]     IR (ν max , KBr): 1692.9, 1597.6, 1508.6, 1246.6, 748.2 cm −1 .  
         [0193]     LCMS (m/z): 606.3 (M+1, 20%).  
       [{4-(Biphenyl-2-ylamino)-6-[3-(2-methoxyphenyl)ureido]-[1,3,5]triazin-2-yl}-[4-fluorobenzyl]amino]acetic acid (Compound No. 42)  
       [0194]     [{4-(Biphenyl-2-ylamino)-6-[3-(2-methoxyphenyl)ureido]-[1,3,5]triazin-2-yl}-[4-fluorobenzyl]amino]acetic acid was prepared by using 3-(4-fluorobenzyl)aminoacetic acid instead of 3-(4-methylbenzyl)aminopropionic acid in Step 3, Example 1.  
         [0195]     m.p.: 120-125° C.  
         [0196]      1 HNMR (DMSO-d 6 , 300 MHz): δ 10.87 (s) &amp; 10.81 (s) [1H, NH], 9.60 (s) &amp; 9.49 (s) [1H, NH], 8.3 [1H, bs, NH], 7.89 (1H, t), 7.64 (d) &amp; 7.53 (d) [1H] and 6.80-7.40 (15H, m) [aromatic], 4.83 (s), 4.60 (s), 4.31 (s) &amp; 4.04 (s) [4H, NCH 2 ×2] and 3.59 (s) &amp; 3.44 (s) [3H, OCH 3 ].  
         [0197]     IR (ν max , KBr): 1695.9, 1599.2, 1535.2, 1221.3, 747.7 cm −1 .  
         [0198]     LCMS (m/z): 594.1 (M+1, 100%).  
       3-[{4-(Biphenyl-2-ylamino]-6-[3-(2-methoxyphenyl)ureido]-[1,3,5]triazin-2-yl}-(4-trifluoromethyl benzyl)amino]propionic acid (Compound No. 73)  
       [0199]     3-[{4-(Biphenyl-2-ylamino]-6-[3-(2-methoxyphenyl)ureido]-[1,3,5]triazin-2-yl}-(4-trifluoromethyl benzyl)amino]propionic acid was prepared by using 3-(4-trifluoromethylbenzyl)aminopropionic acid instead of 3-(4-methylbenzyl)aminopropionic acid in Step 3, Example 1.  
         [0200]     m.p.: 125-128° C.  
         [0201]      1 HNMR (TFA-d, 300 MHz): δ 8.40-9.00 (17H, m, aromatic), 6.33 (s) &amp; 6.18 (s) [2H, NCH 2 Ar], 5.40 (m) &amp; 5.24 (m) [2H, NCH 2 ], 5.30 (s) &amp; 5.18 (s) [3H, OCH 3 ] and 4.22 (t) &amp; 4.03 (t) [2H, CH 2 CO 2 H].  
         [0202]     IR (ν max , KBr): 1707.9, 1533.2, 1325.5, 1123.5, 748.0 cm −1 .  
         [0203]     LCMS (m/z): 658.3 (M+1, 100%).  
       3-[{4-(Biphenyl-2-ylamino)-6-[3-(2-methoxyphenyl)ureido]-[1,3,5]triazin-2-yl}-(thiophen-2-ylmethyl)amino]propionic acid (Compound No. 74)  
       [0204]     3-[{4-(Biphenyl-2-ylamino)-6-[3-(2-methoxyphenyl)ureido]-[1,3,5]triazin-2-yl}-(thiophen-2-ylmethyl)amino]propionic acid was prepared by using 3-(thiophen-2-ylmethyl)aminopropionic acid instead of 3-(4-methylbenzyl)aminopropionic acid in Step 3, Example 1.  
         [0205]     m.p.: 115-120° C.  
         [0206]      1 HNMR (TFA-d, 300 MHz): δ 8.30-9.04 (19H, m, aromatic and 3NH), 6.43 (s) &amp; 6.36 (s) [2H, NCH 2 Ar], 5.44 (m), 5.37 (m), 5.34 (s) &amp; 5.30 (s) [5H, NCH 2  and OCH 3 ] and 4.19 (bs) &amp; 4.05 (bs) [2H, CH 2 CO 2 H].  
         [0207]     IR (ν max , KBr): 1707.2, 1599.0, 1531.6, 1252.1, 748.1 cm −1 .  
         [0208]     LCMS (m/z): 596.2 (M+1, 100%).  
       3-[{4-(Biphenyl-2-ylamino)-6-[3-(2-methoxyphenyl)ureido]-[1,3,5]triazin-2-yl}-(3,4-difluorobenzyl)amino]propionic acid (Compound No. 75)  
       [0209]     3-[{4-(Biphenyl-2-ylamino)-6-[3-(2-methoxyphenyl)ureido]-[1,3,5]triazin-2-yl}-(3,4-difluorobenzyl)amino]propionic acid was prepared by using 3-(3,4-difluorobenzyl)aminopropionic acid instead of 3-(4-methylbenzyl)aminopropionic acid in Step 3, Example 1.  
         [0210]     m.p.: 115-120° C.  
         [0211]      1 HNMR (TFA-d, 300 MHz): δ 8.40-9.00 (19H, m, aromatic and 3NH), 6.27 (s) &amp; 6.12 (s) [2H, NCH 2 Ar], 5.45 (m), 5.34 (s) &amp; 5.20 (m) [5H, NCH 2  and OCH 3 ] and 4.23 (t) &amp; 4.02 (t) [2H, CH 2 CO 2 H].  
         [0212]     IR (ν max , KBr): 1707.7, 1598.7, 1532.8, 1279.5, 748.2 cm −1 .  
         [0213]     LCMS (m/z): 626.2 (M+1, 100%).  
       3-[{4-(Biphenyl-2-ylamino)-6-[3-(2-methoxyphenyl)ureido]-[1,3,5]triazin-2-yl}-(2-((4-hydroxyphenyl)ethyl)amino]propionic acid (Compound No. 76)  
       [0214]     3-[{4-(Biphenyl-2-ylamino)-6-[3-(2-methoxyphenyl)ureido]-[1,3,5]triazin-2-yl}-(2-((4-hydroxyphenyl)ethyl)amino]propionic acid was prepared by reaction 3-(2-(4-hydroxyphenyl)ethyl]aminopropionic acid instead of 3-(4-methylbenzyl)aminopropionic acid in Step 3, Example 1.  
         [0215]     m.p.: 109-115° C.  
         [0216]      1 HNMR (TFA-d, 300 MHz): δ 8.25-9.04 (17H, m, aromatic), 5.55 (s), 5.40 (bs), 5.26 (bs) &amp; 4.70 (s) [7H, NCH 2 ×2 and OCH 3 ], 4.56 (bs), 4.30 (m), 4.14 (m) &amp; 3.90 (m) [4H, CH 2  Ar and CH 2 CO 2 H].  
         [0217]     IR (ν max , KBr): 1695.7, 1602.2, 1533.9, 1255.3, 749.5 cm −1 .  
         [0218]     LCMS (m/z): 620.3 (M+1, 100%).  
       3-[{4-(Biphenyl-2-ylamino)-6-[3-(2-methoxyphenyl)ureido]-[1,3,5]triazin-2-yl}-[2-(1H-indol-3yl)ethyl]amino]propionic acid (Compound No. 77)  
       [0219]     3-[{4-(Biphenyl-2-ylamino)-6-[3-(2-methoxyphenyl)ureido]-[1,3,5]triazin-2-yl}-[2-(1H-indol-3yl)ethyl]amino]propionic acid was prepared by using 3-[2-(1H-indol-3-yl)ethyl]aminopropionic acid instead of 3-(4-methylbenzyl)aminopropionic acid in Step 3, Example 1.  
         [0220]     m.p.: 115-120° C.  
         [0221]      1 HNMR (TFA-d, 300 MHz): δ 8.35-8.85 (18H, m, aromatic), 5.41 (s), 5.31 (bs), 5.27 (bs), 4.99 (s), [7H, NCH 2 ×2 and OCH 3 ], 4.44 (bs), 4.24 (bs), 4.15 (bs) &amp; 4.05 bs) [4H, CH 2  Ar and CH 2 CO 2 H] 
         [0222]     IR (ν max , KBr): 1699.3, 1530.4, 1252.6, 745.4 cm −1 .  
         [0223]     LCMS (m/z): 643.3 (M+1, 100%).  
       4-[{4-(Biphenyl-2-ylamino)-6-[-(2-methoxyphenyl)ureido]-[1,3,5]triazin-2-yl}amino]phenylacetic acid (Compound No. 78)  
       [0224]     4-[{4-(Biphenyl-2-ylamino)-6-[-(2-methoxyphenyl)ureido]-[1,3,5]triazin-2-yl}amino]phenylacetic acid was prepared by using 4-aminophenylacetic acid instead of 3-(4-methyl benzyl)aminopropionic acid in Step 3, Example 1.  
         [0225]     m.p.: &gt;300° C.  
         [0226]      1 HNMR (TFA-d, 300 MHz): δ 8.24-8.90 (17H, m, aromatic) and 5.30 (s), 5.15 (s) &amp; 5.08 (bs) [5H, OCH 3  and CH 2 CO 2 H].  
         [0227]     LCMS (m/z): 562.0 (M+1, 100%).  
       3-[{4-(Biphenyl-4-ylamino)-6-[3-(2-methoxyphenyl)ureido]-[1,3,5]triazin-2-yl}-(3-methylbenzyl)amino]propionic acid (Compound No. 82)  
       [0228]     3-[{4-(Biphenyl-4-ylamino)-6-[3-(2-methoxyphenyl)ureido]-[1,3,5]triazin-2-yl}-(3-methylbenzyl)amino]propionic acid was prepared by using 4-aminobiphenyl instead of 2-aminobiphenyl as in Step 1, Example 1 and 3-(3-methylbenzyl)aminopropionic acid instead of 3-(4-methylbenzyl)aminopropionic acid in Step 3, Example 1.  
         [0229]      1 HNMR (DMSO-d 6 , 300 MHz): δ 11.3 (bs) &amp; 10.89 (bs) [1H, NH], 9.70 (bs) &amp; 9.58 (bs), [1H, NH), 6.90-7.94 (17H, m, aromatic), 4.95 (bs) &amp; 4.90 (m) [2H, NCH 2 Ar], 2.66 (m, CH 2 CO 2 H) and 2.29 (s) &amp; 2.19 (s), [3H, ArCH 3 ].  
         [0230]     IR (ν max , KBr): 1693.1, 1588.8, 1422.0, 1238.4, 761.7 cm −1 .  
         [0231]     LCMS (m/z): 604.2 (M+1, 45%).  
       3-[{4-(Biphenyl-4-ylamino)-6-[3-(2-methoxyphenyl)ureido]-[1,3,5]triazin-2-yl}-(3,4-dichlorobenzyl)amino]propionic acid (Compound No. 93)  
       [0232]     3-[{4-(Biphenyl-4-ylamino)-6-[3-(2-methoxyphenyl)ureido]-[1,3,5]triazin-2-yl}-(3,4-dichlorobenzyl)amino]propionic acid was prepared by using 4-aminobiphenyl in place of 2-aminobiphenyl as in Step 1, Example 1 and 3-(3,4-dichlorobenzyl)aminopropionic acid instead of 3-(4-methylbenzyl)aminopropionic acid in Step 3, Example 1.  
         [0233]     m.p.: 215-220° C.  
         [0234]      1 HNMR (DMSO-d 6 , 300 MHz): δ 10.86 (1H, bs, NH), 9.76 (s) &amp; 9.63 (s) [1H, NH], 7.65-8.00 (2H, m), 7.30-7.60 (12H, m) and 6.9-7.05 (2H, m) [aromatic], 4.95 (s) &amp; 4.90 (s) [2H, NCH 2  Ar] 3.70-3.90 (5H, m, OCH 3  and NH 2 ) and 2.67 (1H, t, J=6 Hz) [CH 2 CO 2 H].  
         [0235]     IR (ν max , KBr): 1691.4, 1538.7, 1422.1, 761.7 cm −1 .  
         [0236]     LCMS (m/z): 658.2 (M+1, 100%).  
       3-[{4-(Biphenyl-2-ylamino)-6-[3-(2-hydroxyphenyl)ureido]-[1,3,5]triazin-2-yl}-(3-methylbenzyl)amino]propionic acid (Compound No. 112)  
       [0237]     To Compound No. 31 (200 mg, 0.33 mmol) in dry dichloromethane (DCM) (10 ml) at −80° C. was added boron tribromide solution in dichloromethane (1.65 ml of 1M solution, 1.65 mmol) and stirred for 2 hours. It was warmed to room temperature, stirred overnight and poured into water (50 ml). The aqueous layer was extracted with dichloromethane (2×25 ml) and the combined organic extracts were washed with brine and dried (anhydrous sodium sulfate). Evaporation of the solvent followed by purification of the residue over a silica gel column using 1-5% MeOH-DCM afforded the title compound (95 mg, 49%) as a white solid.  
         [0238]     m.p.: 122-124° C.  
         [0239]      1 HNMR (TFA-d, 300 MHz): δ 7.5-8.10 (17H, m, aromatic), 5.58 (s) &amp; 5.47 (s) [2H, NCH 2  Ar], 4.5-4.75 (2H, m, NCH 2 ), 3.45 (bs) &amp; 3.31 (bs) [2H, CH 2 CO 2 H].  
         [0240]     IR (ν max , KBr): 1687.5, 1533.1, 1284.1, 748.8 cm −1 .  
         [0241]     LCMS (m/z): 590.1 (M+1, 95%).  
       3-[{4-(Biphenyl-2-ylamino)-6-[3-(2-methoxyphenyl)ureido]-[1,3,5]triazin-2-yl}-(3-fluorobenzyl)amino]propionic acid (Compound No. 114)  
       [0242]     3-[{4-(Biphenyl-2-ylamino)-6-[3-(2-methoxyphenyl)ureido]-[1,3,5]triazin-2-yl}-(3-fluorobenzyl)amino]propionic acid was prepared by using 3-(3-fluorobenzyl)aminopropionic acid instead of 3-(4-methylbenzyl)aminopropionic acid in Step 3, Example 1.  
         [0243]     m.p.: 115-128° C.  
         [0244]      1 HNMR (TFA-d, 300 MHz): δ 7.45-8.40 (17H, m, aromatic), 5.61 (s) &amp; 5.49 (s) [2H, NCH 2 Ar], 4.76 (bs) &amp; 4.58 (bs) [2H, NCH 2 ], 4.62 (s) &amp; 4.60 (s) [3H, OCH 3 ] and 3.53 (bs) &amp; 3.37 (bs), [2H, CH 2 CO 2 H].  
         [0245]     IR (ν max , KBr): 1701.1, 1600.1, 1250.2, 747.2 cm −1 .  
         [0246]     LCMS (m/z): 608.5 (M+1, 100%).  
       3-[{4-(Biphenyl-2-ylamino)-6-[3-(2-methoxyphenyl)ureido]-[1,3,5]triazin-2-yl}-(3-chlorobenzyl)amino]propionic acid (Compound No. 115)  
       [0247]     3-[{4-(Biphenyl-2-ylamino)-6-[3-(2-methoxyphenyl)ureido]-[1,3,5]triazin-2-yl}-(3-chlorobenzyl)amino]propionic acid was prepared by 3-(3-chlorobenzyl)aminopropionic acid instead of 3-(4-methyl benzyl)aminopropionic acid in Step 3, Example 1.  
         [0248]     m.p.: 212-214° C.  
         [0249]      1 HNMR (TFA-d, 300 MHz): δ 7.70-8.30 (14H, m, aromatic), 5.59 (s) &amp; 5.46 (s) [2H, NCH 2 Ar], 4.75 (bs) &amp; 4.52 (bs) [2H, NCH], 4.61 (s) &amp; 4.59 (s) [3H, OCH 3 ] and 3.52 (bs) &amp; 3.36 (bs) [2H, CH 2 CO 2 H].  
         [0250]     IR (ν max , KBr): 1708.7, 1535.2, 1421.2, 747.1 cm −1 .  
         [0251]     LCMS (m/z): 624.2 (M+1, 30%).  
       3-[{4-(Biphenyl-2-ylamino)-6-[3-(2-methoxyphenyl)ureido][1,3,5]triazin-2-yl}-(2-trifluoromethylbenzyl)amino]propionic acid (Compound No. 116)  
       [0252]     3-[{4-(Biphenyl-2-ylamino)-6-[3-(2-methoxyphenyl)ureido][1,3,5]triazin-2-yl}-(2-trifluoromethylbenzyl)amino]propionic acid was prepared by using 3-(2-trifluoromethylbenzyl)aminopropionic acid instead of 3-(4-methylbenzyl)aminopropionic acid in Step 3, Example 1.  
         [0253]     m.p.: 216-219° C.  
         [0254]      1 HNMR (TFA-d, 300 MHz): δ 7.5-8.41 (17H, m, aromatic), 5.80 (s) &amp; 5.73 (s) [2H, NCH 2 Ar], 4.70 (bs) &amp; 4.47 (bs) [2H, NCH 2 ], 4.57 (s) &amp; 4.51 (s) [3H, OCH 3 ] and 3.50 (t), 3.33 (t) [2H, CH 2 CO 2 H].  
         [0255]     IR (ν max , KBr): 1712.6, 1609.8, 1313.2, 1119.4, 747.1 cm −1 .  
         [0256]     LCMS (m/z): 658.1 (M+1, 100%).  
       3-[{4-(Biphenyl-2-ylamino)-6-[3-(2-methoxyphenyl)ureido]-[1,3,5]triazin-2-yl}-(3-trifluoromethylbenzyl)amino]propionic acid (Compound No. 117)  
       [0257]     3-[{4-(Biphenyl-2-ylamino)-6-[3-(2-methoxyphenyl)ureido]-[1,3,5]triazin-2-yl}-(3-trifluoromethylbenzyl)amino]propionic acid was prepared by using 3-(3-trifluoromethylbenzyl)aminopropionic acid instead of 3-(4-methylbenzyl)aminopropionic acid in Step 3, Example 1.  
         [0258]     m.p.: 114-126° C.  
         [0259]      1 HNMR (TFA-d, 300 MHz): δ 7.70-8.30 (17H, m, aromatic), 5.64 (s) &amp; 5.52 (s) [2H, NCH 2 Ar], 4.73 (t, J=6 Hz) &amp; 4.49 (t) [2H, NCH 2 ], 4.57 (s) &amp; 4.55 (s) [3H, OCH 3 ] and 3.49 (t) &amp; 3.33 (t) [2H, CH 2 CO 2 H] 
         [0260]     IR (ν max,  KBr): 1710.4, 1536.1, 1329.2, 1123.5, 747.5 cm −1 .  
         [0261]     LCMS (m/z): 658.1 (M+1, 100%).  
       3-[{4-(Biphenyl-2-ylamino)-6-[3-(2-methoxyphenyl)ureido]-[1,3,5]triazin-2-yl}-(3,5-bis-trifluoromethylbenzyl)amino]propionic acid (Compound No. 118)  
       [0262]     3-[{4-(Biphenyl-2-ylamino)-6-[3-(2-methoxyphenyl)ureido]-[1,3,5]triazin-2-yl}-(3,5-bis-trifluoromethylbenzyl)amino]propionic acid was prepared by using 3-(3,5-bis trifluoromethylbenzyl)aminopropionic acid instead of 3-(4-methylbenzyl)aminopropionic acid in Step 3, Example 1.  
         [0263]     m.p.: 132-135° C.  
         [0264]      1 HNMR (TFA-d, 300 MHz): δ 7.05-8.00 (16H, m, aromatic), 5.11 (s) &amp; 4.98 (s) [2H, NCH 2 Ar], 4.13 (t, J=9 Hz) &amp; 3.88 (t) [2H, NCH 2 ], 3.96 (s) &amp; 3.94 (s), [3H, OCH 3 ] and 2.93 (t) &amp; 2.74 (t) [2H, CH 2 CO 2 H].  
         [0265]     IR (ν max , KBr): 1709.8, 1537.5, 1279.5, 1173.6, 1133.9 cm −1 .  
         [0266]     LCMS (m/z): 726.4 (M+1, 75%).  
       3-[{4-(Biphenyl-2-ylamino)-6-[3-(2-methoxyphenyl)ureido]-[1,3,5]triazin-2-yl}-(biphenyl-4-ylmethyl)amino]propionic acid (Compound No. 119)  
       [0267]     3-[{4-(Biphenyl-2-ylamino)-6-[3-(2-methoxyphenyl)ureido]-[1,3,5]triazin-2-yl}-(biphenyl-4-ylmethyl)amino]propionic acid was prepared by using 3-(biphenyl-4-ylmethyl)aminopropionic acid instead of 3-(4-methylbenzyl)aminopropionic acid in Step 3, Example 1.  
         [0268]     m.p.: 144-147° C.  
         [0269]      1 HNMR (TFA-d, 300 MHz): δ 7.05-7.70 (22H, m, aromatic), 5.00 (s) &amp; 4.87 (s) [2H, NCH 2 Ar], 4.15 (t) &amp; 4.03 (t) [2H, NCH 2 ], 3.95 (s) &amp; 3.92 (s) [3H, OCH 3 ] and 2.90 (bs) &amp; 2.72 (bs) [2H, CH 2 CO 2 H].  
         [0270]     IR (ν max , KBr): 1707.9, 1602.5, 1275.8, 748.6 cm −1 .  
         [0271]     LCMS (m/z): 726.4 (M+1, 75%).  
       3-[{4-(Biphenyl-2-ylamino)-6-{3-(2-methoxyphenyl)ureido]-[1,3,5]triazin-2-yl}-(naphthalen-1-ylmethyl)amino]propionic acid (Compound No. 120)  
       [0272]     3-[{4-(Biphenyl-2-ylamino)-6-{3-(2-methoxyphenyl)ureido]-[1,3,5]triazin-2-yl}-(naphthalen-1-ylmethyl)amino]propionic acid was prepared by reacting 3-(naphthalen-1-ylmethyl)aminopropionic acid instead of 3-(4-methylbenzyl)aminopropionic acid in Step 3, Example 1.  
         [0273]     m.p.: 218-221° C.  
         [0274]      1 HNMR (TFA-d, 300 MHz): δ 7.00-8.00 (20H, m, aromatic), 5.42 (s) &amp; 5.35 (s) [2H, NCH 2 Ar], 4.10 (bs) &amp; 3.98 (bs) [2H, NCH 2 ], 3.95 (s) &amp; 3.88 (s) [3H, OCH 3 ] and 2.70 (bs) &amp; 2.52 (bs) [2H, CH 2 CO 2 H] 
         [0275]     IR (ν max , KBr): 1705.9, 1599.5, 1532.4, 809.7, 748.4 cm −1 .  
         [0276]     LCMS (m/z): 640.5 (M+1, 10%).  
       3-[{4-(Biphenyl-2-ylamino)-6-[3-(2-methoxyphenyl)ureido]-[1,3,5]triazin-2-yl}-(2-pyridin-2-ylethyl)amino]propionic acid (Compound No. 121)  
       [0277]     3-[{4-(Biphenyl-2-ylamino)-6-[3-(2-methoxyphenyl)ureido]-[1,3,5]triazin-2-yl}-(2-pyridin-2-ylethyl)amino]propionic acid was prepared by using 3-(2-pyridin-2-ylethyl)aminopropionic acid instead of 3-(4-methylbenzyl)aminopropionic acid in Step 3, Example 1.  
         [0278]     m.p.: 225-227° C.  
         [0279]      1 HNMR (TFA-d, 300 MHz): δ 7.65-9.40 (17H, m, aromatic), 4.70 (4H, m, NCH 2 ×2), 4.57 (3H, s, OCH 3 ), 4.20 (bs) &amp; 4.08 (bs) [2H, Ar CH 2 ] and 3.56 (bs) &amp; 3.44 (bs) [2H, CH 2 CO 2 H].  
         [0280]     IR (ν max , KBr): 1690.3, 1542.1, 1324.4, 811.5, 746.1 cm −1 .  
         [0281]     LCMS (m/z): 605.2 (M+1, 100%).  
       1-{4-(Biphenyl-2-ylamino)-6-[3-(2-methoxyphenyl)ureido]-[1,3,5]triazin-2-yl}-pyrrolidine-2S-carboxylic acid (Compound No. 125)  
       [0282]     1-{4-(Biphenyl-2-ylamino)-6-[3-(2-methoxyphenyl)ureido]-[1,3,5]triazin-2-yl}-pyrrolidine-2S-carboxylic acid was prepared by using pyrrolidin-2S-carboxylic acid (L-proline) instead of 3-(4-methylbenzyl)aminopropionic acid in Step 3, Example 1.  
         [0283]     m.p.: 175-180° C.  
         [0284]      1 HNMR (TFA-d, 300 MHz): δ 7.94-8.40 (m) and 7.65 (m) [13H, aromatic], 5.41 (s) &amp; 5.25 (s) [1H, NCHCO 2 H], 4.67 (s) &amp; 4.53 (m) [5H, OCH 3  and NCH 2 ] and 3.13 (1H, m) &amp; 2.86 (3H, m) [CH 2 ×2 (ring)].  
         [0285]     IR (ν max , KBr): 1719.0, 1657.2, 1523.1, 1202.1, 749.9 cm −1 .  
         [0286]     LCMS (m/z): 526.1 (M+1, 100%).  
       1-{4-(Biphenyl-2-ylamino)-6-[3-(2-methoxyphenyl)ureido]-[1,3,5]triazin-2-yl}-thiazolidine-4-carboxylic acid (Compound No. 126)  
       [0287]     1-{4-(Biphenyl-2-ylamino)-6-[3-(2-methoxyphenyl)ureido]-[1,3,5]triazin-2-yl}-thiazolidine-4-carboxylic acid was synthesized by using thiazolidine-4-carboxylic acid instead of 3-(4-methyl benzyl)aminopropionic acid in Step 3, Example 1.  
         [0288]     m.p.: 170-175° C.  
         [0289]      1 HNMR (TFA-d, 300 MHz): δ 7.75-8.21 (m), 7.58 (m) [16H, aromatic and 3NH], 5.75 (s) &amp; 5.54 (s) [NCHCO 2 H], 5.36 (2H, AB q , J=9 Hz, NCH 2 S), 4.47 (3H, s, OCH 3 ) and 3.9-4.11 (2H, m, SCH 2 ).  
         [0290]     LCMS (m/z): 544.1 (M+1, 100%).  
       1-{4-(Biphenyl-2-ylamino)-6-[3-(2-methoxyphenyl)ureido]-[1,3,5]triazin-2-yl}-piperidine-3-carboxylic acid (Compound No. 127)  
       [0291]     1-{4-(Biphenyl-2-ylamino)-6-[3-(2-methoxyphenyl)ureido]-[1,3,5]triazin-2-yl}-piperidine-3-carboxylic acid was prepared by using piperidine-3-carboxylic acid instead of 3-(4-methyl benzyl)aminopropionic acid in Step 3, Example 1.  
         [0292]     m.p.: 245-247° C.  
         [0293]      1 HNMR (TFA-d, 300 MHz): δ 8.19 (1H, bs), 7.77-8.00 (10H, m) and 7.55 (2H, m) [aromatic], 4.95 (1H, m) &amp; 4.70 (1H, m) [NCH 2 ], 4.40 (3H, s, OCH 3 ), 4.22 (1H, m) &amp; 4.03 (1H, bs) [NCH 2 ], 3.29 (1H, s, CHCO 2 H) and 2.75 (1H, m), 2.49 (2H, m) &amp; 2.21 (1H, m) [CH 2 ×2 (ring)].  
         [0294]     IR (ν max , KBr): 1703.3, 1574.4, 1337.6, 1276.3, 746.1 cm −1 .  
         [0295]     LCMS (m/z): 540.1 (M+1, 100%).  
       1-{4-(Biphenyl-2-yl-amino)-6-[3-(2-methoxyphenyl)ureido]-[1,3,5]triazin-2-yl}-piperidine-4-carboxylic acid. (Compound No. 128)  
       [0296]     1-{4-(Biphenyl-2-yl-amino)-6-[3-(2-methoxyphenyl)ureido]-[1,3,5]triazin-2-yl}-piperidine-4-carboxylic acid was prepared by using piperidine-4-carboxylic acid instead of 3-(4-methyl benzyl)aminopropionic acid in Step 3, Example 1.  
         [0297]     m.p.: 130-135° C.  
         [0298]      1 HNMR (TFA-d, 300 MHz): δ 7.76-8.15 (11H, m), 7.59 (2H, bs) [aromatic], 5.15 (2H, m, NCH 2 ), 4.61 (s) &amp; 4.46 (s) [3H, OCH 3 ], 3.83 (2H, m, NCH 2 ), 2.69 (1H, m, CHCO 2 H) and 2.39 (2H, m) &amp; 1.90 (2H, m) [CH 2 ×2 (ring)].  
         [0299]     IR (ν max , KBr): 1705.0, 1602.5, 1528.9, 1278.6, 1028.0, 747.9 cm −1    
         [0300]     LCMS (m/z): 540.0 (M+1, 100%).  
       2-{4-(Biphenyl-2-ylamino)-6-[3-(2-methoxyphenyl)ureido]-[1,3,5]triazin-2-yl}-1,2,3,4-tetrahydro-isoquinoline-3-carboxylic acid (Compound No. 129)  
       [0301]     2-{4-(Biphenyl-2-ylamino)-6-[3-(2-methoxyphenyl)ureido]-[1,3,5]triazin-2-yl}-1,2,3,4-tetrahydro-isoquinoline-3-carboxylic acid was prepared by using 1,2,3,4-tetrahydro-isoquinoline-3-carboxylic acid in place of 3-(4-methylbenzyl)aminopropionic acid in Step 3, Example 1.  
         [0302]     m.p.: 138-145° C.  
         [0303]      1 HNMR (TFA-d, 300 MHz): δ 7.60-8.07 (17H, m, aromatic), 5.93 (1H, m) &amp; 5.69 (1H, bs) [NCHCO 2 H], 5.40-5.50 (2H, m, NCH 2 ), 4.48 (s) &amp; 4.46 (s) [3H, OCH 3 ] and 3.90 (2H, m, ArCH 2 ).  
         [0304]     IR (ν max , KBr): 1702.9, 1599.9, 1530.8, 1428.1, 1320 cm −1 .  
         [0305]     LCMS (m/z): 588.3 (M+1, 100%).  
       1-{4-(Biphenyl-2-ylamino)-6-[3-(2-methoxyphenyl)ureido]-[1,3,5]triazin-2-yl}piperidine-2-carboxylic acid (Compound No. 130)  
       [0306]     1-{4-(Biphenyl-2-ylamino)-6-[3-(2-methoxyphenyl)ureido]-[1,3,5]triazin-2-yl}piperidine-2-carboxylic acid was prepared by using piperidine-2-carboxylic acid instead of 3-(4-methylbenzyl)amino-propionic acid in Step 3, Example 1.  
         [0307]     m.p.: 150-154° C.  
         [0308]      1 H NMR (TFA-d, 300 MHz): δ 7.49-7.80 (1H, m) &amp; 7.17 (2H, bs) [aromatic], 5.74 (bs) &amp; 5.58 (bs) [1H, NCH], 4.78 (1H, m) &amp; 3.35 (1H, m) [NCH 2 ], 4.05 (3H, s, OCH 3 ) and 2.60 (1H, m), 2.00 (3H, m) &amp; 1.67 (2H, m) [CH 2 ×3].  
         [0309]     LCMS (m/z): 540.3 (M+1, 100%)  
       Tris salt of 3-[{4-(Biphenyl-2-ylamino)-6-[3-(2-methoxyphenyl)ureido]-[1,3,5]triazin-2-yl}-(3-methylbenzyl)amino]propionic acid (Compound No. 48)  
       [0310]     To Compound No. 31 (100 mg, 0.16 mmol) in dry THF (5 ml) was added tris (hydroxymethyl)aminomethane (9 mg, 0.16 mmol) and the reaction mixture was stirred overnight at room temperature. Solvents were evaporated to dryness to afford the title compound.  
         [0311]     m.p.: 85-92° C.  
         [0312]      1 HNMR (TFA-d, 300 MHz): δ 8.05-8.75 (15H, m, aromatic), 6.04 (s) &amp; 5.93 (s) [2H, NCH 2 Ar], 5.31 (6H, s, CH 2 OH×3), 5.21 (2H, s, NCH 2 ), 5.07 (s) &amp; 5.05 (s) [3H, OCH 3 ], 3.95 (2H, m, CH 2 CO 2 H) and 3.54 (s) &amp; 3.48 (s) [3H, Ar CH 3 ].  
         [0313]     IR (ν max , KBr): 1670.5, 1510.2, 1249.4, 1048.0, 747.3 cm −1    
         [0314]     LCMS (m/z): 122.2 (87%), 604.2 (100%)  
       Na salt of 3-[{4-(Biphenyl-2-ylamino)-6-[3-(2-methoxyphenyl)-ureido]-[1,3,5]triazin-2-yl}-(3-methylbenzyl)amino]propionic acid (Compound No. 49)  
       [0315]     To Compound No. 31 (100 mg, 0.16 mmol) in dry THF:MeOH (2:1 ml) was added sodium methoxide (20 mg, 0.16 mmol) and the reaction mixture stirred at room temperature for 5 hours. Evaporation of the solvents to dryness afforded the title compound.  
         [0316]     m.p.: 122-135° C.  
         [0317]      1 HNMR (TFA-d, 300 MHz): δ 8.0-8.56 (19H, m, aromatic and 2NH), 6.01 (s) &amp; 5.91 (s) [2H, NCH 2 Ar], 5.11 (m, NCH 2 ), 5.04 (s) &amp; 5.02 (s) [OCH 3 ], 3.92 (s) &amp; 3.75 (s) [2H, CH 2 CO 2 H] and 3.45 (s) &amp; 3.42 (s) [3H, ArCH 3 ].  
         [0318]     IR (ν max , KBr): 1692.2, 1599.7, 1535.4, 1248.9, 746.7 cm −1    
         [0319]     LCMS (m/z): 604.2 (M−Na)+2, 100%), 626.5 (M+1, 30%)  
       Example 2  
     Synthesis of 1-{4-(Biphenyl-2-ylamino)-[1,3,5]triazin-2-yl}-3-(2-methoxyphenyl)urea (Compound No. 18)  
       [0320]     To the chlorotriazine (260 mg, 0.58 mmol) as obtained from Step 2, Example 1, in tetrahydrofuran (50 ml) was added triethylamine (1 ml) and 10% Pd/C (dry, 100 mg) and the mixture was taken under H 2  atmosphere at 50 psi for 5 hours. The solids were filtered through a celite pad and the filtrate was concentrated and residue dried under vacuum to obtain the title compound (130 mg, 54%) as a solid.  
         [0321]     m.p.: 219° C.  
         [0322]      1 HNMR (DMSO-d 6 , 300 MHz): δ 11.45 (1H, bs, NH), 9.95 (1H, s, NH), 9.49 (1H, bs, NH), 8.38 (1H, s, triazine H), 8.01 (1H, bs), 7.31-7.50 (9H, m) and 6.89-7.03 (2H, m) [aromatic] and 3.76 (3H, s, OCH 3 ).  
         [0323]     IR (ν max , KBr): 1696.4, 1548.9, 1252.2, 744.5 cm −1 .  
         [0324]     LCMS (m/z): 413.0 (M+1, 45%).  
       Example 3  
     Synthesis 1-{4-(Biphenyl-2-ylamino)-6-methoxy-[1,3,5]triazin-2-yl}-3-(2-methoxyphenyl)urea (Compound No. 19)  
       [0325]     To the chlorotriazine (211 mg, 0.5 mmol) prepared as in Step 2, Example 1, in tetrahydrofuran (9 ml) and methanol (1 ml) was added sodium methoxide (41 mg, 0.75 mmol). The reaction mixture was refluxed for 3 hour and poured over cold water (25 ml). It was extracted with ethyl acetate (2×25 ml) and the organic layer washed with water and brine and dried over anhydrous sodium sulfate. Evaporation of the solvent followed by purification of the residue over a silica gel column using 40% EtOAc-hexane as eluent furnished the title compound (110 mg, 53%) as a solid.  
         [0326]     m.p.: 202° C.  
         [0327]      1 HNMR (DMSO-d 6 , 300 MHz): δ 10.6 (1H, bs, NH), 9.86 (1H, bs, NH), 7.97 (1H, bs, NH), 7.49 (1H, d, J=7.2 Hz), 7.28-7.38 (9H, m) &amp; 6.86-7.03 (3H, m) [aromatic] and 3.81 (3H, s) &amp; 3.68 (3H, s) [OCH 3 ×2].  
         [0328]     IR (ν max , KBr): 1684.7, 1420.6, 816.5, 747.1 cm −1 .  
         [0329]     LCMS (m/z): 443.0 (M+1, 100%).  
       Example 4  
     Synthesis of 3-{(3-Fluorobenzyl)-[4-[3-(2-methoxyphenyl)ureido]-6-(naphthalen-2-yloxy)-[13,5]triazin-2-yl]amino}propionic acid (Compound No. 105)  
     Step 1: Synthesis of 4-Chloro-6-(naphthalen-2-yloxy)-[1,3,5]triazin-2-ylamine  
       [0330]     A solution of β-naphthol (8.78 g, 60 mmol) in acetone (100 ml) was added dropwise to a reaction mixture containing 2-amino-4,6-dichloro-1,3,5-triazine (10 g, 60 mmol) and potassium carbonate (8.4 g, 60 mmol) in acetone (100 ml) maintained at room temperature. The reaction mixture was stirred at room temperature for 16 h and then refluxed for 6 hours. After cooling, the reaction mixture was poured over ice and the preciptated solid filtered, washed water and dried under vacuum. The crude solid was then washed with a solution of 10% CH 2 Cl 2 -hexane (100 ml) and further dried under vacuum to obtain the title compound (15.4 g, 73%) as a white solid.  
         [0331]      1 HNMR (DMSO-d 6 , 300 MHz): δ 8.05-8.15 (3H, m), 8.01 (2H, bs, NH 2 ), 7.77 (1H, s), 7.55 (2H, m) and 7.39 (1H, m) [aromatic].  
         [0332]     IR (ν max , KBr): 1696.2, 1528.4, 1379.9, 800.5 cm −1 .  
         [0333]     LCMS (m/z): 273.0 (M+1, 100%).  
       Step 2: Synthesis of 1-[4-Chloro-6-(naphthalen-2-yloxy)-[1,3,5]triazin-2-yl]-3-(2-methoxyphenyl)urea (Compound No. 1)  
       [0334]     To the amino triazine (15.1 g, 55 mmol) obtained from Step 1, Example 4, in THF (200 ml) at 0° C. was added sodium hydride (2.64 g, 50% dispersion in oil, 55 mmol) followed immediately by 2-methoxyphenyl isocyanate (8.3 g, 55 mmol)). The reaction mixture was stirred at 0° C. for 30 min and at room temperature for 12 h. The reaction mixture was poured into ice-water and extracted with ethyl acetate (2×250 ml). The organic layer were combined, washed with brine and dried (Na 2 SO 4 ). Evaporation of the eluent followed by purification of the residue over a silica gel column using 40% EtOAc:Hexane afforded the title compound (14.1 g, 60%) as a white solid.  
         [0335]      1 HNMR (DMSO-d 6 , 300 MHz): δ 11.12 (1H, s) and 11.08 (1H, s) [NH×2], 8.14 (1H, d, J=7.8 Hz), 7.9-8.05 (3H, m), 7.82 (1H, bs), 7.4-7.6 (3H, m), 7.04 (2H, bs) and 6.91-6.96 (1H, m) [aromatic] and 3.81 (3H, s, OCH 3 ).  
         [0336]     IR (ν max , KBr): 1707.1, 1289, 808, 744 cm −1 .  
         [0337]     LCMS (m/z): 422.2 (M+1, 70%), 424 (M+3, 30%).  
       Step 3: Synthesis of 3-{(3-Fluorobenzyl)-[4-[3-(2-methoxyphenyl)ureido]-6-(naphthalen-2-yloxy)-[1,3,5]triazin-2-yl]amino}propionic acid  
       [0338]     Following the general procedure as mentioned for Example 1, the title compound was prepared from the Li salt of the aminopropionic acid (obtained by the hydrolysis of ethyl 3-(3-fluorobenzyl)aminopropionate (106 mg, 0.47 mmol using LiOH in H 2 O (20 mg, 0.47 mmol) and the chlorotriazine (200 mg, 0.47 mmol)) obtained from Step 2 above. Column chromatography of the crude residue afforded the pure title compound (114 mg, 41%).  
         [0339]     m.p.: 223° C.  
         [0340]      1 HNMR (TFA-d, 300 MHz): δ 7.35-8.70 (15H, m, aromatic), 5.71 (s) &amp; 5.37 (s) [2H, NCH 2 Ar], 4.84 (t) &amp; 4.40 (t) [2H, NCH 2 ] 4.69 (s) &amp; 4.66 (s) [3H, OCH 3 ] and 3.61 (t) &amp; 3.20 (t) [2H, CH 2 CO 2 H].  
         [0341]     IR (ν max , KBr): 1715.6, 1596.6, 1254.1, 748.1 cm −1 .  
         [0342]     LCMS (m/z): 583.4 (M+1, 90%).  
         [0343]     The following compounds were prepared similarly:  
       1-[4-Chloro-6-(nalphthalen-2-yloxy)-[1,3,5]triazin-2-yl]-3-(2-chlorophenyl) urea (Compound No. 2)  
       [0344]     1-[4-Chloro-6-(naphthalen-2-yloxy)-[1,3,5]triazin-2-yl]-3-(2-chlorophenyl) urea was prepared following the procedure of Step 2 Example 4, by using 2-chlorophenyl isocyanate in place of 2-methoxyphenyl isocyanate.  
         [0345]      1 HNMR (DMSO-d 6 , 300 MHz): δ 11.27 (1H, s) &amp; 10.97 (1H, s) [NH×2], 8.16 (1H, d, J=7.8 Hz), 7.91-8.02 [3H, m], 7.86 (1H, bs), 7.51-7.57 (4H, m), 7.31 (1H, t, J=7.5 Hz) and 7.15 (1H, t, J=7.5 Hz) [aromatic].  
         [0346]     IR (ν max , KBr): 1717.0, 1426.4, 1237.1, 745.6 cm −1 .  
         [0347]     LCMS (m/z): 426.1 (M+1, 80%), 428.1 (M+3, 50%).  
       1-[4-Chloro-6-(naphthalen-2-yloxy)-[1,3,5]triazin-2-yl]-3-(4-chlorophenyl) urea (Compound No. 3)  
       [0348]     1-[4-Chloro-6-(naphthalen-2-yloxy)-[1,3,5]triazin-2-yl]-3-(4-chlorophenyl) urea was prepared following the procedure of Step 2 Example 4, by using 4-chlorophenyl isocyanate in place of 2-methoxyphenyl isocyanate.  
         [0349]      1 HNMR (DMSO-d 6 , 300 MHz): δ 11.19 (1H, s) &amp; 9.99 (1H, s) [NH×2], 7.94-8.09 (4H, m), 7.55-7.65 (3H, m), 6.81 (2H, d, J=8.7 Hz) and 6.48 (2H, d, J=8.4 Hz) [aromatic].  
         [0350]     IR (ν max , KBr): 1714.5, 1695.1, 1538.9, 1237.8, 807.3 cm −1 . LCMS (m/z): 426 (M+1, 100%) and 428 (M+3, 50%).  
       1-[4-Chloro-6-(naphthalen-2-yloxy)-[1,3,5]triazin-2-yl]-3-(4-methoxyphenyl) urea (Compound No. 4)  
       [0351]     1-[4-Chloro-6-(naphthalen-2-yloxy)-[1,3,5]triazin-2-yl]-3-(4-methoxyphenyl) urea was prepared by using 4-methoxyphenyl isocyanate in Step 2, Example 4 instead of 2-methoxyphenyl isocyanate.  
         [0352]      1 HNMR (DMSO-d 6 , 300 MHz): δ 11.04 (1H, s) &amp; 9.76 (1H, s) [NH×2], 7.94-8.07 (4H, m), 7.53-7.64 (3H, m) and 6.34 (4H, s) [aromatic] and 3.62 (3H, s, OCH 3 ).  
         [0353]     IR (ν max , KBr): 1694.2, 1564.1, 1540.3, 1227.6 cm −1 .  
         [0354]     LCMS (m/z): 422.0 (M+1, 100%) 424 (M+3, 23%).  
       [4-[3-(2-Methoxyphenyl)ureido]-6-naphthalen-2-yloxy)-[1,3,5]triazin-2-yl]aminoacetic acid (Compound No. 7)  
       [0355]     4-[3-(2-Methoxyphenyl)ureido]-6-naphthalen-2-yloxy)-[1,3,5]triazin-2-yl]aminoacetic acid. prepared by using aminoacetic acid (glycine) instead of 3(3-fluorobenzyl)aminopropionic acid in Step 3, Example 4.  
         [0356]      1 HNMR (DMSO-d 6 , 300 MHz): δ 11.49 (s) &amp; 11.21 (s) [1H, NH], 10.15 (s) &amp; 10.08 (s) [1H, NH] 7.93-8.15 (4H, m), 7.81 (1H, d, J=5.3 Hz), 7.44-7.54 (3H, m) and 6.92-7.03 (3H, m) [aromatic], 4.02 (1H, bs) &amp; 3.72 (1H, bs) [NCH 2 ] and 3.86 (3H, s, OCH 3 ).  
         [0357]     IR (ν max , KBr): 1711.5, 1546.0, 1242.7, 748.1 cm −1 .  
         [0358]     LCMS (m/z): 461.0 (M+1, 100%).  
       [4-[3-(2-Chlorophenyl)ureido]-6(naphthalen-2-yloxy)-[1,3,5]triazin-2-yl]aminoacetic acid (Compound No. 8)  
       [0359]     [4-[3-(2-Chlorophenyl)ureido]-6(naphthalen-2-yloxy)-[1,3,5]triazin-2-yl]aminoacetic acid was synthesized following the procedure of Example 4, by using 2-chlorophenyl isocyanate instead of 2-methoxyphenyl isocyanate in Step 2 and aminoacetic acid (glycine) instead of 3-(3-fluorobenzyl)aminopropionic acid in Step 3, Example 4.  
         [0360]      1 HNMR (DMSO-d 6 , 300 MHz): δ 11.46 (s) &amp; 11.29 (s) [1H, NH], 10.32 (s) &amp; 10.25 (s) [1H, NH] 7.77-7.95 (5H, m), 7.52 (1H, d, J=2.7 Hz) and 7.12-7.53 (6H, m) [aromatic and 1 NH] and 3.90 (1H, d, J=5.7 Hz) &amp; 3.72 (1H, d, J=5.7 Hz) [NCH 2 ].  
         [0361]     IR (ν max , KBr): 1708.0, 1345.8, 1240.1, 746.2 cm −1 .  
         [0362]     LCMS (m/z): 465.0 (M+1, 100%), 467.3 (M+3, 30%).  
       [4-[3-(2-Methylphenyl)ureido]-6-(naphthalen-2-yloxy)-[1,3,5]triazin-2-yl]aminoacetic acid (Compound No. 9)  
       [0363]     [4-[3-(2-Methylphenyl)ureido]-6-(naphthalen-2-yloxy)-[1,3,5]triazin-2-yl]aminoacetic acid was prepared by using 2-methylphenyl isocyanate in Step 2 and aminoacetic acid (glycine) in Step 3 of Example 4 in place of 2-methoxyphenyl isocyanate Step 2 and 3(3-fluorobenzyl)aminopropionic acid in Step 3, Example 4.  
         [0364]      1 HNMR (DMSO-d 6 , 300 MHz): δ 10.84 (s) &amp; 10.76 (s) [1H, NH], 10.09 (s) &amp; 9.99 (s) [1H, NH], 7.78-7.98 (4H, m), 7.39-7.55 (4H, m) and 7.00-7.17 (3H, m) [aromatic] 3.77 (1H, bs) &amp; 3.67 (1H, d, J=4.5 Hz) [NCH 2 ] and 1.85 (s) &amp; 1.99 (s) [3H, ArCH 3 ].  
         [0365]     IR (ν max , KBr): 1703.2, 1590.0, 1241.9, 747.5 cm −1 .  
         [0366]     LCMS (m/z): 445.2 (M+1, 100%).  
       [4-[3-(4-Methoxyphenyl)ureido]-6-(naphthalen-2-yloxy)-[1,3,5]triazin-2-yl]aminoacetic acid (Compound No. 10)  
       [0367]     [4-[3-(4-Methoxyphenyl)ureido]-6-(naphthalen-2-yloxy)-[1,3,5]triazin-2-yl]aminoacetic acid was prepared by taking Compound No. 4 and aminoacetic acid (glycine) as in Step 3, Example 4.  
         [0368]      1 HNMR (DMSO-d 6 , 300 MHz): δ 10.69 (bs) &amp; 10.62 (bs) [1H, NH], 9.97 (s), 9.88 (s) &amp; 9.79 (s) [2H, NH×2], 7.46-8.07 (8H, m), 6.34-7.43 (3H, m) [aromatic] and 3.62-3.72 (5H, MOCH 3  and NCH 2 ).  
         [0369]     IR (ν max , KBr): 1694.9, 1546.0, 1244.0, 808.2 cm −1 .  
         [0370]     LCMS (m/z): 461.0 (M+1, 100%).  
       [4-[3-(4-Chlorophenyl)ureido]-6-(naphthalen-2-yloxy-[1,3,5]triazin-2-yl]aminoacetic acid (Compound No. 11)  
       [0371]     [4-[3-(4-Chlorophenyl)ureido]-6-(naphthalen-2-yloxy)-[1,3,5]triazin-2-yl]aminoacetic acid was prepared by using Compound No. 3 and aminoacetic acid (glycine) as in Step-3, Example 4 instead of 3-(3-fluorobenzyl)aminopropionic acid.  
         [0372]      1 HNMR (DMSO-d 6 , 300 MHz): δ 10.95 (1H, bs, NH), 10.06-10.14 (1H, NH), 6.61-8.01 (12H, m, 11H aromatic &amp; 1 NH) and 3.75 (2H, bs, NCH 2 ).  
         [0373]     IR (ν max , KBr): 1698.4, 1593.1, 1241.5, 810.9 cm −1 .  
         [0374]     LCMS (m/z): 465.0 (M+1, 100%)  
       [4-[3-(4-Methylphenyl)ureido]-6-(naphthalen-2-yloxy]-[1,3,5]triazin-2-yl]aminoacetic acid (Compound No. 12)  
       [0375]     [4-[3-(4-Methylphenyl)ureido]-6-(naphthalen-2-yloxy]-[1,3,5]triazin-2-yl]aminoacetic acid was prepared by using 4-methylphenyl isocyanate in Step 2 and aminoacetic acid (glycine) in Step 3, Example 4 instead of 2-methoxyphenyl isocyanate (Step 2) and 3-(3-fluorobenzyl)aminopropronic acid (Step 4).  
         [0376]      1 HNMR (DMSO-d 6 , 300 MHz): δ 10.89 (s) &amp; 10.72 (s) [1H, NH], 9.86 (bs) &amp; 9.64 (bs) [1H, NH], 6.74-7.97 (12H, m, aromatic and 1NH] and 2.24 (s) &amp; 2.14 (s) [3H, ArCH 3 ] 
         [0377]     IR (ν max , KBr): 1699.5, 1595.1, 1407.2, 1246.1, 812.0 cm −1 .  
         [0378]     LCMS (m/z): 445.2 (M+1, 100%).  
       2S-{4-[3-(2-Methoxyphenyl)-ureido]-6-(naphthalen-2-yloxy)-[1,3,5]triazin-2-ylamino}-3-phenylpropionic acid (Compound No. 13)  
       [0379]     2S-{4-[3-(2-Methoxyphenyl)-ureido]-6-(naphthalen-2-yloxy)-[1,3,5]triazin-2-ylamino}-3-phenylpropionic acid was prepared by using 2-amino-3-phenylpropionic acid (L-phenylalanine) instead of 3-(3-fluorobenzyl)aminopropionic acid in Step 3, Example 4.  
         [0380]     m.p.: 202° C.  
         [0381]      1 HNMR (DMSO-d 6 , 300 MHz): δ 11.42 (s) &amp; 11.15 (s) [1H, NH], 10.07 (s) &amp; 10.05 (s) [1H, NH], 7.79-8.01 (5H, m), 7.15-7.54 (4H, m) and 6.90-7.01 (8H, m) [aromatic], 4.82 (bs) &amp; 4.35 (bs) [1H, NCH], 3.76 (s) &amp; 3.73 (s) [3H, OCH 3 ] and 2.8-3.5 (2H, m, CH 2  Ar).  
         [0382]     IR (ν max , KBr): 1697.1, 1404.4, 1341.3, 1244.5, 744.0 cm −1 .  
         [0383]     LCMS (m/z): 551.2 (M+1, 70%).  
       3-{4-[3-(2-Methoxyphenyl)ureido]-6-(naphthalen-2-yloxy)-[1,3,5]triazin-2-yl amino}3-phenylpropionic acid (Compound No. 14)  
       [0384]     3-{4-[3-(2-Methoxyphenyl)ureido]-6-(naphthalen-2-yloxy)-[1,3,5]triazin-2-yl amino}3-phenylpropionic acid was prepared by using 3-amino-3-phenylpropionic acid instead of 3-(3-fluorobenzyl)aminopropionic acid in Step 3, Example 4.  
         [0385]     m.p.: 149° C.  
         [0386]      1 HNMR (DMSO-d 6 , 300 MHz): δ 11.46 (s) &amp; 10.31 (s) [1H, NH], 10.12 (s) &amp; 10.02 (s) [1H, NH], 8.59 (d) &amp; 8.45 (d) [1H, NH], 6.93-8.3 (16H, m, aromatic), 5.46 (m) &amp; 5.12 (m) [1H, NCH], 3.83 (s) &amp; 3.81 (s) [3H, OCH 3 ] and 2.2-2.94 (2H, m, CH 2 CO 2 H).  
         [0387]     IR (ν max , KBr): 1696.8, 1243.8, 747.9 cm −1 .  
         [0388]     LCMS (m/z): 551.2 (M+1, 25%).  
       3-{Benzo[1,3]dioxo-5-yl-[4-[3-(2-methoxyphenyl)ureido]-6-napthalen-2-yloxy)-[1,3,5]triazin-2-ylamino)propionic acid ethyl ester (Compound No. 15)  
       [0389]     3-{Benzo[1,3]dioxo-5-yl-[4-[3-(2-methoxyphenyl 1,3,5]triazin-2-ylamino)propionic acid ethyl ester. (Compound No. 15) was prepared by reacting 3-amino-3-(benzo[1,3]dioxo-5-yl)propionic acid ethyl ester instead of 3-(3-fluorobenzyl)aminopropionic acid in Step 3, Example 4.  
         [0390]     m.p.: 222° C.  
         [0391]      1 HNMR (DMSO-d 6 , 300 MHz): δ 11.55 (s) &amp; 11.44 (s) [1H, NH], 10.25 (s) &amp; 10.10 (s) [1H, NH], 8.54 (d, J=8.1 Hz) &amp; 8.44 (d, J=8.1 Hz) [1H, NH], 8.02-8.15 (4H, m), 7.87 (1H, s), 7.62 (2H, bs), 7.50 (1H, t, J=8.1 Hz), 7.11 (1H, d, J=4.8 Hz), 7.01 (1H, bs), 6.84 (1H, m) and 6.62 (d) &amp; 6.34 (d) [1H] [aromatic], 6.02 (2H, s, OCH 2 O), 5.47 (m) &amp; 5.02 (m) [1H, NCH], 3.8-4.09 (2H, m, OCH 2 ), 3.89 (3H, s, OCH 3 ), 2.5-3.0 (2H, m, CH 2 CO) and 1.06-1.17 (3H, m, CH 3 ).  
         [0392]     IR (ν max , KBr): 1737.6, 1691.7, 1595.6, 1558.8, 1241.6 cm −1 .  
         [0393]     LCMS (m/z): 623.1 (M+1, 100%).  
       3-{Benzo[1,3]dioxo-5-yl-([4-[3-(2-methoxyphenyl)-ureido]-6-napthalen-2-yloxy)-[1,3,5]triazin-2-ylamino}propionic acid (Compound No. 16)  
       [0394]     3-{Benzo[1,3]dioxo-5-yl-([4-[3-(2-methoxyphenyl)-ureido]-6-napthalen-2-yloxy)-[1,3,5]triazin-2-ylamino}propionic acid was prepared by using 3-amino-3-(benzo-[1,3]-dioxo-5-yl)propionic acid instead of 3-(3-fluorobenzyl) aminopropionic acid in Step 3, Example 4.  
         [0395]     m.p.: 221° C.  
         [0396]      1 HNMR (DMSO-d 6 , 300 MHz): δ 11.46 (s) &amp; 11.38 (s) [1H, NH], 10.16 (s) &amp; 10.03 (s) [1H, NH], 8.47 (d) &amp; 8.41 (d) [1H, NH], 7.92-8.07 (4H, m), 7.79 (1H, d, J=9.2 Hz), 7.55 (2H, t, J=3.9 Hz), 7.31-7.55 (5H, m), 6.90-7.10 (4H, m), 6.6-6.90 (2H, m) and 6.53 (d) &amp; 6.30 (d) [1H] [aromatic], 5.97 (s) &amp; 5.94 (s) [2H, OCH 2 O], 5.34 (m) &amp; 4.91 (m) [NCH], 3.84 (s) &amp; 3.82 (s) [3H, OCH 3 ] and 2.5-2.85 (2H, m, CH 2 CO).  
         [0397]     IR (ν max , KBr): 1711.4, 1690.3, 1594.2, 1554.9, 1241.8, 747.5 cm −1 .  
         [0398]     LCMS (m/z): 595.2 (M+1, 65%).  
       3-{4-[3-(2-Methoxyphenyl)ureido]-6-napthalen-2-yloxy)-[1,3,5]triazin-2-yl amino}propionic acid (Compound No. 43)  
       [0399]     3-{4-[3-(2-Methoxyphenyl)ureido]-6-napthalen-2-yloxy)-[1,3,5]triazin-2-yl amino}propionic acid was prepared by using 3-aminopropionic acid (β-alanine) instead of 3-(3-fluorobenzyl)aminopropionic acid in Step 3, Example 4.  
         [0400]     m.p.: 222-230° C.  
         [0401]      1 HNMR (DMSO-d 6 , 300 MHz): δ 12.1 (1H, bs, CO 2 H), 11.45 (s) &amp; 11.30 (s) [1H, NH], 10.10 (s) &amp; 10.00 (s) [1H, NH], 7.78-8.10 (5H, m), 7.45-7.54 (3H, m) &amp; 6.90-7.10 (3H, m) [aromatic], 3.86 (1H, t, J=6 Hz) &amp; 3.53 (1H, t, J=3 Hz) [NCH 2 ], 3.80 (3H, s, OCH 3 ) and 2.47 (m, CH 2 CO 2 H).  
         [0402]     IR (ν max , KBr): 1690.1, 1600.8, 1549.5, 811.0, 747.4 cm −1 .  
         [0403]     LCMS (m/z): 500.2 (M+1, 100%).  
       3-{(3-Methoxybenzyl)-[4-[3-(2-methoxyphenyl)ureido]-6-(nalphthalen-2-yloxy)-[1,3,5]triazin-2-yl]amino}propionic acid (Compound No. 44)  
       [0404]     3-{(3-Methoxybenzyl)-[4-[3-(2-methoxyphenyl)ureido]-6-(naphthalen-2-yloxy)-[1,3,5]triazin-2-yl]amino}propionic acid was prepared by using 3-(3-methoxybenzyl)aminopropionic acid instead of 3-(3-fluorobenzyl)aminopropionic acid in Step 3, Example 4.  
         [0405]     m.p.: 189-194° C.  
         [0406]      1 HNMR (TFA-d, 300 MHz): δ 7.70-9.10 (17H, m, 15H aromatic and 2NH), 6.07 (s) &amp; 5.79 (s) [2H, NCH 2 Ar], 5.21 (1H, t) &amp; 4.79 (1H, bs) [NCH 2 ], 5.06 (s), 5.03 (s), 4.97 (s) &amp; 4.96 (s) [6H, OCH 3 ×2] and 3.96 (1H, s) &amp; 3.56 (1H, s), [CH 2 CO 2 H].  
         [0407]     IR (ν max , KBr): 1716.3, 1597.8, 1535.5, 1253.5, 747.9 cm −1 .  
         [0408]     LCMS (m/z): 595.1 (M+1, 100%).  
       3-{(4-Methoxybenzyl)-[4-[3-(2-methoxyphenyl)ureido]-6-(naphthalen-2-yloxy)-[1,3,5]triazin-2-yl]amino}propionic acid (Compound No. 45)  
       [0409]     3-{(4-Methoxybenzyl)-[4-[3-(2-methoxyphenyl)ureido]-6-(naphthalen-2-yloxy)-[1,3,5]triazin-2-yl]amino}propionic acid was prepared by using 3-(4-methoxybenzyl)aminopropionic acid instead of 3-(3-fluorobenzyl)aminopropionic acid in Step 3, Example 4.  
         [0410]     m.p.: 197-205° C.  
         [0411]      1 HNMR (DMSO-d 6 , 300 MHz): δ 12.1 (1H, bs, CO 2 H), 11.26 (s) &amp; 11.13 (s) [1H, NH], 10.19 (s) &amp; 10.17 (s) [1H, NH], 7.20-8.05 (8H, m) &amp; 6.65-7.10 (7H, m) [aromatic], 4.89 (s) &amp; 4.42 (s) [2H, NCH 2 Ar], 3.70-3.80 (2H, m, NCH 2 ), 3.72 (s) &amp; 3.71 (s) [6H, OCH 3 ×2] and 2.40 (1H, m, CH 2 CO 2 H).  
         [0412]     IR (ν max , KBr): 1708.7, 1599.5, 1243.4, 1028.7, 750.5 cm −1 .  
         [0413]     LCMS (m/z): 595.0 (M+1, 100%).  
       3-{(4-Fluorobenzyl)-[4-[3-(2-methoxyphenyl)-ureido]-6-(naphthalen-2-yloxy)-[1,3,5]triazin-2-yl]amino}propionic acid (Compound No. 46)  
       [0414]     3-{(4-Fluorobenzyl)-[4-[3-(2-methoxyphenyl)-ureido]-6-(naphthalen-2-yloxy)-[1,3,5]triazin-2-yl]amino}propionic acid was prepared by using 3-(4-fluorobenzyl)aminopropionic acid instead of 3-(3-fluorobenzyl)aminopropionic acid in Step 3, Example 4.  
         [0415]     m.p.: 211-217° C.  
         [0416]      1 HNMR (TFA-d, 300 MHz): δ 7.83-9.10 (15H, m, aromatic), 6.05 (s) &amp; 5.69 (s) [2H, NCH 2 Ar], 5.19 (1H, bs) &amp; 4.72 (1H, bs) [NCH 2 ], 5.04 (s) &amp; 5.02 (s) [3H, OCH 3 ] and 3.95 (s) &amp; 3.52 (s) [CH 2 CO 2 H].  
         [0417]     IR (ν max , KBr): 1714.1, 1603.9, 1242.8, 747.2 cm −1 .  
         [0418]     LCMS (m/z): 582.9 (M+1, 85%).  
       3-{(4-Methylbenzyl)-[4-[3-(2-methoxyphenyl)ureido]-6-(naphthalen-2-yloxy)-[1,3,5]triazin-yl]amino}propionic acid (Compound No. 47)  
       [0419]     3-{(4-Methylbenzyl)-[4-[3-(2-methoxyphenyl)ureido]-6-(naphthalen-2-yloxy)-[1,3,5]triazin-yl]amino}propionic acid was prepared by using 3-(4-methylbenzyl)aminopropionic acid instead of 3-(3-fluorobenzyl)aminopropionic acid in Step 3, Example 4.  
         [0420]     m.p.: 202-205° C.  
         [0421]      1 HNMR (DMSO-d 6 , 300 MHz): δ 12.2 (1H, bs, CO 2 H), 11.19 (s) &amp; 11.07 (s) [1H, NH], 10.16 (1H, s, NH), 7.80-8.05 (5H, m), 7.40-7.5 (3H, m) &amp; 6.85-7.15 (7H, m) [aromatic], 4.45 (s) &amp; 3.90 (s) [2H, NCH 2 Ar], 3.76 (bs) &amp; 3.70 (bs) [5H, NCH 2 , and OCH 3 ] and 2.41 (1H, m, CH 2 CO 2 H) and 2.24 (3H, s, Ar CH 3 ).  
         [0422]     IR (ν max , KBr): 1713.0, 1597.6, 1402.9, 1243.3, 748.9 cm −1 .  
         [0423]     LCMS (m/z): 579.2 (M+1, 100%).  
       3-{Benzo[1,3]dioxo-5-ylmethyl-[4-[3(2-methoxyphenly-ureido]-6-(naphthalene-2-yloxy)-[1,3,5]triazin-2-yl]amino}propionic acid (Compound No. 50)  
       [0424]     3-{Benzo[1,3]dioxo-5-ylmenthuyl-[4-[3(2-methoxyphenly-ureido-6-(naphthalene-2-yloxy)-[1,3,5]triazin-2-yl]amino}propionic acid was prepared by using 3-(benzo[1,3]dioxo-5-ylmethyl)aminopropionic acid instead of 3-(3-fluorobenzyl)aminopropionic acid in Step 3, Example 4.  
         [0425]     m.p.: 214-222° C.  
         [0426]      1 HNMR (TFA-d, 300 MHz): δ 7.50-9.10 (14H, m, aromatic), 7.06 (s) &amp; 7.02 (s) [2H, OCH 2 O], 5.98 (s) &amp; 5.66 (s) [2H, NCH 2 Ph], 5.16 (s) &amp; 5.04 (s) [5H, NCH 2  and OCH 3 ] and 3.92 (s) &amp; 3.53 (s) [2H, CH 2  CO 2 H].  
         [0427]     IR (ν max , KBr): 1715.2, 1596.4, 1558.0, 1243.9, 748.9 cm −1 .  
         [0428]     LCMS (m/z): 609.1 (M+1, 100%).  
       3-{(2-Methoxybenzyl)-[4-[3-(2-methoxyphenyl)ureido]-6-(naphthalen-2-yloxy)-[1,3,5]triazin-2-yl]amino}propionic acid (Compound No. 51)  
       [0429]     3-{(2-Methoxybenzyl)-[4-[3-(2-methoxyphenyl)ureido]-6-(naphthalen-2-yloxy)-[1,3,5]triazin-2-yl]amino}propionic acid was prepared by using 3-(2-methoxybenzyl)aminopropionic acid instead of (3-fluorobenzyl)amino propionic in Step 3, Example 4.  
         [0430]     m.p.: 185-197° C.  
         [0431]      1 HNMR (TFA-d, 300 MHz): δ 7.8-9.10 (15H, m, aromatic), 6.12 (s) &amp; 5.82 (s) [2H, NCH 2  Ar], 5.40 (bs) &amp; 4.87 (bs) [2H, NCH 2 ], 5.19 (s), 5.06 (s), 5.03 (s) &amp; 4.97 (s) [6H, 2×OCH 3 ] and 3.98 (s) &amp; 3.50 (s) [2H, CH 2 CO 2 H].  
         [0432]     IR (ν max , KBr): 1713.5, 1597.0, 1244.2, 1028.9. 750.3 cm −1 .  
         [0433]     LCMS (m/z): 595.1 (M+1, 85%).  
       3-{(3,4-Dimethoxybenzyl)-[4-[3-(2-methoxyphenyl)ureido]-6-(naphthalen-2-yloxy)-[1,3,5]triazin-2-yl]amino}propionic acid (Compound No. 52)  
       [0434]     3-{(3,4-Dimethoxybenzyl)-[4-[3-(2-methoxyphenyl)ureido]-6-(naphthalen-2-yloxy)-[1,3,5]triazin-2-yl]amino}propionic acid was prepared by using 3-(3,4-dimethoxybenzyl)aminopropionic acid instead of 3-(3-fluorobenzyl)aminopropionic acid in Step 3, Example 4.  
         [0435]     m.p.: 190-196° C.  
         [0436]      1 HNMR (DMSO-d 6 , 300 MHz): δ 11.26 (s) &amp; 11.11 (s) (1H, NH), 10.17 (s) &amp; 10.16 (s) [1H, NH], 7.80-8.10 (5H, m), 7.50 (3H, m), 6.50-7.00 (6H, m) [aromatic], 4.86 (s) &amp; 4.44 (s) [2H, NCH 2  Ar], 3.83 (s), 3.77 (s), 3.71 (s), 3.69 (s) &amp; 3.60 (s) [11H, NCH 2  and OCH 3 ×3] and 2.40 (m, CH 2  CO 2 H).  
         [0437]     IR (ν max , KBr): 1710.8, 1596.4, 1242.7, 1027.9, 750 cm −1 .  
         [0438]     LCMS (m/z): 625.1 (M+1, 100%).  
       3-{(3-Methylbenzyl)-[4-[3-(2-methoxyphenyl)ureido]-6-(naphthalen-2-yloxy)-[1,3,5]triazin-2-yl]amino}propionic acid (Compound No. 53)  
       [0439]     3-{(3-Methylbenzyl)-[4-[3-(2-methoxyphenyl)ureido]-6-(naphthalen-2-yloxy)-[1,3,5]triazin-2-yl]amino}propionic acid was prepared by using 3-(3-methylbenzyl)aminopropionic acid instead of 3-(3-fluorobenzyl)aminopropionic acid in Step 3, Example 4.  
         [0440]     m.p.: 105-125° C.  
         [0441]      1 HNMR (TFA-d, 300 MHz): δ 7.80-9.15 (15H, m, aromatic), 6.20 (s), 6.08 (s) &amp; 5.76 (s) [2H, NCH 2  Ar], 5.42 (bs), 4.99 (bs) &amp; 4.78 (bs) [NCH 2 ], 5.20 (s), 5.08 (s), 5.05 (s) [3H, OCH 3 ], 3.95 (bs), 3.53 (bs) &amp; 3.48 (bs), [2H, CH 2 CO 2 H] and 3.43 (s), 3.32 (s) &amp; 3.21 (s) [3H, ArCH 3 ].  
         [0442]     IR (ν max , KBr): 1709.6, 1596.0, 1245.6, 749.3 cm −1 .  
         [0443]     LCMS (m/z): 579.2 (M+1, 100%).  
       3-{(2-Fluorobenzyl)-[4-[3-(2-methoxyphenyl)ureido-6-(naphthalen-2-yloxy)-[1,3,5]triazin-2-yl]amino}propionic acid (Compound No. 54)  
       [0444]     3-{(2-Fluorobenzyl)-[4-[3-(2-methoxyphenyl)ureido-6-(naphthalen-2-yloxy)-[1,3,5]triazin-2-yl]amino}propionic acid was prepared by using 3-(2-fluorobenzyl)aminopropionic acid instead of 3-(3-fluorobenzyl)aminopropionic acid in Step 3, Example 4.  
         [0445]     m.p.: 218-230° C.  
         [0446]      1 HNMR (TFA-d, 300 MHz): δ 7.6-9.15 (15H, m, aromatic), 6.18 &amp; 5.82 (s) [2H, NCH 2 Ar], 5.28 (bs) &amp; 4.78 (m), [2H, NCH 2 ], 5.08 (s) &amp; 5.07 (s) [3H, OCH 3 ] and 3.99 (bs) &amp; 3.51 (m) [2H, CH 2 CO 2 H].  
         [0447]     IR (ν max , KBr): 1716.5, 1594.9, 1556.0, 1361.6, 1244.0, 750.6 cm −1 .  
         [0448]     LCMS (m/z): 583.1 (M+1, 100%).  
       3-{(2-Chlorobenzyl)-[4-[3-(2-methoxyphenyl)ureido-6-(naphthalen-2-yloxy)-[1,3,5]triazin-2-yl]amino]propionic acid (Compound No. 55)  
       [0449]     3-{(2-Chlorobenzyl)-[4-[3-(2-methoxyphenyl)ureido-6-(naphthalen-2-yloxy)-[1,3,5]triazin-2-yl]amino]propionic acid was prepared by using 3-(2-chlorobenzyl)aminopropionic acid instead of 3-(3-fluorobenzyl)aminopropionic acid in Step 3, Example 4.  
         [0450]     m.p.: 190-215° C.  
         [0451]      1 HNMR (TFA-d, 300 MHz): δ 8.15-9.10 (17H, m, aromatic and 2NH), 6.23 (s) &amp; 5.88 (s) [24, NCH 2 Ar], 5.22 (bs) &amp; 4.76 (bs) [2H, NCH 2 ], 5.06 (s) &amp; 5.02 (s) [3H, OCH 3 ] and 3.93 (bs) &amp; 3.48 (bs) [CH 2 CO 2 H].  
         [0452]     IR (ν max , KBr): 1717.5, 1598.8, 1537.4, 1243.3, 749.4 cm −1 .  
         [0453]     LCMS (m/z): 599.0 (M+1, 100%).  
       3-{(2,4-Dichlorobenzyl)-[4-[3-(2-methoxyphenyl)ureido-6-(naphthalen-2-yloxy)-[1,3,5]triazin-2-yl]amino}propionic acid (Compound No. 56)  
       [0454]     3-{(2,4-Dichlorobenzyl)-[4-[3-(2-methoxyphenyl)ureido-6-(naphthalen-2-yloxy)-[1,3,5]triazin-2-yl]amino}propionic acid was prepared using 3-(2,4-dichlorobenzyl)aminopropionic acid instead of 3-(3-fluorobenzyl)aminopropionic acid in Step 3, Example 4.  
         [0455]     m.p.: 225-230° C.  
         [0456]      1 HNMR (TFA-d, 300 MHz): δ 7.85-9.05 (16H, m, aromatic and 2NH), 6.22 (s) &amp; 5.81 (s) [2H, NCH 2  Ar], 5.27 (bs) &amp; 4.78 (bs) [2H, NCH 2 ], 5.09 (s) &amp; 5.06 (s) [3H, OCH 3 ] and 4.01 (bs) &amp; 3.54 (m) [2H, CH 2 CO 2 H].  
         [0457]     IR (ν max , KBr): 1710.4, 1597.9, 1368.3, 750.4 cm −1 .  
         [0458]     LCMS (m/z): 633.2 (M+1, 65%).  
       3-{(3,4-Dichlorobenzyl)-[4-[3-(2-methoxyphenyl)ureido-6-(naphthalen-2-yloxy)-[1,3,5]triazin-2-yl]amino}propionic acid (Compound No. 57)  
       [0459]     3-{(3,4-Dichlorobenzyl)-[4-[3-(2-methoxyphenyl)ureido-6-(naphthalen-2-yloxy)-[1,3,5]triazin-2-yl]amino}propionic acid was prepared by using 3-(3,4-dichlorobenzyl)aminopropionic instead of 3-(3-fluorobenzyl)aminopropionic acid in Step 3, Example 4.  
         [0460]     m.p.: 194-206° C.  
         [0461]      1 HNMR (TFA-d, 300 MHz): δ 8.00-8.70 (19H, m, aromatic and 2NH), 5.99 (s) &amp; 5.89 (s) [2H, NCH 2 Ar], 5.14 (bs), 5.03 (s) &amp; 5.01 (s) [5H, NCH 2  and OCH 3 ], 3.74 (bs) &amp; 3.51 (bs) [2H, CH 2 CO 2 H], 3.43 (s) &amp; 3.40 (s) [3H, Ar—CH 3 ].  
         [0462]     IR (ν max , KBr): 1709.4, 1599.7, 1534.3, 1249.8, 746.9 cm −1 .  
         [0463]     LCMS (m/z): 604.1 (M+1, 90%).  
       3-{(1H-Indol-3-yl)-2S-([4-(2-methoxyphenyl)ureido]-6-(naphthalen-2-yloxy)-[1,3,5]triazin-2-yl)amino}propionic acid (Compound No. 60)  
       [0464]     3-{(1H-Indol-3-yl)-2S-([4-(2-methoxyphenyl)ureido]-6-(naphthalen-2-yloxy)-[1,3,5]triazin-2-yl)amino}propionic acid was prepared by using 2S-amino-3-(1H-indol-3-yl)propionic acid (L-tryptophan) instead of 3-(3-fluorobenzyl)aminopropionic acid in Step 3, Example 4.  
         [0465]     m.p.: 147-152° C.  
         [0466]      1 HNMR (DMSO-d 6 , 300 MHz): δ 11.41 (s) &amp; 11.19 (s) [1H, CO 2 H], 10.83 (s) &amp; 10.78 (s) [1H, NH], 10.03 (1H, s, NH), 7.90-8.00 (5H, m), 7.78 (1H, bs), 7.25-7.55 (6H, m) &amp; 6.85-7.10 (6H, m), [aromatic and 2NH], 4.81 (t) &amp; 4.47 (bs) [1H, NCHCO 2 H], 3.74 (s) &amp; 3.64 (s) [3H, OCH 3 ] and 3.15 (m, CH 2  Ar).  
         [0467]     LCMS (m/z): 590.2 (M+1, 100%).  
       2-{4-[3-(2-Methoxyphenyl)ureido]-6-(naphthalen-2-yloxy)-[1,3,5]triazin-2-yl} 1,2,3,4-tetrahydro-isoquinoline-3-carboxylic acid (Compound No. 61)  
       [0468]     2-{4-[3-(2-Methoxyphenyl)ureido]-6-(naphthalen-2-yloxy)-[1,3,5]triazin-2-yl} 1,2,3,4-tetrahydro-isoquinoline-3-carboxylic acid was prepared by using 1,2,3,4-tetrahydro-isoquinoline-3-carboxylic acid instead of 3-(3-fluorophenyl)aminopropionic acid in Step 3, Example 4.  
         [0469]     m.p.: 230-235° C.  
         [0470]      1 HNMR (DMSO-d 6 , 300 MHz): δ 11.14 (s) &amp; 10.90 (s) [1H, CO 2 H], 10.20 (s) &amp; 10.10 (s) [1H, NH], 8.08 (d, J=9 Hz), 7.75-8.00 (5H, m), 7.52 (d, J=9 Hz), 7.44 (bs) &amp; 7.38 (bs) [3H], 7.16 (bs) &amp; 7.01 (m) [7H] [aromatic, 1NH], 5.61 (s) &amp; 5.16 (s), [1H, NCHCO 2 H], 5.06 (d) &amp; 4.75 (d) [1H] &amp; 4.82 (1H, t) [NCH 2 Ar], 3.81 (s) &amp; 3.77 (s) [3, OCH 3 ] and 3.17 (2H, bs, CH 2  Ar).  
         [0471]     IR (ν max , KBr): 1709.5, 1594.8, 1528.2, 1243.0, 748.7 cm −1 .  
         [0472]     LCMS (m/z): 563.1 (M+1, 100%).  
       2-{(4-Fluorobenzyl)-[4-[3-(2-methoxyphenyl)ureido-6-(naphthalen-2-yloxy)-[1,3,5]triazin-2-yl]amino}-acetic acid (Compound No. 62)  
       [0473]     2-{(4-Fluorobenzyl)-[4-[3-(2-methoxyphenyl)ureido-6-(naphthalen-2-yloxy)-[1,3,5]triazin-2-yl]amino}-acetic acid was prepared by using 2-(4-fluorobenzyl)aminoacetic acid instead of 3-(3-fluorobenzyl)aminopropionic acid in Step 3, Example 4.  
         [0474]     m.p.: 196-200° C.  
         [0475]      1 HNMR (TFA-d, 300 MHz): δ 7.90.9.20 (15H, m, aromatic), 6.31 (s), 6.21 (s), 5.83 (s), 5.75 (s), 5.73 (s), 5.57 (s), 5.44 (s), 5.31 (s), 5.27 (s), 5.15 (s) &amp; 5.13 (s) [7H, NCH 2 Ar, NCH 2 CO 2 H and OCH 3 ].  
         [0476]     LCMS (m/z): 569.0 (M+1, 100%).  
       2-{(4-Methoxybenzyl)-[4-[3-(2-methoxyphenyl)ureido-6-(naphthalen-2-yloxy)-[1,3,5]triazin-2-yl]amino}acetic acid (Compound No. 63)  
       [0477]     2-{(4-Methoxybenzyl)-[4-[3-(2-methoxyphenyl)ureido-6-(naphthalen-2-yloxy)-[1,3,5]triazin-2-yl]amino}acetic acid was prepared by using 2-(4-methoxybenzyl)aminoacetic acid instead of 3-(3-fluorobenzyl)amino propionic acid in Step 3, Example 4.  
         [0478]     m.p.: 214-217° C.  
         [0479]      1 HNMR (DMSO-d 6 , 300 MHz): δ 11.10 (s) &amp; 11.02 (s) [1H, CO 2 H], 10.21 (s) &amp; 10.14 (s) [1H, NH], 7.90-8.02 (4H, m), 7.86 (1H, d, J=18 Hz), 7.50 (3H, m), 7.25 (1H, d, J=6 Hz), 6.55-7.00 (5H, m) and 6.57 (1H, d, J=6 Hz), 4.83 (s) &amp; 3.91 (s), [2H, NCH 2 Ar], 4.35 (s) &amp; 4.30 (s), [2H, NCH 2 CO 2 H] and 3.82 (s), 3.75 (s), 3.69 (s) &amp; 3.65 (s) [6H, 2×OCH 3 ].  
         [0480]     IR (ν max , KBr): 1750.7, 1706.2, 1594.2, 1536.5, 1246.4, 745.3 cm −1 .  
         [0481]     LCMS (m/z): 581.2 (M+1, 100%).  
       2-{(4-Methylbenzyl)-[4-[3-(2-methoxyphenyl)ureido-6-(naphthalen-2-yloxy)-[1,3,5]triazin-2-yl]amino}acetic acid (Compound No. 64)  
       [0482]     2-{(4-Methylbenzyl)-[4-[3-(2-methoxyphenyl)ureido-6-(naphthalen-2-yloxy)-[1,3,5]triazin-2-yl]amino} acetic acid was prepared by using 2-(4-methylbenzyl)aminoacetic acid instead of 3-(3-fluorobenzyl)aminopropionic acid in Step 3, Example 4.  
         [0483]     m.p.: 205-210° C.  
         [0484]      1 HNMR (TFA-d, 300 MHz): δ 7.6-8.80 (15H, m, aromatic), 5.81 (s) &amp; 4.94 (s), [2H, NCH 2 Ar], 5.46 (s) &amp; 5.36 (s) [2H, NCH 2 CO 2 H], 4.90 (s) &amp; 4.70 (s) [3H, OCH 3 ] and 3.15 (s) &amp; 3.09 (s), [3H, ArCH 3 ].  
         [0485]     IR (ν max , KBr): 1702.1, 1594.2, 1244.1, 747.1 cm −1 .  
         [0486]     LCMS (m/z): 565.1 (M+1, 100%).  
       3-{(3,4-Difluorobenzyl)-[4-[3-(2-methoxyphenyl)ureido-6-naphthalen-2-yloxy-[1,3,5]triazin-2-yl]amino}propanoic acid (Compound No. 65)  
       [0487]     3-{(3,4-Difluorobenzyl)-[4-[3-(2-methoxyphenyl)ureido-6-naphthalen-2-yloxy)-[1,3,5]triazin-2-yl]amino}propanoic acid was prepared by using 3-(3,4-difluorobenzyl)aminopropionic acid instead of 3-(3-fluorobenzyl)aminopropionic acid in Step 3, Example 4.  
         [0488]     m.p.: 194-196° C.  
         [0489]      1 HNMR (TFA-d, 300 MHz): δ 8.50-9.50 (14H, m, aromatic), 6.15 (s) &amp; 5.94 (s) [2H, NCH 2 Ar], 5.64 (bs) &amp; 5.43 (bs) [2H, NCH 2 ], 5.53 (s) &amp; 5.52 (s) [3H, OCH 3 ] and 5.22 (t) &amp; 4.46 (t) [2H, CH 2 CO 2 H].  
         [0490]     IR (ν max , KBr): 1701.4, 1596.3, 1553.5, 1243.5, 746.4 cm −1 .  
       3-{4-[3-(2-Methoxyphenyl)ureido]-6-(naphthalen-2-yloxy)-[1,3,5]triazin-2-yl]-thiophen-2-yl-methylamino}propionic acid (Compound No. 66)  
       [0491]     3-{4-[3-(2-Methoxyphenyl)ureido]-6-(naphthalen-2-yloxy)-[1,3,5]triazin-2-yl]-thiophen-2-yl-methylamino}propionic acid was prepared by using 3-{(thiophen-2-yl)methylamino}propionic acid instead of 3-(3-fluorobenzyl)aminopropionic acid in Step 3, Example 4.  
         [0492]     m.p.: 204-208° C.  
         [0493]      1 HNMR (TFA-d, 300 MHz): δ 7.00-8.50 (14H, m, aromatic), 5.53 (s) &amp; 5.25 (s) [2H, NCH 2 Ar], 4.48 (t) &amp; 4.12 (t) [2H, NCH 2 ], 4.37 (s) &amp; 4.28 (s) [3H, OCH 3 ] and 3.28 (t) &amp; 2.93 (t) [CH 2 CO 2 H].  
         [0494]     IR (ν max , KBr): 1710.8, 1596.4, 1536.5, 1241.2, 748.7 cm −1 .  
         [0495]     LCMS (m/z): 571.1 (M+1, 100%).  
       3-{(4-Trifluoromethylbenzyl)-[4-[3-(2-methoxyphenyl-ureido-6-(naphthalen-2-yloxy}-[1,3,5]triazin-2-yl]amino}propanoic acid (Compound No. 67)  
       [0496]     3-{(4-Trifluoromethylbenzyl)-[4-[3-(2-methoxyphenyl)ureido-6-(naphthalen-2-yloxy}-[1,3,5]triazin-2-yl]amino}propanoic acid was prepared by using 3-(4-trifluoromethylbenzyl)aminopropionic acid instead of 3-(3-fluorobenzyl)aminopropionic acid in Step 3, Example 4.  
         [0497]     m.p.: 198-200° C.  
         [0498]      1 HNMR (TFA-d, 300 MHz): δ 9.10-9.50 (m), 8.84-8.95 (m), 8.66 (m) &amp; 8.44 (d, J=9 Hz) [17H, aromatic and 2NH], 6.63 (s) &amp; 6.24 (s), [2H, NCH 2 Ar], 5.74 (t) 5.25 (t, J=9 Hz) [2H, NCH 2 ] and 5.53 (s), 5.50 (s), 5.47 (s) &amp; 5.43 (s) [3H, OCH 3 ].  
         [0499]     IR (ν max , KBr): 1717.5, 1598.0, 1541.0, 1327.0, 1166.3, 747.0 cm −1 .  
         [0500]     LCMS (m/z): 633.4 (M+1, 100%).  
       3-{[2-(1H-Indol-3-yl)ethyl]-[4-[3-(2-methoxyphenyl)ureido]-6-(naphthalen-2-yloxy)]-[1,3,5]triazin-2-yl]amino}propanoic acid (Compound No. 68)  
       [0501]     3-{[2-(1H-Indol-3-yl)ethyl]-[4-[3-(2-methoxyphenyl)ureido]-6-(naphthalen-2-yloxy)]-[1,3,5]triazin-2-yl]amino}propanoic acid was prepared by using 3-[(2-(1H-indol-3-yl)ethyl]aminopropionic acid instead of 3-(3-fluorobenzyl)aminopropionic acid in Step 3, Example 4.  
         [0502]     m.p.: 114-120° C.  
         [0503]      1 HNMR (DMSO-d 6 , 300 MHz): δ 11.24 (s) &amp; 11.18 (s) [1H, NH], 10.75 (s) &amp; 10.66 (s) [1H, NH], 10.12 (s) &amp; 10.10 (s) [1H, NH], 7.80-8.10 (m), 7.51 (m), 7.27 (t, J=9 Hz), 6.9-7.05 (m) &amp; 6.64 (m) [16H, aromatic], 3.91 (m), 3.87 (s), 3.85 (s), 3.78 (s) &amp; 3.64 (bs) [NCH 2 ×2 and OCH 2 ], 3.35-3.50 (2H, m, ArCH 2 ) and 2.93 (t) &amp; 2.77 (t) [2H, CH 2 CO 2 H].  
         [0504]     IR (ν max , KBr): 1705.2, 1596.6, 1559.9, 1244.1, 746.6 cm −1 .  
         [0505]     LCMS (m/z): 618.2 (M+1, 100%).  
       1-[4-[2-(4-Hydroxyphenyl)ethylamino]-6-(naphthalen-2-yloxy}-[1,3,5]triazin-2-yl]-3-(2-methoxyphenyl)urea (Compound No. 69)  
       [0506]     1-[4-[2-(4-Hydroxyphenyl)ethylamino]-6-(naphthalen-2-yloxy}-[1,3,5]triazin-2-yl]-3-(2-methoxyphenyl)urea was prepared by using 2-(4-hydroxyphenyl)ethylamine in place of 3-(3-fluorophenyl)aminopropionic acid in Step 3, Example 4.  
         [0507]     m.p.: 238° C.  
         [0508]      1 HNMR (DMSO-d 6 , 300 MHz): δ 11.62 (s) &amp; 11.27 (s) [1H, NH], 10.09 (s) &amp; 9.999 (s) [1H, NH], 9.15 (s) &amp; 9.08 (s) [1H, NH], 7.79-8.10 (6H, m), 7.50-7.57 (3H, m), 7.02 (bs), 6.95 (d, J=8.1 Hz), 6.88 (d, J=8.4 Hz) [4H], 6.53 (1H, d, J=8.4 Hz) &amp; 6.48 (dd), [aromatic], 3.82 (s) &amp; 3.62 (s) [3H, OCH 3 ], 3.48 (m) &amp; 3.06 (t) [2H, NCH 2 ] and 2.65 (t) &amp; 2.43 (t) [2H, CH 2  Ar].  
         [0509]     IR (ν max , KBr): 1702.5, 1600.1, 1343.9, 1243.5, 743.8 cm −1 .  
         [0510]     LCMS (m/z): 523.3 (M+1, 100%).  
       1-[4-[2-(1H-Indol-3-yl)ethylamino]-6-(naphthalen-2-yloxy)-[1,3,5]triazin-2-yl]-3-(2-methoxyphenyl)urea (Compound No. 70)  
       [0511]     1-[4-[2-(1H-Indol-3-yl)ethylamino]-6-(naphthalen-2-yloxy)-[1,3,5]triazin-2-yl]-3-(2-methoxyphenyl)urea was prepared by using 2-(1H-indol-2-yl)ethylamine in place of 3-(3-fluorobezyl)aminopropionic acid in Step 3, Example 4.  
         [0512]     m.p.: 243-248° C.  
         [0513]      1 HNMR (DMSO-d 6 , 300 MHz): δ 11.55 (s) &amp; 11.34 (s) [1H, NH], 10.75 (s) &amp; 10.72 (s) [1H, NH], 10.07 (s) &amp; 9.98 (s) [1H, NH], 7.79-8.10 (m), 7.51 (m), 7.43 (d, J=8.4 Hz), 7.28 (t), 6.65-7.05 (m) [16H aromatic], 3.77 (bs) &amp; 3.63 (bs) &amp; [OCH 3 ] and 2.89 (t, J=7.2 Hz) and 2.79 (t, J=8.1 Hz) [2H, CH 2 Ar].  
         [0514]     IR (ν max , KBr): 1696.5, 1599.7, 1546.9, 1245.6, 741.6 cm −1 .  
         [0515]     LCMS (m/z): 546.2 (M+1, 100%).  
       1-(2-Methoxyphenyl)-3-[(4-(3-methylbenzyl)amino)-6-(nalphthalen-2-yloxy)-[1,3,5]triazin-2-yl]urea (Compound No. 71)  
       [0516]     1-(2-Methoxyphenyl)-3-[(4-(3-methylbenzyl)amino)-6-(naphthalen-2-yloxy)-[1,3,5]triazin-2-yl]urea was prepared by using 3-methylbenzylamine instead of 3-(3-fluorophenyl)aminopropionic acid in Step 3, Example 4.  
         [0517]     m.p.: 245-247° C.  
         [0518]      1 HNMR (TFA-d, CDCl 3 , 300 MHz): δ 7.00-8.37 (15H, m, aromatic), 5.12 (s) &amp; 4.73 (AB q ) [2H, NCH 2 Ar], 4.25 (s) &amp; 3.93 (bs) [3H, OCH 3 ], 2.63 (s) &amp; 2.55 (s) [3H, Ar CH 3 ].  
         [0519]     IR (ν max , KBr): 1701.5, 1603.5, 1246.1, 744.5 cm −1 .  
         [0520]     LCMS (m/z): 507.2 (M+1, 100%).  
       1-[(4-(3,4-Dichlorobenzyl)amino)-6-(naphthalen-2-yloxy)-[1,3,5]triazin-2-yl]-3-(2-methoxyphenyl)urea (Compound No. 72)  
       [0521]     1-[(4-(3,4-Dichlorobenzyl)amino)-6-(naphthalen-2-yloxy)-[1,3,5]triazin-2-yl]-3-(2-methoxyphenyl)urea was prepared by using 3,4-dichlorobenzylamine instead of 3-(3-fluorobenzyl)aminopropionic acid in Step 3, Example 4.  
         [0522]     m.p.: 265-268° C.  
         [0523]      1 HNMR (TFA-d, CDCl 3 , 300 MHz): δ 7.05-8.47 (14H, m, aromatic), 5.17 (s) &amp; 4.75 (AB q , J=8.1 Hz) [2H, NCH 2 Ar], 4.33 (s) &amp; 3.93 (bs) [3H, OCH 3 ].  
         [0524]     LCMS (m/z): 561.1 (M+1, 100%)  
       4-[{4-{3-(2-Methoxyphenyl)ureido}-6-(naphthalen-2-yloxy)-[1,3,5]triazin-2-yl}amino]phenylacetic acid (Compound No. 79)  
       [0525]     4-[{4-{3-(2-Methoxyphenyl)ureido}-6-(naphthalen-2-yloxy)-[1,3,5]triazin-2-yl}amino]phenylacetic acid was prepared by using 4-aminophenylacetic acid in place of 3-(3-fluorophenyl)amino propionic acid in Step 3, Example 4.  
         [0526]     m.p.: 232-240° C.  
         [0527]      1 HNMR (TFA-d, CDCl 3 , 300 MHz): δ 8.2-9.21 (15H, m, aromatic) and 5.15 (s), 5.10 (s), 5.07 (s), 4.89 (s) [5H, OCH 3  and CH 2 CO 2 H].  
         [0528]     IR (ν max , KBr): 1704.9, 1665.1, 1548.6, 1347.2, 1164.3 cm −1 .  
         [0529]     LCMS (m/z): 537.0 (M+1, 100%).  
       3-{[4-[3-(2-Methoxyphenyl)ureido]-6-(naphthalen-2-yloxy)-[1,3,5]triazin-2-yl]-methylamino}-propionic acid (Compound No. 104)  
       [0530]     3-{[4-[3-(2-Methoxyphenyl)ureido]-6-(naphthalen-2-yloxy)-[1,3,5]triazin-2-yl]-methylamino}-propionic acid was prepared by using 3-(methylamino)propionic acid instead of 3-(3-fluorobenzyl)amino propionic acid in Step 3, Example 4.  
         [0531]     m.p.: 178-180° C.  
         [0532]      1 HNMR (DMSO-d 6 , 300 MHz): δ 11.04 (s) &amp; 11.01 (s), [1H, NH], 10.17 (s) &amp; 10.11 (s) [1H, NH], 7.75-8.10 (4H, m), 7.19-7.55 (4H, m), 6.9-7.05 (3H, m) &amp; [aromatic], 4.43 (s) &amp; 4.11 (s) [2H, NCH 2 ], 3.81 (s) &amp; 3.78 (s) [3H, OCH 3 ], 3.17 (s) &amp; 2.91 (s) [3H, N—CH 3 ] 
         [0533]     IR (ν max , KBr): 1717.1, 1597.4, 1242.5, 748.5 cm −1 .  
         [0534]     LCMS (m/z): 475.3 (M+1, 100%).  
       3-{(3-Chlorobenzyl)-[4-[3-(2-methoxyphenyl)ureido]-6-(naphthalen-2-yloxy)-[1,3,5]triazin-2-yl]amino}propionic acid (Compound No. 106)  
       [0535]     3-{(3-Chlorobenzyl)-[4-[3-(2-methoxyphenyl)ureido]-6-(naphthalen-2-yloxy)-[1,3,5]triazin-2-yl]amino}propionic acid was prepared by using 3-(3-chlorobenzyl)aminopropionic acid instead of 3-(3-fluorobenzyl)aminopropionic acid in Step 3, Example 4.  
         [0536]     m.p.: 215-218° C.  
         [0537]      1 HNMR (TFA-d, 300 MHz): δ 7.35-8.58 (15H, m, aromatic), 5.58 (s) &amp; 5.24 (s) [2H, NCH 2 Ar], 4.73 (t) &amp; 4.29 (t) [2H, NCH 2 ], 4.57 (s) &amp; 4.54 (s) [3H, OCHz] and 3.50 (s) &amp; 3.08 (s) [2H, CH 2 CO 2 H].  
         [0538]     IR (ν max , KBr): 1715.7, 1537.0, 1243.0, 747.7 cm −1 .  
         [0539]     LCMS (m/z): 599.2 (M+1, 20%).  
       3-{[4-[3-(2-Methoxyphenyl)ureido]-6-(naphthalen-2-yloxy)-[1,3,5]triazin-2-yl]-(2-trifluoromethylbenzyl)amino}propionic acid (Compound No. 107)  
       [0540]     3-{[4-[3-(2-Methoxyphenyl)ureido]-6-(naphthalen-2-yloxy)-[1,3,5]triazin-2-yl]-(2-trifluoromethylbenzyl)amino}propionic acid was prepared by using 3-(2-trifluoromethylbenzyl)aminopropionic acid instead of 3-(3-fluorobenzyl)aminopropionic acid in Step 3, Example 4.  
         [0541]     m.p.: 232-233° C.  
         [0542]      1 HNMR (TFA-d, 300 MHz): δ 8.00-8.70 (11H, m), 7.74 (4H, m) [aromatic], 5.87 (s) &amp; 5.54 (s) [2H, NCH 2 Ar], 4.75 (t) &amp; 4.30 (t, J=6 Hz) [2, NCH 2 ], 4.60 (s) &amp; 4.54 (s) [3H, OCH 3 ], 3.52 (t) &amp; 3.13 (t, J=9 Hz) (2H, CH 2 CO 2 H).  
         [0543]     LCMS (m/z): 633.5 (M+1, 8.5%).  
       3-{[4-[3-(2-Methoxyphenyl)ureido]-6-(naphthalen-2-yloxy)-[1,3,5]triazin-2-yl]-(3-trifluoromethylbenzyl)aminopropionic acid (Compound No. 108)  
       [0544]     3-{[4-[3-(2-Methoxyphenyl)ureido]-6-(naphthalen-2-yloxy)-[1,3,5]triazin-2-yl]-(3-trifluoromethylbenzyl)aminopropionic acid was prepared by using 3-(3-trifluoromethylbenzyl)aminopropionic acid instead of 3-(3-fluorobenzyl)aminopropionic acid in Step 3, Example 4.  
         [0545]     m.p.: 185-188° C.  
         [0546]      1 HNMR (TFA-d, 300 MHz): δ 8.00-8.60 (9H, m), 7.50-8.00 (6H, m) [aromatic] 5.67 (s) &amp; 5.33 (s) [2H, NCH 2 Ar], 4.73 (t) &amp; 4.29 (t) [2H, NCH 2 ], 4.57 (s) &amp; 4.54 (s) [3H, OCH 3 ] and 3.50 (t) [2H, CH 2 CO 2 H].  
         [0547]     IR (ν max , KBr): 1716.9, 1596.9, 1123.3, 748.4 cm −1 .  
         [0548]     LCMS (m/z): 633.5 (M+1, 75%).  
       3-{(2,4-Bis-trifluoromethylbenzyl)-[4-[3-(2-methoxyphenyl)ureido]-6-(naphthalen-2-yloxy)-[1,3,5]triazin-2-yl]amino}propionic acid (Compound No. 109)  
       [0549]     3-{(2,4-Bis-trifluoromethylbenzyl)-[4-[3-(2-methoxyphenyl)ureido]-6-(naphthalen-2-yloxy)-[1,3,5]triazin-2-yl]amino}propionic acid was prepared by using 3-(2,4-bis trifluoromethylbenzyl)aminopropionic acid instead of 3-(3-fluorobenzyl)aminopropionic acid in Step 3, Example 4.  
         [0550]     m.p.: 192° C.  
         [0551]      1 HNMR (TFA-d, 300 MHz): δ 7.6-8.6 (14H, m, aromatic), 5.76 (s) &amp; 5.42 (s) [2H, NCH 2 Ar], 4.72 (t) &amp; 4.31 (t) [2H, NCH 2 ], 4.58 (s) &amp; 4.55 (s) [3H, OCH 3 ], 3.53 (t) &amp; 3.16 (t, J=6 Hz) [2H, CH 2 CO 2 H].  
         [0552]     IR (ν max , KBr): 1728.9, 1560.0, 1280.4, 747.3 cm −1 .  
         [0553]     LCMS (m/z): 701.3 (M+1, 65%).  
       3-{(Biphenyl-4-ylmethyl)-[4-[3-(2-methoxyphenyl)ureido]-6-naphthalen-2-yloxy-[1,3,5]triazin-2-yl]amino}propionic acid (Compound No. 110)  
       [0554]     3-{(Biphenyl-4-ylmethyl)-[4-[3-(2-methoxyphenyl)ureido]-6-naphthalen-2-yloxy)-[1,3,5]triazin-2-yl]amino}propionic acid was prepared by using 3-(biphenyl-4-ylmethyl)aminopropionic acid instead of 3-(3-fluorobenzyl)aminopropionic acid in Step 3, Example 4.  
         [0555]     m.p.: 202-203° C.  
         [0556]      1 HNMR (TFA-d, 300 MHz): δ 7.50-8.60 (20H, m, aromatic), 5.64 (s) &amp; 5.30 (s), [2H, NCH 2 Ar], 4.79 (t) &amp; 4.32 (t) [2H, NCH 2 ], 4.57 (s) &amp; 4.53 (s) [3H, OCH 3 ] and 3.52 (t) &amp; 3.08 (t) [2H, CH 2 CO 2 H].  
         [0557]     IR (ν max , KBr): 1710.6, 1595.8, 1245.7, 748.2 cm −1 .  
         [0558]     LCMS (m/z): 641.4 (M+1, 100%).  
       3-{[4-[3-(2-Methoxyphenyl)ureido]-6-(naphthalen-2-yloxy)-[1,3,5]triazin-2-yl]-(naphthalen-1-ylmethyl)amino}-propionic acid (Compound No. 111)  
       [0559]     3-{[4-[3-(2-Methoxyphenyl)ureido]-6-(naphthalen-2-yloxy)-[1,3,5]triazin-2-yl]-(naphthalen-1-ylmethyl)amino}-propionic acid was prepared by using 3-(napthalen-1-ylmethyl)aminopropionic acid instead of 3-(2-fluorobenzyl)aminopropionic acid in Step 3, Example 4.  
         [0560]     m.p.: 230-233° C.  
         [0561]      1 HNMR (TFA-d, 300 MHz): δ 7.60-8.60 (18H, m, aromatic), 6.08 (s) &amp; 5.77 (s) [2H, NCH 2 Ar], 4.77 (t) &amp; 4.30 (t) [2H, NCH 2 ], 4.57 (s) &amp; 4.49 (s) [3H, OCH 3 ] and 3.33 (t) &amp; 2.83 (t) [2H, CH 2 CO 2 H].  
         [0562]     IR (ν max , KBr): 1717.5, 1558.2, 1244.7, 748.2 cm −1 .  
         [0563]     LCMS (m/z): 615.3 (M+1, 70%).  
       Example 5  
     Preparation of 2-[-4-[3-(2-Methoxyphenyl)ureido]-6-(napthalen-2-yloxy)-[1,3,5]triazin-2-yl] malonic acid di tert butyl ester (Compound No. 5)  
     Step 1: Preparation of [2-amino-6-(naphthalen-2-yloxy)-[1,3,5]triazin-2-yl] malonic acid di tert butyl ester  
       [0564]     To a suspension of sodium hydride (352 mg, 50% dispersion in oil, 7.34 mmol) in dry THF (40 ml) at 0° C. was added di-tert-butyl malonate (1.59 g, 7.34 mmol) slowly and stirred for 30 min. Maintaining the same temperature, 4-chloro-6-(naphthalen-2-yloxy)-[1,3,5]triazin-2-ylamine (prepared as in Example 4) (1 gm, 3.67 mmol) was added and stirred for 30 min at 0° C. and then at room temperature overnight. It was poured over ice water and extracted with ethyl acetate (3×50 ml). The combined extracts were washed with brine and dried (Na 2 SO 4 ). Evaporation of the solvent and purification of the residue over a silica gel column using 10-40% EtOAc. Hexane afforded the title compound (850 mg, 53%) as a white solid.  
         [0565]     1HNMR (300 MHz, CDCl 3 ): δ 7.75-7.87 (3H, m), 7.59 (1H, s), 7.45-7.50 (2H, m), and 7.25-7.32 (1H, m) [aromatic], 5.73 (bs) &amp; 5.57 (bs) [H, NH 2 ], 4.53 (1H, s, Ch) and 1.42 (18H, s, CH 3 ×6).  
         [0566]     IR (ν max , KBr): 1746.2, 1644.3, 1374.5, 1137.6, 749.4 cm −1    
         [0567]     LCMS (m/z): 453.2 (M+1, 100%).  
       Step 2: Preparation of 2-[-4-[3-(2-methoxyphenyl)ureido]-6-(napthalen-2-yloxy)-[1,3,5]triazin-2-yl]malonic acid di tert butyl ester  
       [0568]     To a solution of the intermediate (160 mg, 0.35 mmol) obtained from Step 1 Example 5 above in dry THF (2 ml) maintained at 0° C., was added sodium hydride (17 mg, 50% dispersion in oil, 0.35 mmol) followed by 2-methoxyphenyl isocyanate (52 mg, 0.35 mmol) and stirred at rt for 3 hours. The mixture was poured over ice water and extracted with ethyl acetate (3×20 ml). The combined extracts were washed with brine and dried (Na 2 SO 4 ) and concentrated. The residue was purified over a silica gel column using 15% ethyl acetate-hexane as eluent to obtain the title compound (140 mg, 67%) as a white solid.  
         [0569]     1HNMR (DMSO-d 6 , 300 MHz): δ 11.20 (1H, s) and 10.91 (1H, s) [NH×2], 7.84-8.15 (5H, m), 7.52-7.56 (3H, m) and 7.04-7.07 (3H, m) [aromatic], 4.67 (1H, s, CH), 3.86 (3H, s, OCH 3 ) and 1.24 (18H, s, CH 3 ×6].  
         [0570]     IR (ν max , KBr): 1733.5, 1541.8, 1246.3, 1160.8, 748.8 cm −1 .  
         [0571]     LCMS (m/z): 602.1 (M+1, 100%).  
       Example 6  
     Preparation of 1-[4-Methoxy-6-(naphthalen-2-yloxy)-[1,3,5]triazin-2-yl]-3-(2-methoxyphenyl)urea (Compound No. 6)  
       [0572]     To the chlorotriazine (211 mg, 0.5 mmol) (prepared as in Step 2, Example 4) in THF (9 ml) and methanol (1 ml) was added sodium methoxide (41 mg, 0.75 mmol). The reaction mixture was refluxed for 3 h and poured over cold water (25 ml). The mixture was extracted with ethyl acetate (2×25 ml) and washed with water and brine and dried over anhydrous Na 2 SO 4 . Evaporation of the solution followed by purification of the residue over silica gel column using 40% EtOAc-hexane as eluent furnished the title compound (110 mg, 53%) as a solid.  
         [0573]     1HNMR (CDCl 3,  300 MHz): δ 11.26 (1H, s, NH), 8.19 (1H, bs), 7.80-7.89 (3H, m), 7.65 (1H, s), 7.51 (2H, t, J=2.6 Hz), 7.34 and 7.32 (2H, dd, J=9 and 4.8 Hz) and 6.86-7.26 (3H, m) [aromatic] and 3.99 (3H, s) &amp; 3.85 (3H, s) [2×OCH 3 ].  
         [0574]     IR (ν max , KBr): 1714.7, 1581.6, 1342.9, 737.3 cm −1 .  
         [0575]     LCMS (m/z): 418.1 (M+1, 100%).  
       Example 7  
     Synthesis of 3-[{4-[[Benzo[1,3]dioxo-5-ylmethyl)amino]-6-[3-(2-methoxy phenyl)ureido]-[1,3,5]triazin-2-yl}-(3,4-dichlorobenzyl)amino]propionic acid (Compound No. 97)  
     Step 1: Preparation of 3-[(4-amino-6-chloro-[1,3,5]triazin-2-yl)-(3,4-dichloro benzyl)amino]propionic acid  
       [0576]     2-amino-4,6-dichloro-1,3,5 triazine (2 g, 12 mmol) and K 2 CO 3  (1.68 g, 12 mmol) were added to a solution of the lithium salt of 3-aminopropionic acid derivative (obtained by the LiOH.H 2 O (512 mg, 12.1 mmol) hydrolysis of ethyl 3-(3,4-dichlorobenzyl) aminopropionate (3.3 g, 12.1 mmol) in acetone (50 ml) and stirred at room temperature overnight. It was poured into cold water, acidified with HCl and the precipitated solid filtered and dried under vacuum to obtain the title compound (4.3 g, 95%).  
         [0577]     m.p.: 105-110° C.  
         [0578]     1HNMR (TFA-d, 300 MHz): δ 8.71 (1H, d, J=6 Hz), 8.66 (1H, s) &amp; 8.42 (1H, d, J=9 Hz) [aromatic], 6.28 (s) &amp; 6.23 (s) [2H, NCH 2 Ar], 5.33 (t, J=6 Hz) &amp; 5.26 (t, J=6 Hz), [2H, NCH 2 ] and 4.15 (2H, t, J=6 Hz, CH 2 CO 2 H).  
         [0579]     IR (ν max , KBr): 1709.9, 1574.3, 1522.8, 1322.9, 804.6 cm −1 .  
         [0580]     LCMS (m/z): 375.9 (M+1, 82%), 377.9 (M+3, 100%).  
       Step 2: Preparation of 3-[{4-(2-methoxyphenyl)ureido)-6-chloro-[1,3,5]triazin-2-yl}-(3,4-dichlorobenzyl)amino]propionic acid (Compound No. 59)  
       [0581]     Following the general protocol, reaction of the aminotriazine (4 g, 10.6 mmol) obtained from Step 1, Example 7, above, with sodium hydride (1.02 g, 50% dispersion in oil, 21.3 mmol) and 2-methoxyphenyl isocyanate (1.58 g, 10.6 mmol) afforded after purification the title compound (3.7 g, 66%) as a white solid.  
         [0582]     m.p.: 210-212° C.  
         [0583]     1HNMR (TFA-d, 300 MHz): δ 8.3-9.00 (7H, m, aromatic), 5.42 (bs), 5.19 (s) &amp; 5.18 (s) [5H, NCH 2  and OCH 3 ] and 4.16 (2H, bs, CH 2 CO 2 H).  
         [0584]     IR (ν max , KBr): 1728.9, 1555.7, 1266.5, 804.5 cm −1 .  
         [0585]     LCMS (m/z): 525.0 (M+1, 100%), 527.1 (M+3, 96%).  
       Step 3: Preparation of 3-[{4-[{benzo[1,3]dioxo-5-ylmethyl)amino]-6-[3-(2-methoxyphenyl)ureido]-[1,3,5]triazin-2-yl}-(3,4-dichloro-benzyl)amino]-propionic acid (Compound No. 97)  
       [0586]     To the chlorotriazine (200 mg, 0.45 mmol) in THF (10 ml) was added piperonyl-amine (104 mg, 6.8 mmol) and triethylamine (93 mg, 0.9 mmol) and refluxed for 3 h. After cooling, the mixture was poured into cold water, acidified with HCl and extracted with EtOAc (2×50 ml). The combined organic extracts were washed with brine and dried anhydrous (Na 2 SO 4 ) and concentrated. The residue was treated with hexane-dichloromethane (25:5 ml) and the white solid filtered and dried under vacuum to afford the title compound (141 mg, 53%).  
         [0587]     m.p.: 120° C.  
         [0588]     1HNMR (DMSO-d 6,  300 MHz): δ 11.17 (s) &amp; 11.12 (s) [CO 2 H] 10.88 (s) &amp; 10.84 (s) [1H, NH], 9.59 (s), 9.47 (s) &amp; 9.43 (s) [1, NH], 7.97 (1H, s) and 6.65-7.55 (10H, m) [aromatic], 5.96 (s), 5.93 (s) &amp; 5.92 (s) [2H, OCH 2 O], 4.83 (s) &amp; 4.80 (s) [2H, NCH 2 Ar], 4.47 (ABq, J=6 Hz), 4.38 (ABq, J=6 Hz) &amp; 4.27 (ABq, J=6 Hz) [2H, NCH 2 Ar] and 3.64-3.79 (5H, m, OCH 3  and NCH 2 ).  
         [0589]     IR (ν max , KBr): 1692.5, 1600.7, 1250.0, 1037.1, 750.3 cm −1 .  
         [0590]     LCMS (m/z): 640.2 (M+1, 100%).  
         [0591]     The following compounds were prepared similarly:  
       Preparation of 3-[(4-[3-(2-Methoxyphenyl)ureido]-6-chloro-[1,3,5]triazin-2-yl)(3-methyl benzyl)amino]propionic acid (Compound No. 58)  
     Step 1: Preparation of 3-[(4-Amino-6-chloro-[1,3,5]triazin-2-yl)-(3-methylbenzyl)-amino]propionic acid  
       [0592]     3-[(4-Amino-6-chloro-[1,3,5]triazin-2-yl)-(3-methylbenzyl)-amino]propionic acid was prepared by using 3-(3-methylbenzyl)aminopropionic acid instead of 3-(3,4-dichlorobenzyl)aminopropionic acid in Step 1, Example 7.  
         [0593]     m.p.: 168-170° C.  
         [0594]     1HNMR (TFA-d, 300 MHz): δ 7.62 (2H, m) &amp; 7.57 (2H, m) [aromatic] 5.39 (s) &amp; 5.33 (s) [2H, NCH 2 ], 4.40 (t, J=6.9 Hz) &amp; 4.32 (t, J=6.9 Hz) [2H, NCH 2 ], 3.17 (2H, t, J=6.9 Hz, CH 2 CO 2 H) and 2.74 (3H, s, Ar—CH 3 ).  
         [0595]     IR (ν max , KBr): 1713.0, 1568.4, 1321.5, 803.4, 777.9 cm −1 .  
         [0596]     LCMS (m/z): 322.1 (M+1, 100%).  
       Step 2: Preparation of 3-[(4-[3-(2-Methoxyphenyl)ureido]-6-chloro-[1,3,5]triazin-2-yl)(3-methyl benzyl)amino]propionic acid (Compound No. 58)  
       [0597]     3-[(4-[3-(2-Methoxyphenyl)ureido]-6-chloro-[1,3,5]triazin-2-yl)(3-methyl benzyl)amino]propionic acid was prepared by using compound of Step 1 immediately above and 2-methoxyphenyl isocyanate as in Step 2, Example 7.  
         [0598]     m.p.: 205° C.  
         [0599]     1HNMR (DMSO-d 6,  300 MHz): δ 11.01 (s) &amp; 10.91 (s) [1H, NH] 10.45 (1H, s, NH), 8.14 &amp; 8.09 (1H, dd, J=14.1 Hz &amp; 8.1 Hz), 7.23 &amp; 7.13 (1H, t of d, J=17.1 and 8.1 Hz), 7.09 (bs) &amp; 7.03 (bs) [5H] and 6.93 &amp; 6.91 (1H, dd, J=7.8 and 3.9 Hz) [aromatic], 4.91 (s) &amp; 4.84 (s) [2H, NCH 2 Ar], 3.85 (s) &amp; 3.81 (s) [3H, OCH 3 ], 3.65 (m, NCH 2 ), 2.57 (m, CH 2 CO 2 H) and 2.30 (s) &amp; 2.22 (s) [3H, ArCH 3 ].  
         [0600]     IR (ν max , KBr): 1721.2, 1608.3, 1560.7, 1270.0, 743.4 cm −1 .  
         [0601]     LCMS (m/z): 471.3 (M+1, 100%).  
       3-[(3,4-Dichlorobenzyl)-{4-isopropylamino-6-{3-(2-methoxyphenyl)ureido}-[1,3,5]triazin-2-yl}amino]propionic acid (Compound No. 80)  
       [0602]     3-[(3,4-Dichlorobenzyl)-{4-isopropylamino-6-{3-(2-methoxyphenyl)ureido}-[1,3,5]triazin-2-yl}amino]propionic acid was prepared by using isopropylamine instead of piperonylamine in Step 3, Example 7.  
         [0603]     m.p.: 95-101° C.  
         [0604]     1HNMR (TFA-d, 300 MHz): δ 8.45-9.00 (7H, m, aromatic), 6.38 (s) &amp; 6.35 (s) [2H, NCH 2 Ar], 5.46 (bs), 5.34 (s) &amp; 5.32 (s), [6H, OCH 3 , NCH and NCH 2 ], 4.28 (2H, t, CH 2 CO 2 H] and 2.83 (d, J=6 Hz) &amp; 2.72 (d, J=9 Hz) [6H, CH 3 ×2].  
       3-[(3,4-Dichlorobenzyl)-{4-(3-(2-methoxyphenyl)ureido)-6-(morpholin-4-yl) [1,3,5]triazin-2-yl}amino]propionic acid (Compound No. 81)  
       [0605]     3-[(3,4-Dichlorobenzyl)-{4-(3-(2-methoxyphenyl)ureido)-6-(morpholin-4-yl) [1,3,5]triazin-2-yl}amino]propionic acid was prepared by using morpholine instead of piperonylamine in Step 3, Example 7.  
         [0606]     m.p.: 198-203° C.  
         [0607]     1HNMR (TFA-d, 300 MHz): δ 8.35-9.00 (7H, m, aromatic), 6.34 (2H, bs, NCH 2 Ar), 5.46 (s), 5.39 (bs), 5.34 (bs) &amp; 5.30 (bs) [13H, OCH 2 ×2, OCH 3 , NCH 2 ×2 (ring) and NCH 2 ] and 4.34 (2H, t, CH 2 CO 2 H).  
         [0608]     IR (ν max , KBr): 1704.5, 1587.6, 1515.3, 1248.1, 750.4 cm −1 .  
         [0609]     LCMS (m/z): 576.2 (M+1, 100%), 578.1 (M+3, 70%).  
       3-[(3,4-Dichlorobenzyl)-{4-(3-[2-methoxyphenyl)ureido]-6-(naphthalen-2-yl amino)-[1,3,5]triazin-2-yl}amino]-propionic acid (Compound No. 94)  
       [0610]     3-[(3,4-Dichlorobenzyl)-{4-(3-[2-methoxyphenyl)ureido]-6-(naphthalen-2-yl amino)-[1,3,5]triazin-2-yl}amino]-propionic acid was prepared by using 2-aminonaphthalene instead of piperonylamine in Step 3, Example 7.  
         [0611]     m.p.: 115-120° C.  
         [0612]     1HNMR (DMSO-d 6,  300 MHz): δ 10.91 (1H, bs, NH), 9.73 (bs) &amp; 9.66 (bs) [1H, NH], 6.92-7.95 (14H, m, aromatic), 4.98 (s) &amp; 4.96 (s) [2H, NCH 2 Ar], 3.4-3.85 (5H, m, OCH 3  and NCH 2 ) and 3.19 (2H, m, CH 2 CO 2 H).  
         [0613]     IR (ν max , KBr): 1712.4, 1687.0, 1441.5, 809.3, 742.3 cm −1 .  
         [0614]     LCMS (m/z): 632.3 (M+1, 100%).  
       3-[{4-[(Benzo[1,3]dioxo-5-ylmethyl)amino]-6-[3-(2-methoxyphenyl)ureido]-[1,3,5]triazin-2-yl}-(3-methylbenzyl)amino]-propionic acid (Compound No. 84)  
       [0615]     3-[{4-[(Benzo[1,3]dioxo-5-ylmethyl)amino]-6-[3-(2-methoxyphenyl)ureido]-[1,3,5]triazin-2-yl}-(3-methylbenzyl)amino]-propionic acid was prepared following the procedure of Example 7, by using Compound No. 58 and piperonylamine as in Step 3, Example 7.  
         [0616]     m.p.: 165° C.  
         [0617]     1HNMR (DMSO-d 6,  300 MHz): δ 11.14 (s) &amp; 10.90 (s) [1H, NH], 9.53 (s) &amp; 9.39 (s) [1H, NH], 7.97 (s) and 7.94 (s) [1H, NH], 6.68-7.60 (11H, m, aromatic), 5.96 (s) &amp; 5.93 (s) [2H, OCH 2 O], 4.84 (s) &amp; 4.79 (s) [2H, NCH 2 Ar], 4.45 (s) &amp; 4.37 (ABq, J=5.1 Hz) [NCH 2 Ar}, 3.48-3.76 (5H, m, OCH 3  and NCH 2 ), 2.56 (m, CH 2 CO 2 H) and 2.28 (s), 2.25 (s), 2.19 (s) &amp; 2.07 (s) [3H, ArCH 3 ].  
         [0618]     IR (ν max , KBr): 685.2, 1596.6, 1251.7, 811.2, 747.2 cm −1 .  
         [0619]     LCMS (m/z): 586.2 (M+1, 100%).  
       3-[{4-[3-(2-Methoxyphenyl)ureido]-6-[(thiophen-2-yl-methyl)amino]-[1,3,5]triazin-2-yl}-(3-methylbenzyl)amino]propionic acid (Compound No. 85)  
       [0620]     3-[{4-[3-(2-Methoxyphenyl)ureido]-6-[(thiophen-2-yl-methyl)amino]-[1,3,5]triazin-2-yl}-(3-methylbenzyl)amino]propionic acid was prepared following the procedure of Example 7, by using Compound No. 58 and thiophen-2-yl-methylamine as in Step 3, Example 7.  
         [0621]     m.p.: 89-95° C.  
         [0622]     1HNMR (DMSO-d 6,  300 MHz): δ 10.93 (1H, bs, NH), 9.54 (1H, bs, NH), 7.35-8.05 (2H, m), 7.7 (1H, bs), 7.36 (1H, m), 7.18 (1H, t, J=7.5 Hz), 7.05 (5H, s) &amp; 6.89 (2H, m) [aromatic], 4.87 (s), 4.76 (m), 4.66 (d, J=5.1 Hz) &amp; 4.61 (m), [4H, NCH 2 Ar×2), 3.85 (s), 3.79 (s) &amp; 3.74 (s) [5H, OCH 3  and NCH2] and 2.20 (s) &amp; 2.07 (s) [3H, ArCH 3 ].  
         [0623]     IR (ν max , KBr): 1690.5, 1595.5, 1429.3, 1251.7, 748.7 cm −1 .  
         [0624]     LCMS (m/z): 548.2 (M+1, 100%).  
       3-[{4-(2,3-Dihydro-indol-1-yl)-6-[3-(2-methoxyphenyl)-ureido]-[1,3,5]triazin-2-yl}-(3-methylbenzyl)amino]propionic acid (Compound No. 86)  
       [0625]     3-[{4-(2,3-Dihydro-indol-1-yl)-6-[3-(2-methoxyphenyl)-ureido]-[1,3,5]triazin-2-yl}-(3-methylbenzyl)amino]propionic acid was prepared following the procedure of Example 8, by using Compound No. 58 and indoline as in Step 3, Example 8.  
         [0626]     m.p.: 201° C.  
         [0627]     1HNMR (DMSO-d 6,  300 MHz): δ 10.77 (1H, s, CO 2 H), 9.98 (bs) &amp; 9.69 (bs) (1H, NH), 8.54 (bs) &amp; 8.2 (bs) [1H, NH], 8.02 &amp; 7.99 (1H, dd, J=6.3 and 5.1 Hz), 6.9-7.25 (11H, m) [aromatic], 4.94 (s) &amp; 4.90 (s) [2H, NCH 2 Ar] 4.21 (bs), 3.78 (bs). 3.77 (s) &amp; 3.60 (bs) [7H, NCH 2 ×2 and OCH 3 ], 3.05 (2H, ABq. J=7.5 Hz, ArCH 2 ), 2.65 (2H, t, J=6.6 Hz, CH 2 CO 2 H) and 2.29 (s) &amp; 2.22 (s) [3H, ArCH 3 ].  
         [0628]     IR (ν max , KBr): 1723.1, 1674.1, 1579.3, 1518.8, 1247.3, 747.8 cm −1 .  
         [0629]     LCMS (m/z): 554.3 (M+1, 100%).  
       3-[{4-[3-(2-Methoxyphenyl)ureido]-6-piperidin-1-yl-[1,3,5]triazin-2-yl}-(3-methylbenzyl)amino]propionic acid (Compound No. 87)  
       [0630]     3-[{4-[3-(2-Methoxyphenyl)ureido]-6-piperidin-1-yl-[1,3,5]triazin-2-yl}-(3-methylbenzyl)amino]propionic acid was prepared following the procedure of Example 7, by using Compound No. 58 and piperidine as in Step 3, Example 7.  
         [0631]     m.p.: 91-92° C.  
         [0632]     1HNMR (DMSO-d 6,  300 MHz): δ 10.82 (1H, s, NH), 9.41 (1H, s, NH), 7.98 (1H, t), 6.75-7.25 (7H, m) (aromatic), 4.86 (s) &amp; 4.77 (s), (2H, NCH 2 Ar), 3.79 (s), 3.74 (s) &amp; 3.63 (t) [9H, NCH 2 ×3, OCH 3 ], 2.29 (s) &amp; 2.21 (s) [3H, ArCH 3 ] and 1.62 (bs) &amp; 1.52 (bs) [6H, CH 2 ×3].  
         [0633]     IR (ν max , KBr): 1711.8, 1589.0, 1512.1, 1254.1, 748.4 cm −1 .  
         [0634]     LCMS (m/z): 520.1 (M+1, 100%).  
       3-[{4-[3-(2-Methoxyphenyl)ureido]-6-pyrrolidin-1-yl-[1,3,5]triazin-2-yl}-(3-methylbenzyl)amino]propionic acid (Compound No. 88)  
       [0635]     3-[{4-[3-(2-Methoxyphenyl)ureido]-6-pyrrolidin-1-yl-[1,3,5]triazin-2-yl}-(3-methylbenzyl)amino]propionic acid was prepared by following the procedure of Example 7, by using Compound No. 58 and pyrrolidine as in Step 3, Example 7.  
         [0636]     m.p.: 190° C.  
         [0637]     1HNMR (DMSO-d 6,  300 MHz): δ 10.98 (1H, s, NH), 9.39 (1H, s, NH), 8.02 (1H, t), 7.19 (1H, t), 7.09 (5H, m) and 7.04 (1H, t) [aromatic], 4.83 (s) &amp; 4.79 (s) [2H, NCH 2 Ar], 3.79 (s), 3.77 (s) &amp; 3.17-3.56 (m), [9H, OCH 3  and NCH 2 ×3], 2.56 (m, CH 2 CO 2 H), 2.29 (s) &amp; 2.24 (s) [3H, ArCH 3 ] and 1.92 (4H, bs, CH 2 ×3).  
         [0638]     IR (ν max , KBr): 1715.8, 1589.7, 1512.5, 748.9 cm −1 .  
         [0639]     LCMS (m/z): 506.1 (M+1, 100%).  
       3-[{4-[3-(2-Methoxyphenyl)ureido]-6-morpholin-4-yl-[1,3,5]triazin-2-yl}-(3-methylbenzyl)amino]propionic acid (Compound No. 89)  
       [0640]     3-[{4-[3-(2-Methoxyphenyl)ureido]-6-morpholin-4-yl-[1,3,5]triazin-2-yl}-(3-methylbenzyl)amino]propionic acid was prepared following the procedure of Example 7, by using Compound No. 58 and morpholine as in Step 3, Example 7.  
         [0641]     m.p.: 101-102° C.  
         [0642]     1HNMR (DMSO-d 6,  300 MHz): δ 10.79 (1H, s, NH), 9.52 (1H, s, NH), 7.99 (1H, t, J=7.5 Hz), 7.18 (1H, m), 7.04 (5H, m) and 6.91 (1H, bs) [aromatic], 4.87 (s) and 4.79 (s) [2H, NCH 2 Ar], 3.74 (s) &amp; 3.67 (t, J=5.7 Hz) [13H, OCH 3 , OCH 2 ×2 and NCH 2 ×3] and 2.29 (s) &amp; 2.22 (s) [3H, ArCH 3 ].  
         [0643]     IR (ν max , KBr): 1710.5, 1588.8, 1515.2, 1248.7, 749.3 cm −1 .  
         [0644]     LCMS (m/z): 522.1 (M+1, 100%).  
       3-[{4-Allylamino-6-[3-(2-methoxyphenyl)ureido]-[1,3,5]triazin-2-yl}-(3-methyl benzyl)amino]propionic acid (Compound No. 90)  
       [0645]     3-[{4-Allylamino-6-[3-(2-methoxyphenyl)ureido]-[1,3,5]triazin-2-yl}-(3-methyl benzyl)amino]propionic acid was prepared following the procedure of Example 7, by using Compound No. 58 and allylamine as in Step 3, Example 7.  
         [0646]     m.p.: 182-183° C.  
         [0647]     1HNMR (DMSO-d 6,  300 MHz): δ 11.17 (s) &amp; 10.91 (s) [1, NH], 9.44 (s) &amp; 9.37 (s) [1H, NH], 7.61 (1H, bs, NH) 7.99 &amp; 7.96 (1H, dd, J=7.2 Hz), 7.19 (1H, m), 7.03 (5H, m) and 6.90 (1H, bs) [aromatic], 5.83 (1H, m, olefinic CH), 5.13 (1H, t, J=17.7 Hz) &amp; 5.04 (t, J=10.2 Hz) [olefinic CH 2 ], 4.86 (s) &amp; 4.79 (s) [2H, NCH 2  Ar], 4.01 (bs) &amp; 3.92 (bs), 3.79 (s), 3.74 (s) &amp; 3.63 (m) [7H, NCH 2 ×2 and OCH 3 ] and 2.29 (s) &amp; 2.19 (s) [3H, ArCH 3 ].  
         [0648]     IR (ν max , KBr): 1690.5, 1504.8, 1249.5, 812 cm −1 .  
         [0649]     LCMS (m/z): 492.1 (M+1, 100%).  
       3-[(3,4-Dichlorobenzyl)-{4-[4-(2-isopropoxyphenyl)-piperazin-1-yl]-6-[3-(2-methoxyphenyl)ureido]-[1,3,5]triazin-2-yl}amino]-propionic acid (Compound No. 95)  
       [0650]     3-[(3,4-Dichlorobenzyl)-{4-[4-(2-isopropoxyphenyl)-piperazin-1-yl]-6-[3-(2-methoxyphenyl)ureido]-[1,3,5]triazin-2-yl}amino]-propionic acid was prepared by using 4-(2-isopropoxyphenyl)piperazine instead of piperonyl-amine in Step 3, Example 7.  
         [0651]     m.p.: 115-118° C.  
         [0652]     1HNMR (DMSO-d 6,  300 MHz): δ 10.77 (s) &amp; 10.75 (s) [1H, NH], 9.60 (s) &amp; 9.57 (s) [1, NH], 8.03 &amp; 7.99 (1H, dd, J=10.8 and 6.6 Hz), 7.58 (2H, t, J=9.6 Hz), 7.28 (1H, d, J=8.4 Hz), 7.04 (2H, s), 6.93 (4H, s) and 6.88 (1H, d, J=5.1 Hz) [aromatic] 4.86 (s) &amp; 4.81 (s) [2H, NCH 2 Ar], 4.63 (1H, bs, CHCH 3 ), 3.93 (bs), 3.82 (s), 3.79 (s) &amp; 3.74 (t, J=6.6 Hz) [9H, OCH 3  and NCH 2 ×3], 3.05 (4H, m, NCH 2 ×2), 2.57 (2H, m, CH 2 CO 2 H) and 1.29 (d, J=5.1 Hz) &amp; 1.27 (d, J=4.8 Hz) [6H, CH 3 ×2].  
         [0653]     IR (ν max , KBr): 1708.8, 1587.6, 1154.2, 1240.3, 748.8 cm −1 .  
         [0654]     LCMS (m/z): 709.3 (M+1, 100%).  
       3-[(3,4-Dichlorobenzyl)-{4-[4-(2-methoxyphenyl)piperazin-1-yl]-6-[3-(2-methoxyphenyl)ureido]-[1,3,5]triazin-2-yl}amino]propionic acid (Compound No. 96)  
       [0655]     I3-[(3,4-Dichlorobenzyl)-{4-[4-(2-methoxyphenyl)piperazin-1-yl]-6-[3-(2-methoxyphenyl)ureido]-[1,3,5]triazin-2-yl}amino]propionic acid was prepared by using 4-(2-methoxyphenyl)piperazine instead of piperonyl-amine in Step 3, Example 7.  
         [0656]     1HNMR (DMSO-d 6,  300 MHz): δ 10.79 (s) &amp; 10.77 (s) [1H, NH], 9.61 (s) &amp; 9.58 (s) [1H, NH], 8.01 &amp; 7.99 (1H, dd, J=7.2 Hz), 7.59 (2H, t, J=5.4 Hz), 7.28 (1H, d, J=8.4 Hz) 7.04 (s), 6.96 (s) &amp; 6.90 (m) [7H] [aromatic], 4.86 (s) &amp; 4.81 (s) [2H, NCH 2 Ar], 3.92 (s), 3.82 (s), 3.81 (s), 3.79 (s) and 3.71 (t, J=7.2 Hz) [12H, OCH 3 ×2 and NCH 2 ×3], 3.03 (4H, m, NCH 2 ×2) and 2.57 (m, CH 2 CO 2 H).  
         [0657]     IR (ν max , KBr): 1719.8, 1591.6, 1511.9, 747.8 cm −1 .  
         [0658]     LCMS (m/z): 681.2 (M+1, 100%).  
       3-[(3,4-Dichlorobenzyl)-{4-[4-[3-(2-methoxyphenyl)ureido]-6-[(thiophen-2-ylmethyl)amino]-[1,3,5]triazin-2-yl}amino]propionic acid (Compound No. 98)  
       [0659]     3-[(3,4-Dichlorobenzyl)-{4-[4-[3-(2-methoxyphenyl)ureido]-6-[(thiophen-2-ylmethyl)amino]-[1,3,5]triazin-2-yl}amino]propionic acid was prepared by using thiophen-2-ylmethylamine instead of piperonylamine in Step 3, Example 7.  
         [0660]     m.p.: 197° C.  
         [0661]     1HNMR (DMSO-d 6,  300 MHz): δ 12.24 (1H, bs, CO 2 H), 11.15 (s), 11.10 (s) &amp; 10.88 (s) [1H, NH], 9.61 (s), 9.51 (s) &amp; 9.49 (s) [1H, NH], 6.80-8.00 (11H, m, aromatic and 1 NH), 4.86 (s) &amp; 4.05-4.82 (m) [4H, NCH 2 Ar×2], 3.70-3.80 (5H, m, OCH 3  and NCH 2 ).  
         [0662]     IR (ν max , KBr): 1707.5, 1688.5, 1598.9, 812.5 cm −1 .  
         [0663]     LCMS (m/z): 602.1 (M+1, 100%), 604.0 (M+3, 96%).  
       3-[(3,4-Dichlorobenzyl)-{4-(2,3-dihydro-indol-1-yl)-6-[3-(2-methoxyphenyl) ureido]-[1,3,5]triazin-2-yl}amino]propionic acid (Compound No. 99)  
       [0664]     It 3-[(3,4-Dichlorobenzyl)-{4-(2,3-dihydro-indol-1-yl)-6-[3-(2-methoxyphenyl) ureido]-[1,3,5]triazin-2-yl}amino]propionic acid was prepared by using indoline instead of piperonylamine in Step 3, Example 7.  
         [0665]     m.p.: 145-148° C.  
         [0666]     1HNMR (DMSO-d 6,  300 MHz): δ 12.38 (1H, bs, CO 2 H), 10.84 (1H, bs, NH), 9.89 (1H, bs, NH), 7.01-8.40 (1H, m, aromatic), 5.00 (2H, s, NCH 2  Ar), 3.26-4.31 (9H, m, OCH 3 , NCH 2 ×2 and CH 2 Ar) and 2.75 (m, CH 2 CO 2 H).  
         [0667]     IR (ν max , KBr): 1709.1, 1582.9, 1516.5, 749.7 cm −1 .  
         [0668]     LCMS (m/z): 608.3 (M+1, 100%).  
       3-[(3,4-Dichlorobenzyl)-{4-[3-(2-methoxyphenyl)ureido]-6-piperidin-1-yl-[1,3,5]triazin-2-yl}amino)propionic acid (Compound No. 100)  
       [0669]     3-[(3,4-Dichlorobenzyl)-{4-[3-(2-methoxyphenyl)ureido]-6-piperidin-1-yl-[1,3,5]triazin-2-yl}amino)propionic acid was prepared by using piperidine in place of piperonylamine in Step 3, Example 7.  
         [0670]     m.p.: 111-115° C.  
         [0671]     1HNMR (DMSO-d 6,  300 MHz): δ 12.28 (1H, bs, CO 2 H), 10.77 (s), 10.76 (s), [1H, NH], 9.52 (s) &amp; 9.47 (s) [1H, NH], 7.99 (1H, t), 7.56 (2H, t), 7.27 (1H, d, J=6.9 Hz), 7.03 (2H, s) &amp; 6.92 (1H, s) [aromatic], 4.85 (s) &amp; 4.78 (s) [NCH 2 Ar], 3.79 (s), 3.77 (s) &amp; 3.68 (m) [9H, OCH 3  and NCH 2 ×3] and 1.54 (6H, m, CH 2 ×3).  
         [0672]     IR (ν max , KBr): 1711.7, 1590.5, 1027.1, 748.4 cm −1 .  
         [0673]     LCMS (m/z): 574.1 (M+1, 100%), 576.1 (M+3, 93%).  
       3-[(3,4-Dichlorobenzyl)-{4-[3-(2-methoxyphenyl)ureido]-6-pyrrolidin-1-yl-[1,3,5]triazin-2-yl}amino)propionic acid (Compound No. 101)  
       [0674]     3-[(3,4-Dichlorobenzyl)-{4-[3-(2-methoxyphenyl)ureido]-6-pyrrolidin-1-yl-[1,3,5]triazin-2-yl}amino)propionic acid was prepared by using pyrrolidine instead of piperonylamine in Step 3, Example 7.  
         [0675]     m.p.: 201-203° C.  
         [0676]     1HNMR (DMSO-d 6,  300 MHz): δ 10.94 (1H, s, NH), 9.52 (s) &amp; 9.49 (s) [1H, NH], 8.02 (1H, d, J=7.5 Hz), 7.59 (2H, d, J=7.84 Hz), 7.29 (1H, d, J=8.1 Hz), 7.03 (2H, d, J=3.6 Hz), 3.78 (s), 3.73 (s) &amp; 3.70 (m) [9H, OCH 3  and NCH 2 ×3], 2.55 (2H, m, CH 2 CO 2 H) and 1.76 (4H, bs, CH 2 ×2).  
         [0677]     IR (ν max , KBr): 1702.9, 1589.0, 1509.5, 749.4 cm −1 .  
         [0678]     LCMS (m/z): 560.1 (M+1, 100%).  
       3-[{4-Allylamino-6-[3-(2-methoxyphenyl)ureido]-[1,3,5]triazin-2-yl}-(3,4-dichlorobenzyl)-amino]propionic acid (Compound No. 102)  
       [0679]     3-[{4-Allylamino-6-[3-(2-methoxyphenyl)ureido]-[1,3,5]triazin-2-yl}-(3,4-dichlorobenzyl)-amino]propionic acid was prepared by using allylamine instead of piperonylamine in Step 3, Example 7.  
         [0680]     m.p.: 201° C.  
         [0681]     1HNMR (DMSO-d 6,  300 MHz): δ 12.21 (1H, bs, CO 2 H), 11.19 (s), 11.16 (s) &amp; 10.86 (s) [1H, NH], 9.52 (s), 9.46 (s) &amp; 9.43 (s) [1H, NH], 7.96 (1H, d, J=7.5 Hz), 7.54 (2H, m), 7.27 (1H, m), 7.02 (2H, s) &amp; 6.91 (1H, m) [aromatic], 5.84 (1H, bs, olefinic CH), 4.9-5.20 (2H, m, olefinic CH 2 ), 4.85 (s) &amp; 4.80 (s) [2H, NCH 2  Ar] and 4.01 (m), 3.92 (m), 3.79 (s) &amp; 3.67 (m) [7H, OCH 3  and NCH 2 ×2].  
         [0682]     IR (ν max , KBr): 1712.3, 1688.2, 1546.3, 1259.1, 810.3 cm −1 .  
         [0683]     LCMS (m/z): 546.0 (M+1, 100%).  
       1-{4-[(2-Carboxyethyl)-(3,4-dichlorobenzyl)amino]-6-[3-(2-methoxyphenyl) ureido]-[1,3,5]triazin-2-yl}-pyrrolidine-2S-carboxylic acid (Compound No. 113)  
       [0684]     1-{4-[(2-Carboxyethyl)-(3,4-dichlorobenzyl)amino]-6-[3-(2-methoxyphenyl) ureido]-[1,3,5]triazin-2-yl}-pyrrolidine-2S-carboxylic acid was prepared by using pyrrolidine-2S-carboxylic acid (L-proline) instead of piperonyl-amine in Step 3, Example 7.  
         [0685]     m.p.: 158° C.  
         [0686]     1HNMR (DMSO-d 6,  300 MHz): δ 10.93 (1H, s, NH), 9.59 (s) &amp; 9.56 (s), [1H, NH], 8.03 (t, J=6 Hz) &amp; 7.86 (t) [1H], 7.57 (2H, m), 7.27 (1H, m), 7.04 (2H, s) &amp; 6.92 (1H, s) [aromatic], 4.7-4.85 (2H, m, NCH 2 Ar), 4.25-4.60 (1H, m, NCHCO 2 H), 3.79 (s, OCH 3 ), 2.29 (2H, m, CH 2 CO 2 H) and 1.98 (4H, m, CH 2 ×2) (ring)).  
         [0687]     IR (ν max , KBr): 3449.3, 1718.2, 1587.7, 1027.9, 749.7 cm −1 .  
         [0688]     LCMS (m/z): 604.2 (M+1, 35%).  
       3-[(3,4-Dichlorobenzyl)-{4-(4-hydroxypiperidinyl)-6-[3-(2-methoxyphenyl) ureido]-[1,3,5]triazin-2-yl}amino]propionic acid (Compound No. 123)  
       [0689]     3-[(3,4-Dichlorobenzyl)-{4-(4-hydroxypiperidinyl)-6-[3-(2-methoxyphenyl) ureido]-[1,3,5]triazin-2-yl}amino]propionic acid was prepared by using 4-hydroxypiperidine instead of piperonylamine in Step 3, Example 7.  
         [0690]     m.p.: 121-124° C.  
         [0691]     1HNMR (TFA-d, 300 MHz): δ 8.25 (1H, bs), 8.07 (1H, d, J=9 Hz), 7.96 (2H, m) &amp; 7.73 (3H, m), [aromatic], 5.54 (2H, s, NCH 2 Ar) 4.93 (2H, bs), 4.50-4.75 (m), 4.55 (s) &amp; 4.52 (s) [8H, OCH 3 , NCHOH and NCH 2 ×3], 3.52 (2H, bs, CH 2 CO 2 H) and 2.25-2.80 (4H, m, CH 2  (ring)×2).  
         [0692]     IR (ν max , KBr): 1707.8, 1589.0, 1512.8, 808.1 cm −1 .  
         [0693]     LCMS (m/z): 590.2 (M+1, 100%).  
       3-[{4-(4-Hydroxypiperidinyl-1-yl)-6-[3-(2-methoxyphenyl)ureido]-[1,3,5] triazin-2-yl}-(3-methylbenzyl)-amino]propionic acid (Compound No. 124)  
       [0694]     3-[{4-(4-Hydroxypiperidinyl-1-yl)-6-[3-(2-methoxyphenyl)ureido]-[1,3,5] triazin-2-yl}-(3-methylbenzyl)-amino]propionic acid was prepared by following the procedure of Example 7, by using Compound No. 58 and 4-hydroxypiperidine as in Step 3, Example 7.  
         [0695]     m.p.: 120-123° C.  
         [0696]     1HNMR (TFA-d, 300 MHz): δ 8.38 (1H, bs), 7.89 (4H, m) &amp; 7.72 (3H, m) [aromatic], 5.59 (s) &amp; 5.50 (s) [2H, NCH 2 Ar], 4.97 (bs) &amp; 4.74 (t, J=6 Hz), 4.56 (s), 4.53 (s) &amp; 4.30 (m) [10H, NCH, OCH 3  and NCH 2 ×3, 3.52 (t, J=9 Hz) &amp; 3.47 (t) [2H, CH 2 CO 2 H] and 2.81 (2H, m) &amp; 2.45 (2H, m) [CH 2  (ring) x 2].  
         [0697]     IR (ν max , KBr): 1715.8, 1590.3, 1513.1, 748.0 cm −1 .  
         [0698]     LCMS (m/z): 536.3 (M+1, 100%).  
       Example 8  
     Preparation of 3-[(3,4-Dichlorobenzyl)-{6-[3-(2-methoxyphenyl)ureido]-4-oxo-4,5-dihydro-[1,3,5]triazin-2-yl}amino]propionic acid (Compound No. 92)  
       [0699]     To the chlorotriazine (250 mg, 0.47 mmol) obtained from Step 2, Example 3 in THF- t BuOH (9:1 ml) was added potassium tert-butoxide (160 mg, 1.42 mmol). The reaction mixture was refluxed for 6 hours and poured into cold water (50 ml). The mixture was acidified with concentrated. HCl and the solid that precipitated was filtered and dried in vacuum to obtain the title compound (110 mg, 46%) as a white solid.  
         [0700]     m.p.: 188° C.  
         [0701]     1HNMR (DMSO-d 6,  300 MHz): δ 8.02 (1H, d, J=9 Hz), 7.57 (2H, m), 7.28 (1H, s), 7.04 (2H, s) &amp; 6.93 (1H, s) [aromatic], 4.81 (2H, s, NCH 2  Ar) and 3.83 (5H, s, OCH 3  and NCH 2 ).  
         [0702]     IR (ν max , KBr): 1717.7, 1514.1, 1029.3, 750.9 cm −1 .  
         [0703]     LCMS (m/z): 507.1 (M+1, 100%).  
         [0704]     The following compound was prepared similarly:  
       3-[{6-[3-(2-Methoxyphenyl)ureido]-4-oxo-4,5-dihydro-[1,3,5]triazin-2-yl}-(3-methylbenzyl)amino]propionic acid (Compound No. 83)  
       [0705]     3-[{6-[3-(2-Methoxyphenyl)ureido]-4-oxo-4,5-dihydro-[1,3,5]triazin-2-yl}-(3-methylbenzyl)amino]propionic acid was prepared following the procedure of Example 8, and starting from Compound No. 58.  
         [0706]     m.p.: 156° C.  
         [0707]     1HNMR (DMSO-d 6,  300 MHz): δ 9.17 (1H, bs, NH), 8.00 (1H, bs, NH), 7.23 (1H, t). 7.09 (6H, s) &amp; 6.94 (s) [aromatic], 4.83 (s) &amp; 4.78 (s), (2H, NCH 2  Ar), 3.85 (s) &amp; 3.82 (s) [3H, OCH 3 ], 3.59 (2H, m, NCH 2 ]), 2.55 (m, CH 2 CO 2 H) and 2.30 (s) &amp; 2.27 (s) [3H, ArCH 3 ].  
         [0708]     IR (ν max , KBr): 3260.4, 1714.7, 1603.3, 1515.8, 749.9 cm −1 .  
         [0709]     LCMS (m/z): 453.2 (M+1, 100%).  
       3-[{4-Methoxy-6-[3-(2-methoxyphenyl)ureido]-[1,3,5]triazin-2-yl}-(3-methyl benzyl)amino]propionic acid (Compound No. 91)  
       [0710]     3-[{4-Methoxy-6-[3-(2-methoxyphenyl)ureido]-[1,3,5]triazin-2-yl}-(3-methyl benzyl)amino]propionic acid was prepared by following the procedure of Example 6, starting from Compound no. 58 and sodium methoxide.  
         [0711]     m.p.: 160-162° C.  
         [0712]     1HNMR (DMSO-d 6,  300 MHz): δ 11.25 (s) &amp; 11.18 (s) [1H, NH], 9.98 (1H, s, NH) 8.08 (1H, t, J=8.7 Hz), 7.20 (1H, m), 7.0-7.15 (5H, m) &amp; 6.91 (1H, t, J=3.6 Hz) [aromatic], 4.90 (s) &amp; 4.85 (s) [2H, NCH 2 Ar], 3.94 (s), 3.89 (s), 3.82 (s), 3.78 (s) &amp; 3.70 (t, J=7.8 Hz) [8H, OCH 3 ×2 and NCH 2 ], 2.59 (m, CH 2 CO 2 H) and 2.29 (s) &amp; 2.24 (s) [3H, ArCH 3 ].  
         [0713]     IR (ν max , KBr): 1709.8, 1596.8, 1530.5, 1255.0 cm −1 .  
         [0714]     LCMS (m/z): 467.2 (M+1, 100%).  
         [0715]     The following compound was prepared similarly:  
       3-[(3,4-Dichlorobenzyl)-{4-methoxy-6-[3-(2-methoxyphenyl)-ureido]-[1,3,5]triazin-2-yl}amino]propionic acid (Compound No. 103)  
       [0716]     3-[(3,4-Dichlorobenzyl)-{4-methoxy-6-[3-(2-methoxyphenyl)-ureido]-[1,3,5]triazin-2-yl}amino]propionic acid was prepared by following the procedure of Example 6, and using Compound No. 59 and sodium methoxide.  
         [0717]     m.p.: 208-210° C.  
         [0718]     1HNMR (DMSO-d 6,  300 MHz): δ 11.16 (1H, bs, NH), 10.05 (1H, s, NH), 8.08 (1H, t, J=6 Hz), 7.60 (1H, d, J=6 Hz), 7.57 (1H, d, J=9 Hz), 7.31 (1H, t), 7.02 (2H, s) &amp; 6.92 1H, m) [aromatic], 4.88 (s) &amp; 4.86 (s) [2H, NCH 2 Ar], 3.94 (s), 3.92 (s), 3.87 (s), 3.82 (s) &amp; 3.80 (m) [8H, OCH 3 ×2 and NCH 2 ] and 2.58 (m, CH 2 CO 2 H).  
         [0719]     IR (ν max , KBr): 1708.5, 1596.2, 1253.5, 752.2 cm −1 .  
         [0720]     LCMS (m/z): 521.2 (M+1, 100%).  
       Example 9  
     Primary Screening—Cell Adhesion Assay  
       [0721]     VCAM-1 (100 ng/well) is coated in Maxisorp microtitre modules at 4° C. overnight. Non-specific blocking is carried out with 3% BSA for two hours and the wells washed with TBS (50 mM) Tris, 0.15M NaCl pH 7.4, 0.1 mM CaCl 2 , 0.1 mM MgCl 2 ). U937 cells are suspended in fresh medium and incubated at 37° C. for two hours before the assay. Cells are then washed in TBS solution and 180 μI of cell suspension (1×10 6  cells/ml in TBS buffer) is added per well in VCAM-1 coated wells. 20 μl of sample solution in 50% DMSO and 50% TBS is then added and the cells are incubated at 37° C. for one hour three to five dilutions of each sample are tested in duplicate in a primary screen, samples are tested at 1, 10 and 100 μm. If activity is present, the compounds are tested at lower (&lt;1 μm) concentrates. After incubation, the non-adherent cells are removed by washing with TBS and the number of adhered cells are quantified by LDH activity estimation. The percent adhesion is calculated as compared to control.  
         [0722]     The compounds disclosed herein for utility for the treatment of asthma and the symptoms of asthma, as well as for the treatment of multiple sclerosis, rheumatoid arthritis, allergic rhinitis, inflammatory bowel disease, and other cell adhesion—associated diseases and conditions and relief from the symptoms thereof.